Antibody molecules that bind to PD-L1 and CD137
Antibody molecules with CDR-based PD-L1 and CD137 binding sites, targeting the tumor microenvironment, address the limitations of existing CD137 agonists by enhancing anti-tumor efficacy and reducing hepatotoxicity, offering improved cancer treatment options.
Patent Information
- Application Number
- JP2023169756
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-02-26
- Filing Date
- 2023-09-29
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2039-07-12
AI Technical Summary
Current CD137 agonist molecules face limitations such as high-grade liver inflammation or low clinical efficacy, hindering their effective use in cancer therapy, and existing PD-L1 monotherapies show response in less than 50% of cancer patients, necessitating improved treatments that combine PD-L1 blockade with CD137 agonism.
Development of antibody molecules with a CDR-based PD-L1 binding site and a CD137 antigen binding site located in the constant domain, which require cross-linking for activation and are designed to target the tumor microenvironment, reducing hepatotoxicity and enhancing anti-tumor efficacy by conditional agonism of CD137.
The antibody molecules effectively activate CD137 in the presence of PD-L1, demonstrating enhanced tumor growth inhibition and reduced hepatotoxicity, with improved therapeutic potential for various cancers.
Smart Images

Figure 0007587656000160 
Figure 0007587656000161 
Figure 0007587656000162
Abstract
Description
[Technical Field]
[0001] Technical Field The present invention relates to antibody molecules that can bind to both PD-L1 and CD137 and induce agonism of CD137. The antibody molecules comprise a CDR-based binding site for PD-L1 and a CD137 antigen-binding site located in the constant domain of the antibody molecule. The antibody molecules of the present invention find use, for example, in the treatment of diseases such as cancer. [Background technology]
[0002] Background of the Invention Programmed cell death 1 (PD-1) and its ligands PD-L1 (CD274, B7-H1) and PD-L2 (B7-DC) transmit inhibitory signals that regulate the balance of T cell activation, tolerance, and immunopathology. PD-L1 is transiently expressed on all immune cells and some tumor cells. PD-L1 is a member of the B7 protein family and shares approximately 20% amino acid sequence identity with B7.1 and B7.2. Human PD-L1 shares 70% and 93% amino acid identity with the mouse and cynomolgus monkey orthologs of PD-L1, respectively.
[0003] PD-L1 binds to its receptor PD-1 with an affinity (KD) of 770 nM. PD-1 is expressed on activated T cells, B cells, and myeloid cells and regulates the activation or inhibition of cellular immune responses. When PD-L1 binds to PD-1, it transmits an inhibitory signal, reducing cytokine production and T cell proliferation. Consequently, PD-L1 expression by cells can mediate protection against cytotoxic T lymphocyte (CTL) killing, a regulatory mechanism that attenuates chronic immune responses during viral infections. Cancer, as a chronic and pro-inflammatory disease, subverts this immune protective pathway through upregulation of PD-L1 expression, evading the host immune response. During active immune responses, interferon-gamma (IFN-γ) also upregulates PD-L1 expression.
[0004] PD-L1 also mediates immunosuppression through its interaction with another protein, B7.1 (also known as CD80), blocking the ability of T cells to deliver one of the secondary signals of activation through CD28. Regarding PD-L1 expression on tumor cells and its association with B7.1, the relevance of this particular interaction in tumor immune resistance is still unclear.
[0005] PD-L1 expression has been demonstrated in a wide variety of solid tumors. Of 654 samples examined in one study, 89 (14%) were PD-L1 positive (≥5% frequency), spanning 19 tumors from different sites. The highest PD-L1 positivity frequencies were observed in head and neck (17 / 54; 31%), cervix (10 / 34; 29%), carcinoma of unknown primary site (CUP; 8 / 29; 28%), glioblastoma multiforme (GBM; 5 / 20; 25%), bladder (8 / 37; 21%), esophagus (16 / 80; 20%), triple-negative (TN) breast (6 / 33; 18%), and hepatocellular carcinoma (6 / 41; 15%) (Grosso et al., 2013). It has been shown that associated expression may confer immune resistance and protect tumor cells from T cell-mediated apoptosis.
[0006] Clinical trials have shown the clinical benefit of targeting PD-L1 in patients, and three anti-PD-L1 targeted monoclonal antibodies have been approved to date: Atezolizumab (MPDL3280A, RG7466, Tecentriq™), a humanized IgG1 antibody that binds to PD-L1, has been approved for the first-line treatment of non-small cell lung cancer (NSCLC) and bladder cancer after demonstrating objective response rates (ORR) of 38% and 43%, respectively, in patients with PD-L1 positive tumors in clinical trials. Avelumab (MSB0010718C, Bavencio™) is a fully human IgG1 antibody that binds to PD-L1 and is approved for the treatment of Merkel cell carcinoma and second-line treatment of bladder cancer, while the fully human IgG1 antibody durvalumab (MEDI4736, Imfinzi™) is approved for the treatment of second-line bladder cancer. These antibodies and Additional trials with these and other anti-PD-L1 therapeutics are underway, focusing on expanding the range of treatable solid tumors, including colorectal, gastric, breast, head and neck, pancreatic, ovarian, and renal cell carcinoma.
[0007] CD137 (4-1BB; TNFRSF9) is a costimulatory molecule of the tumor necrosis factor receptor superfamily (TNFRSF). CD137 mediates CD8 activation after activation. + It is widely known to be upregulated in T cells and activated CD4 + It can also be expressed in helper T cells, B cells, regulatory T cells, natural killer (NK) cells, natural killer T (NKT) cells, and dendritic cells (DCs) (Bartkowiak & Curran, 2015). The primary functional role of CD137 in enhancing tumor toxicity was first described in 1997 (Shuford et al., 1997), and soon thereafter, anti-CD137 mAbs were proposed as anti-cancer therapeutic agents.
[0008] CD137 is a transmembrane protein with four extracellular cysteine-rich domains, designated CRD1-4, and a cytoplasmic region involved in CD137 signaling. The ligand for CD137 is CD137L. Although no crystal structure of the CD137 / CD137L complex exists, CD137 is predicted to form a trimeric / trimeric complex with CD137L (Won et al., 2010). CD137L engagement leads to the formation of receptor trimers and subsequent clustering of multiple receptor trimers, activating the CD137 signaling cascade. This signaling cascade provides T cells with a survival signal against activation-induced cell death (Hurtado et al., 1997), thereby playing an important role in maintaining effective T cell immune responses and generating immunological memory (Bartkowiak & Curran, 2015).
[0009] CD137 is expressed by activated T cells and binds antigen-specific CD4 + and CD8+ It has been used as a marker to identify T cells (Wolfl et al., 2007; Ye et al., 2014). Usually, CD137 expression is associated with CD4 + CD8 rather than T cells + High in T cells (Wen et al., 2002). CD8 + For T cells, interferon gamma and interleukin Proliferation, survival, and cytotoxic effector functions via the production of phospholipase 2 have been attributed to CD137 cross-linking. + It also contributes to the differentiation and maintenance of T cells (Chacon et al., 2013). + Some subsets of T cells express CD137 Cross-linking similarly induces proliferation and activation, resulting in the release of cytokines such as interleukin-2 (Makkouk et al., 2016). CD137 has also been demonstrated to be expressed on tumor-responsive subsets of tumor-infiltrating lymphocytes (TILs). CD137 monotherapy has been shown to be effective in several preclinical immunogenic tumor models, including MC38, CT26, and B-cell lymphoma.
[0010] Clinical development of CD137 mAbs has been delayed due to the dose-limiting high-grade liver inflammation associated with CD137 agonist antibody treatment. Urelumab (BMS-663513), a nonligand-blocking human IgG4 isotype antibody (Chester et al., 2018), has entered clinical trials. The first anti-CD137 antibodies were discontinued after significant on-target, dose-dependent hepatotoxicity was observed (Chester et al., 2018; Segal et al., 2017; and Segal et al., 2018). More recently, clinical trials of urelumab in the treatment of solid tumors have resumed, with urelumab treatment combined with radiation therapy (NCT03431948) or other therapeutic antibodies, such as rituximab (NCT01775631), cetuximab (NCT02110082), the anti-PD-1 antibody nivolumab (NCT02253992, NCT02534506, NCT02845323), and the combination of nivolumab with the anti-LAG-3 antibody BMS986016 (NCT02658981). However, there are still significant adverse events associated with urelumab treatment. To reduce hepatotoxicity, urelumab dosing had to be limited in these trials, and efficacy results were disappointing ( Chester et al., 2018 ).
[0011] Pfizer's anti-CD137 antibody utomilumab (PF-05082566), a human IgG2 isotype antibody, has not observed dose-limiting toxicities at doses ranging from 0.03 mg / kg to 10 mg / kg in phase I clinical trials for advanced cancer (Chester et al., 2016; Segal et al., 2018). However, the overall objective response rate with this antibody was only 3.8% in patients with solid tumors, potentially indicating that utomilumab has weaker efficacy and clinical effectiveness than urelumab, but a more favorable safety profile (Chester et al., 2018; Segal et al., 2018). Utomilumab has been shown to be effective in combination with radiation therapy (NCT03217747) or chemotherapy, as well as with other antibody therapies, including the anti-PD-L1 antibody avelumab (NCT02554812) and the anti-PD-1 antibody pembrolizumab (NCT02179918). Combinations have been tested to assess the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated doses (MTDs), and efficacy of different treatment combinations. These trials are ongoing, and early results show no DLTs at doses up to 5 mg / kg, and a 26% patient response rate with the combination of utomilumab and pembrolizumab (Tolcher et al., 2016) (Perez-Ruiz et al., 2017).
[0012] Clinical trials are underway to test the anti-CD137 antibody utomilumab in combination with the anti-PD-L1 antibody avelumab (NCT02554812, NCT3390296). Three combinations of mab with avelumab and other therapies are also being tested (NCT02554812, NCT03217747, NCT03440567, NCT03414658).
[0013] Many bispecific molecules targeting CD137 are also in early stages of development, such as CD137 and FAP-alpha (Link et al., 2018; Reichen et al., 2018), and HER2. (Hinner et al., 2015 and WO 2016 / 177802 A1), or Eph A2 (Liu et al., 2017). CD137L fusion proteins, for example, targeting tumors via FAP-alpha (Claus et al., 2017), have also been developed. The most clinically advanced CD137 bispecific is the CD137 / HER2 bispecific molecule PRS-343, which recently entered a Phase I clinical trial for the treatment of a range of solid tumors to evaluate its safety, tolerability, and efficacy (NCT03330561).
[0014] Other approaches exist that combine anti-CD137 and anti-PD-L1 activity into bispecific therapies. One approach utilizes Bichronix technology to generate a full-length heterodimeric human IgG that monovalently binds both CD137 and PD-L1 (WO 2018056821), resulting in a molecule that binds both CD137 and PD-L1 and can induce CD137 agonism in the presence of high levels of PD-L1. A second approach has been described using an sdAb-Fc fusion that targets both CD137 and PD-L1 (WO 2017123650). Both approaches are capable of binding to CD137 in the absence of PD-L1 binding and induce low levels of CD137 agonism in the absence of PD-L1. This agonism increases in the presence of high levels of PD-L1. A further heterodimeric bispecific antibody that monovalently binds to both CD137 and PD-L1 has been described (WO 2019 / 025545 A1), comprising a humanized anti-CD137 binding region and a human anti-PD-L1 region that elicits CD137 agonism in the presence of PD-L1 levels.
[0015] Current data indicate that overall treatment with anti-PD-L1 monotherapy results in a response in less than 50% of cancer patients. Thus, there remains a need in the art for additional molecules that can target PD-L1 and find use in cancer therapy.
[0016] Although PD-1 / PD-L1 blockade has strong clinical validation, fewer than 50% of patients respond in the monotherapy setting. Combining PD-L1 with additional immune modulators is expected to demonstrate improved efficacy. However, such combinations may be associated with increased treatment-related adverse events, potentially limiting efficacy to a narrow therapeutic window. Agonistic molecules targeting CD137 have yet to demonstrate significant responses in cancer patients, which may be due in part to relatively low dose levels due to a limited therapeutic index. Therefore, there remains a need in the art to develop treatments that combine PD-L1 blockade with CD137 agonism to induce safe and effective therapy. Summary of the Invention [Problem to be solved by the invention]
[0017] Description of the invention As discussed in the Background section above, clinical development of CD137 agonist molecules has been limited due to treatments associated with either dose-limiting high-grade liver inflammation (urelumab) or poor clinical efficacy (utomilumab). [Means for solving the problem]
[0018] The present inventors have recognized that there is a need in the art for CD137 agonist molecules that exhibit high activity and can localize agonist action to the tumor microenvironment. Such molecules can be administered to an individual at a dose that optimizes the potency and thus efficacy of the molecule, and can be used, for example, as immunotherapeutic agents in the treatment of cancer.
[0019] The antibody molecules of the present invention comprise a CD137 antigen-binding site located in the constant domain of the antibody molecule. The inventors have performed an extensive selection and affinity maturation program to isolate a panel of CD137 antigen-binding sites, including molecules (also referred to herein as "Fcabs") that bind to dimeric CD137 with higher affinity than to monomeric CD137.
[0020] The "affinity" referred to herein is K D As will be readily apparent to one of skill in the art, when an antibody molecule is capable of forming multiple binding interactions with an antigen (e.g., when the antibody molecule is capable of bivalently binding the antigen, and optionally when the antigen is dimeric), K D Affinity, as measured by , can also be affected by avidity, where avidity refers to the overall strength of the antibody-antigen complex.
[0021] Expression of CD137 by T cells is upregulated upon activation. Without wishing to be bound by theory, it is believed that due to the high expression of CD137 on activated T cells, CD137 is in the form of dimers, trimers, and higher-order multimers on the surface of such cells. In contrast, naive immune cells, such as naive T cells, express low or negligible levels of CD137 on their cell surface, so the CD137 present may be in a monomeric form. Therefore, antibody molecules containing a CD137 antigen-binding site that binds with high avidity to dimeric or multimeric CD137 are expected to preferentially bind to activated immune cells, such as activated T cells, over naive immune cells.
[0022] These features of the CD137 antigen-binding site are believed to distinguish the antibody molecules of the present invention from known antibodies that bind to CD137, such as the antibodies described in WO2018056821. WO2018056821 describes antibodies containing a monovalent CD137-binding domain that bind to CD137 with high affinity (low nM range, see Table 6 in WO2018056821). These antibodies do not distinguish between monomeric and dimeric or multimeric CD137, which explains the limited binding of these prior art antibodies to activated immune cells. It is not expected that they will show the same preferential binding.
[0023] As discussed in the Background section above, initial ligation of a CD137 ligand to CD137 is thought to initiate a cascade of events that leads to receptor trimerization, subsequent receptor clustering, activation, and subsequent initiation of potent antitumor T cell activity. Therefore, for a therapeutic agent to efficiently achieve CD137 activation, it would be expected that several receptor monomers would need to be crosslinked together in a manner that mimics crosslinking by a trimeric ligand.
[0024] Utomilumab is an IgG2 molecule and relies on cross-linking by Fcγ receptors for its agonistic activity. Urelumab is an IgG4 molecule with constitutive activity and does not require cross-linking by Fcγ receptors for activity, but its agonistic activity is enhanced by cross-linking by some Fcγ receptors. Fcγ receptors are found throughout the human body. Therefore, the immune cell activation activity of utomilumab and urelumab is not restricted to a specific site in the body and can therefore occur in locations outside the tumor microenvironment, such as the liver.
[0025] The present inventors have shown that the CD137 antigen-binding site present in the antibody molecule of the present invention requires cross-linking to cluster and activate CD137. However, it should be noted that this is not an inherent feature of CD137 binders. Rather, many of the CD137 binders isolated during the screening program bound to CD137 but did not require cross-linking for CD137 clustering and activation, and induced limited CD137 clustering and activation in the absence of cross-linking.
[0026] As described above, Fcγ receptor-mediated cross-linking has the disadvantage that Fcγ receptors are found throughout the human body, and therefore CD137 activation is not restricted to a specific site. Therefore, the present inventors introduced mutations into the CH2 domain of Fcab to reduce or inhibit Fcγ receptor binding. Thus, in the absence of cross-linking via agents other than Fcγ receptors, the antibody molecules of the present invention do not exhibit CD137 agonist activity. Furthermore, these mutations result in the inability of the antibody molecules of the present invention to induce antibody cell cytotoxicity, and therefore, the antibody molecules are expected not to induce the death of the immune cells they activate.
[0027] The present inventors have demonstrated that antibody molecules containing the above-described CD137 antigen-binding site and a CDR-based binding site for PD-L1 are highly effective in activating immune cells where CD137 and PD-L1 are co-expressed, for example in the tumor microenvironment. Co-expression in this sense encompasses situations where CD137 and PD-L1 are expressed on the same cell, e.g., T cells, as well as situations where CD137 and PD-L1 are expressed on different cells, e.g., T cells and tumor cells, respectively.
[0028] Antibody molecules can bind to CD137 and PD-L1 simultaneously, and therefore, where PD-L1 and CD137 are co-expressed, antibody binding to PD-L1 may result in cross-linking of the antibody molecules, leading to clustering and activation of bound CD137 on the T cell surface.
[0029] As shown by the present inventors, by reducing or inhibiting Fcγ receptor binding, the agonistic activity of the antibody molecule is dependent on the presence of both PD-L1 and CD137. In other words, the agonistic activity is conditional; therefore, the antibody molecule is expected to be able to activate immune cells only in locations where PD-L1 is present, such as the tumor microenvironment. This targeted activation of immune cells is expected to be beneficial in avoiding the liver inflammation seen with, for example, urelumab treatment.
[0030] Indeed, the present inventors demonstrate that antibody molecules having the above characteristics do not exhibit severe hepatotoxicity when administered to mouse models at therapeutic doses. Minimal liver lesions were observed in mice administered these antibody molecules, which was not considered to represent the severe hepatotoxicity previously reported for other anti-CD137 agonist antibodies. Preliminary studies in cynomolgus monkeys also demonstrated that the antibody molecules were safe and well tolerated up to 30 mg / kg. Without wishing to be bound by theory, the results from these animal models can be translated to clinical use in predicting the risk of hepatotoxicity in human patients. Therefore, it is expected that the antibody molecules of the present invention will have a low risk of inducing hepatotoxicity in human patients treated at therapeutic doses.
[0031] The present inventors also provide in vitro evidence that the level of CD137 agonist activity induced by the antibody molecules correlates with the amount of PD-L1 expression on the cell surface. The present inventors demonstrate that the antibody molecules can agonize CD137 even when the level of PD-L1 expression is low, and that CD137 agonist activity increases as the level of PD-L1 in the system increases. These results further support the evidence that CD137 agonist activity is dependent on PD-L1 expression and suggest that the antibody molecules of the present invention have a broad range of activity against tumors expressing various levels of PD-L1 on the tumor cell surface.
[0032] The above-described PD-L1 CDR-based binding site can efficiently block the binding of PD-L1 to its receptor PD-1. PD-1 is expressed on activated T cells, B cells, and myeloid cells and regulates the activation or inhibition of cellular immune responses. When PD-L1 binds to PD-1, an inhibitory signal is transmitted, reducing cytokine production and T cell proliferation, thereby weakening the immune response. In cancer, the interaction between PD-L1 on tumor cells and PD-1 on T cells reduces T cell activity and prevents the immune system from attacking tumor cells. Therefore, by blocking the binding of PD-L1 to PD-1, the antibody molecule of the present invention is expected to be able to prevent tumor cells from evading the immune system in this way. Without wishing to be bound by theory, it is believed that this efficient blockade of PD-L1 binding to PD-1 works together with the above-described CD137 agonist activity to increase the anti-tumor efficacy of the antibody molecule.
[0033] The present inventors have also shown that such bispecific antibody molecules comprising the above-described CD137 antigen-binding site and a CDR-based binding site for PD-L1 can inhibit tumor growth in vivo. Furthermore, compared with the combination of two monospecific antibody molecules, one of which contains the CDR-based antigen-binding site for PD-L1 and the other of which contains the CDR-based antigen-binding site for CD137, more effective tumor growth inhibition was observed with the bispecific antibody molecule. This demonstrates that enhanced clustering and signaling of CD137, and thus T cell activation and corresponding anti-tumor effects, are observed with the antibody molecules of the present invention.
[0034] Antibody molecules comprising a CD137 antigen-binding site of the present invention may further be capable of bivalently binding to PD-L1, such that the antibody molecule bivalently binds to both CD137 and PD-L1. This is expected to be advantageous because bivalent binding of both targets is expected to more stable bridges between CD137-expressing T cells and PD-L1-expressing cells, thereby extending the time that T cells localize to sites where PD-L1 co-expresses with CD137, such as in the tumor microenvironment, and can act on disease, e.g., tumors. This differs from most conventional bispecific antibody formats, which are heterodimers and bind each target antigen monovalently via one Fab arm. Such monovalent interactions not only have lower stability but also are less efficient at inducing clustering of TNF receptors, such as CD137, and / or are less effective at inhibiting such clustering and / or inhibiting the proliferation of TNF receptors. It is expected that higher expression of one or both targets will be required to induce T cell activation in some cases. This is due to the fact that mAbs contain a bivalent Fab binding site for PD-L1 and a monovalent binding site for CD137 in one of the CH3 domains of the molecule. 2 mAb, a molecule that binds bivalently to both targets 2 This is supported by experiments performed by the inventors showing that it induces lower levels of T cell activation as measured by IFNγ release.
[0035] A further feature of the antibody molecule identified by the present inventors is that both the antigen-binding site of CD137 and the CDR-based binding site of PD-L1 are contained within the antibody structure itself. Notably, the antibody molecule does not require the fusion of other proteins to the antibody molecule via a linker or other means to result in a molecule that bivalently binds to both of its targets. This has many advantages. Specifically, because the antibody molecules do not contain additional fusion moieties, they can be produced using methods similar to those used to produce standard antibodies. This structure is also expected to lead to improved antibody stability, as linkers can degrade over time, resulting in a heterogeneous population of antibody molecules. In such a heterogeneous population, antibodies within the population that are fused to only one protein and therefore only monovalently bind to one target are not expected to induce conditional agonism of TNF receptors such as CD137 as efficiently as antibodies fused to two proteins that can bivalently bind to both targets. Cleavage / degradation of the linker can occur before or after administration of the therapeutic agent to a patient (e.g., via enzymatic cleavage or the patient's in vivo pH), thereby reducing its efficacy while circulating in the patient. Because the antibody molecules of the present invention lack a linker, the antibody molecule is expected to retain the same number of binding sites both before and after administration. Furthermore, the structure of the antibody molecule is also preferable from the standpoint of the immunogenicity of the molecule, because the introduction of a fusion protein or a linker, or both, can induce immunogenicity when the molecule is administered to a patient, resulting in reduced efficacy of the therapeutic agent.
[0036] Thus, the present invention provides the following:
[0037] [1] (a) a complementarity-determining region (CDR)-based antigen-binding site of PD-L1; and (b) CD137 antigen-binding site located in the CH3 domain of the antibody molecule and the CDR-based antigen binding site comprises (i) SEQ ID NOs: 1, 2, 3, 4, 5 and 6 [E12v2], respectively; (ii) SEQ ID NOs: 1, 2, 3, 18, 19 and 20 [E05v2], respectively; or (iii) SEQ ID NOs: 1, 2, 3, 18, 19 and 29 [G12v2], respectively and a CD137 antigen-binding site comprising a first sequence and a second sequence located in the AB, CD, and EF structural loops of the CH3 domain, respectively, wherein the first and second sequences have the sequences set forth in SEQ ID NOs: 113 and 114 [FS22-172-003], or 79 and 80 [FS22-53-008], respectively. Antibody molecules that bind to 137.
[0038] [2] (a) a complementarity-determining region (CDR)-based antigen-binding site of PD-L1; and (b) CD137 antigen-binding site located in the CH3 domain of the antibody molecule and the CDR-based antigen binding site comprises (i) SEQ ID NOs: 7, 8, 9, 10, 11 and 6 [E12v2], respectively; (ii) SEQ ID NOs: 21, 8, 9, 22, 11, and 20 [E05v2], respectively; or (iii) SEQ ID NOs: 21, 8, 9, 22, 11, and 29 [G12v2], respectively and the CD137 antigen binding site comprises a first sequence and a second sequence located in the AB, CD, and EF structural loops of the CH3 domain, respectively. and the first and second sequences have the sequences set forth in SEQ ID NOs: 113 and 114 [FS22-172-003], or 79 and 80 [FS22-53-008], respectively. L1) and an antibody molecule that binds to CD137.
[0039] [3] The antibody molecule according to [1] or [2], which comprises CDRs 1 to 6 according to (i) or (ii) of [1] or [2].
[0040] [4] The antibody molecule according to [1] or [2], which comprises CDRs 1 to 6 according to (i) of [1] or [2].
[0041] [5] The antibody molecule according to any one of [1] to [4], wherein the antibody molecule comprises a heavy chain variable (VH) domain and / or a light chain variable (VL) domain, preferably a VH domain and a VH domain.
[0042] [6] The antibody molecule according to any one of [1] to [5], wherein the antibody molecule comprises an immunoglobulin heavy chain and / or an immunoglobulin light chain, preferably an immunoglobulin heavy chain and an immunoglobulin light chain.
[0043] [7] The antibody molecule comprises a VH domain and / or a VL domain, and preferably the VH domain and the VL domain are: (i) SEQ ID NOs: 12 and 14 [E12v2], respectively; (ii) SEQ ID NOs: 23 and 25 [E05v2], respectively; or (iii) SEQ ID NOs: 23 and 30 [G12v2], respectively The antibody molecule according to any one of [5] to [6], which is described in
[0044] [8] The antibody molecule according to [7], which comprises the VH domain and VL domain described in (i) or (ii).
[0045] [9] The antibody molecule according to [8], which comprises the VH domain and VL domain described in (i).
[0046]
[10] The antibody molecule of any one of [1] to [9], wherein the first sequence is located between positions 14 and 17 of the CH3 domain of the antibody molecule, and the numbering of amino acid residues is according to the IMGT numbering scheme.
[0047]
[11] The antibody molecule of
[10] , wherein the first sequence is located at positions 15, 16, 16.5, 16.4, 16.3, 16.2, and 16.1 of the CH3 domain of the antibody molecule, and the numbering of amino acid residues is according to the IMGT numbering scheme.
[0048]
[12] The antibody molecule of any one of [1] to
[11] , wherein the second sequence is located at positions 92 to 98 of the CH3 domain of the antibody molecule, and the numbering of amino acid residues is according to the IMGT numbering scheme.
[0049]
[13] The antibody molecule of any one of [1] to
[12] , further comprising a third sequence located in the CD structure loop of the CH3 domain.
[0050]
[14] The antibody molecule of
[13] , wherein the third sequence is located at positions 43 to 78 of the CH3 domain of the antibody molecule, and the numbering of amino acid residues is according to the IMGT numbering scheme.
[0051]
[15] The method according to
[13] to
[14] , wherein the third sequence has the sequence set forth in SEQ ID NO: 73. The antibody molecule of any one of claims 1 to 4.
[0052]
[16] The antibody molecule (i) SEQ ID NO: 115 [FS22-172-003]; or (ii) SEQ ID NO: 81 [FS22-53-008] An antibody molecule described in any one of [1] to
[15] , which comprises a CH3 domain sequence described in
[0053]
[17] The antibody molecule of any one of [1] to
[15] , wherein the first and second sequences have the sequences set forth in SEQ ID NOs: 113 and 114 [FS22-172-003], respectively.
[0054]
[18] The antibody molecule according to any one of [1] to
[15] and
[17] , wherein the antibody molecule comprises the CH3 domain sequence [FS22-172-003] set forth in SEQ ID NO: 115.
[0055]
[19] The antibody molecule according to any one of [1] to
[18] , wherein the antibody molecule is a human IgG1 molecule.
[0056]
[20] The antibody molecule is an antibody: (i) FS22-172-003-AA / E12v2 set forth in SEQ ID NOs: 134 and 17, respectively; (ii) FS22-172-003-AA / E05v2 set forth in SEQ ID NOs: 137 and 28, respectively; (iii) FS22-172-003-AA / G12v2 set forth in SEQ ID NOs: 140 and 33, respectively; (iv) FS22-053-008-AA / E12v2 set forth in SEQ ID NOs: 143 and 17, respectively; (v) FS22-053-008-AA / E05v2 set forth in SEQ ID NOs: 146 and 28, respectively; or (vi) FS22-053-008-AA / G12v2 set forth in SEQ ID NOs: 149 and 33, respectively The antibody molecule according to any one of [1] to
[19] , comprising a heavy chain and a light chain of
[0057]
[21] The antibody molecule according to
[20] , comprising a light chain and a heavy chain according to any one of (i) to (iv) of
[20] .
[0058]
[22] The antibody molecule according to
[20] , comprising the light chain and heavy chain according to (i) of
[20] .
[0059]
[23] An antibody molecule described in any one of
[20] to
[22] , wherein the proline (P) at position 114 in the CH2 domain of the antibody is substituted with alanine (A), and the numbering of amino acid residues is according to the IMGT numbering scheme.
[0060]
[24] The antibody molecule of any one of [1] to
[23] , wherein the antibody molecule binds to human PD-L1 and human CD137.
[0061]
[25] The antibody molecule of
[24] , wherein PD-L1 consists of or comprises the sequence set forth in SEQ ID NO: 180.
[0062]
[26] The antibody molecule according to
[24] or
[25] , wherein the human CD137 consists of or comprises the sequence set forth in SEQ ID NO: 186.
[0063]
[27] The antibody molecule of any one of [1] to
[26] , wherein the antibody molecule is capable of activating CD137 on immune cells in the presence of PD-L1 bound to the surface of cancer cells.
[0064]
[28] An antibody molecule described in any one of [1] to
[0026] , wherein binding of the antibody molecule to CD137 on immune cells and to PD-L1 bound to the surface of tumor cells causes clustering of CD137 on the immune cells.
[0065]
[29] The antibody molecule according to
[27] or
[28] , wherein the immune cell is a T cell, a B cell, a natural killer (NK) cell, a natural killer T (NKT) cell, or a dendritic cell (DC).
[0066]
[30] The antibody molecule of claim
[29] , wherein the immune cell is a T cell.
[0067]
[31] The antibody molecule of any one of [1] to
[30] , wherein the antibody molecule is modified to reduce or inhibit binding of the CH2 domain of the antibody molecule to one or more Fcγ receptors.
[0068]
[32] The antibody molecule of any one of [1] to
[31] , wherein the antibody molecule does not bind to one or more Fcγ receptors.
[0069]
[33] The antibody molecule according to
[31] or
[32] , wherein the Fcγ receptor is selected from the group consisting of FcγRI, FcγRIIa, FcγRIIb, and FcγRIII.
[0070]
[34] A conjugate comprising the antibody molecule according to any one of [1] to
[33] and a biologically active molecule.
[0071]
[35] A conjugate comprising the antibody molecule according to any one of [1] to
[33] and a detectable label.
[0072]
[36] One or more nucleic acid molecules encoding the antibody molecule described in any one of [1] to
[33] .
[0073]
[37] A nucleic acid molecule comprising: (i) FS22-172-003-AA / E12v2 as set forth in SEQ ID NOs: 32 and 39, or 135 and 136, respectively, preferably SEQ ID NOs: 32 and 39, respectively; (ii) FS22-172-003-AA / E05v2, as set forth in SEQ ID NOs: 138 and 139, respectively; (iii) FS22-172-003-AA / G12v2 set forth in SEQ ID NOs: 141 and 142, respectively; (iv) FS22-053-008-AA / E12v2 set forth in SEQ ID NOs: 144 and 145, respectively; (v) FS22-053-008-AA / E05v2 set forth in SEQ ID NOs: 147 and 148, respectively; or (vi) FS22-053-008-AA / G12v2 set forth in SEQ ID NOs: 150 and 151, respectively One or more nucleic acid molecules encoding the antibody molecule of any one of [1] to [2], [5] to [7],
[10] to
[16] ,
[19] to
[20] and
[23] to
[33] , comprising a heavy chain nucleic acid sequence and / or a light chain nucleic acid sequence.
[0074]
[38] One or more vectors comprising one or more nucleic acid molecules according to any one of
[36] to
[37] .
[0075]
[39] A recombinant host cell comprising one or more nucleic acid molecules according to any one of
[36] to
[37] , or one or more vectors according to
[38] .
[0076]
[40] A method for producing the antibody molecule of any one of [1] to
[33] , comprising culturing the recombinant host cell of
[39] under conditions for producing the antibody molecule.
[0077]
[41] The method of
[40] , further comprising isolating and / or purifying the antibody molecule.
[0078]
[42] A pharmaceutical composition comprising the antibody molecule or conjugate according to any one of [1] to
[35] and a pharmaceutically acceptable excipient.
[0079]
[43] The antibody molecule or conjugate of any one of [1] to
[35] for use in a method for treating cancer in an individual.
[0080]
[44] A method for treating cancer in an individual, comprising administering to the individual a therapeutically effective amount of the antibody molecule or conjugate described in any one of [1] to
[35] .
[0081]
[45] Use of the antibody molecule or conjugate according to any one of [1] to
[35] in the preparation of a medicament for the treatment of cancer.
[0082]
[46] The antibody molecule or conjugate for use, method, or use according to any one of
[43] to
[45] , wherein the cancer is selected from the list consisting of melanoma, bladder cancer, brain cancer, breast cancer, ovarian cancer, lung cancer, colorectal cancer, cervical cancer, liver cancer, head and neck cancer, pancreatic cancer, renal cancer, gastric cancer, and gastrointestinal stromal tumor (GIST).
[0083]
[47] The antibody molecule or conjugate for use according to
[43] , wherein treatment comprises administering to the individual the antibody molecule or conjugate in combination with a second therapeutic agent.
[0084]
[48] The method of
[44] , wherein the method further comprises administering to the individual a therapeutically effective amount of a second treatment. [Brief explanation of the drawings]
[0085] BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1A] FIG. 1A shows an alignment of the sequences of the CH3 domains of Fcabs FS22-053, FS22-053-008, FS22-053-009, FS22-053-010, FS22-053-011, FS22-053-012, FS22-053-013, FS22-053-014, FS22-053-015, FS22-053-016, FS22-053-017, FS22-172, FS22-172-001, FS22-172-002, FS22-172-003, FS22-172-004, FS22-172-005 and FS22-172-006, and wild-type (WT) Fcabs. Residue numbers according to the IMGT, IMGT exon (consecutive numbering), EU and Kabat numbering systems are indicated. [Figure 1B] Figure 1B shows an alignment of the sequences of the CH3 domains of Fcabs FS22-053, FS22-053-008, FS22-053-009, FS22-053-010, FS22-053-011, FS22-053-012, FS22-053-013, FS22-053-014, FS22-053-015, FS22-053-016, FS22-053-017, FS22-172, FS22-172-001, FS22-172-002, FS22-172-003, FS22-172-004, FS22-172-005 and FS22-172-006, and wild-type (WT) Fcabs. Residue numbers according to the IMGT, IMGT exon (consecutive numbering), EU and Kabat numbering systems are indicated. [Figure 1C]Figure 1C shows an alignment of the sequences of the CH3 domains of Fcabs FS22-053, FS22-053-008, FS22-053-009, FS22-053-010, FS22-053-011, FS22-053-012, FS22-053-013, FS22-053-014, FS22-053-015, FS22-053-016, FS22-053-017, FS22-172, FS22-172-001, FS22-172-002, FS22-172-003, FS22-172-004, FS22-172-005 and FS22-172-006, and wild-type (WT) Fcabs. Residue numbers according to the IMGT, IMGT exon (consecutive numbering), EU and Kabat numbering systems are indicated. [Figure 2] Figure 2 shows that CD137 / PD-L1 mAb2 FS22-172-003-AA / E12v2 can bind to activated CD4+ (Figure 2A) and CD8+ (Figure 2B) T cells. Anti-human CD137 / PD-L1 mAb2 FS22-172-003-AA / E12v2 bound to activated T cells with EC50 values of 0.8 nM for CD8+ T cells and 0.9 nM for CD4+ T cells. The positive control anti-human PD-L1 antibody (G1-AA / E12v2) showed very similar affinity to mAb2 with an EC50 value of 0.8 nM for both cell types. The positive control anti-human CD137 antibody (G1-AA / MOR7480.1) showed low binding to CD4+ and CD8+ cells, indicating low levels of CD137 expression on these cell types. [Figure 3]Figure 3 shows that anti-human CD137 / PD-L1 mAb2 FS22-172-003-AA / E12v2 does not bind to CHO cells overexpressing Fcγ receptors. Anti-human CD137 / PD-L1 mAb2 FS22-172-003-AA / E12v2, a positive control antibody for Fcγ receptor binding, G1 / 4420, and a negative control antibody without Fcγ receptor binding, G1-AA / 4420, were tested in a cell-binding assay against CHO cell lines overexpressing five different Fcγ receptors ((A) FcgRIIA 131H, (B) FcgRIIA 131E, (C) FcgRIIB, (D) FcgRIIIA 158F, (E) FcgRIIIA 158V, and (F) a CHO WT cell line used as a negative control). Anti-human CD137 / PD-L1 mAb2, which contains the LALA mutation in its CH2 region, did not bind to any of the Fcγ receptors tested and did not bind nonspecifically to CHO WT cells (solid black triangles). The positive control antibody bound to Fcγ receptors (solid black circles), and the negative control antibody G1-AA / 4420, which contains the LALA mutation in its CH2 region, did not bind to Fcγ receptors, as expected (open gray squares). [Figure 4] Figure 4 shows the release of human IL-2 (HIL-2) in a human primary CD8+ T cell activation assay in the presence of anti-human CD137 / PD-L1 mAb2 or the positive control anti-human CD137 antibody G1-AA / 20H4.9. All tested mAb2s drove CD137 clustering and CD8+ T cell activation only when mAb2 was cross-linked with HEK cells overexpressing human PD-L1, which resulted in the release of human IL-2. The EC50 value of anti-human CD137 / PD-L1 mAb2 was lower than that of the positive control anti-human CD137 antibody, G1-AA / 20H4.9, when cross-linked with an anti-human CH2 secondary antibody (solid black circles, dotted line). This indicates that improved T cell activation was achieved with mAb2. All showed increased hIL-2 release, with the positive control antibody having a greater IL-2 release (Emax) than anti-human CD137 / PD-L1 mAb2. [Figure 5]Figure 5 shows the release of human IL-2 (HIL-2) in a human primary CD8+ T cell activation assay in the presence of anti-human CD137 / PD-L1 mAb2 or the positive control anti-human CD137 antibody G1-AA / 20H4.9. All tested mAb2s drove CD137 clustering and CD8+ T cell activation only when mAb2 was cross-linked with MDA-MD-231, which endogenously expresses human PD-L1, resulting in the release of human IL-2. The EC50 value of anti-human CD137 / PD-L1 mAb2 was lower than that of the positive control anti-human CD137 antibody, G1-AA / 20H4.9, when cross-linked with the anti-human CH2 secondary antibody (solid circles, dotted line). This indicates that better activity was achieved with mAb2. All showed increased hIL-2 release, with the positive control antibody having a greater IL-2 release (Emax) than anti-human CD137 / PD-L1 mAb2. [Figure 6] Figure 6 shows the release of human IL-2 (HIL-2) in a human primary CD8+ T cell activation assay in the presence of anti-human CD137 / PD-L1 mAb2 FS22-172-003-AA / E12v2 or the positive control anti-human CD137 antibody G1-AA / 20H4.9. All mAb2s tested drove CD137 clustering and CD8+ T cell activation only when the mAb2 was crosslinked by HEK.hPD-L1 cells, which comprised at least 6.5% of the total HEK cell population, resulting in the release of human IL-2. The EC50 values of anti-human CD137 / PD-L1 mAb2s remained similar when adjusting for the percentage of HEK.hPD-L1 cells present in the assay, but maximal activation (Emax) increased in relation to increasing percentages of HEK.hPD-L1 crosslinked cells in the assay. This indicated that better maximal activity was achieved with mAb2 overall when 100% of HEK cells expressed PD-L1. [Figure 7]Figure 7 shows that anti-human CD137 / PD-L1 mAb2 can activate T cells. (A) and (B): IFN-γ release in a primary human mixed lymphocyte reaction (MLR) assay was tested in the presence of anti-human CD137 / PD-L1 mAb2, anti-human PD-L1 positive control antibody G1 / S70, or anti-human CD137 positive control antibody G1-AA / 20H4.9 (crosslinked with anti-human CH2 antibody). (A) FS22-053-008 Fcab-based mAb2 and (B) FS22-172-003 Fcab-based mAb2 showed greater activity in this assay than either positive control antibody, indicating that PD-L1 blockade and CD137 agonism within the same molecule induces greater T cell activation, likely through PD-L1-based clustering and activation of CD137. (C) IFN-γ release in an MLR assay was tested in the presence of anti-human CD137 / PD-L1 mAb2, anti-human PD-L1 antibody G1-AA / E12v2, anti-human CD137 positive control antibody G1-AA / 20H4.9 (crosslinked with anti-human CH2 antibody), or anti-human CD137 Fcab (FS22-172-003-AA / D1.3) in mock mAb2 format. FS22-172-003-AA / E12v2 mAb2 exhibited greater T cell activation activity in this assay than either the positive control antibody or its component Fcabs in mock mAb2 format, indicating that PD-L1 blockade and CD137 agonism within the same molecule induce greater T cell activation, likely through PD-L1-based crosslinking of CD137 leading to clustering and activation. [Figure 8]Figure 8 shows IL-2 release in a T cell activation assay, in which T cells were engineered to overexpress cynomolgus monkey CD137 in the presence of anti-human CD137 / PD-L1 mAb2 and the positive control anti-human CD137 antibody G1-AA / MOR7480.1. All mAb2s tested drove CD137 clustering and activation only when crosslinked with HEK cells overexpressing cynomolgus monkey PD-L1 (solid and hollow black and gray symbols and connecting dashes), resulting in the release of murine interleukin-2 (mIL-2) in a DO11.10 T cell activation assay. At increasing concentrations, a positive control anti-human CD137 antibody, G1-AA / MOR7480.1, previously shown by others to cross-react with cynomolgus monkey CD137, shows increased mIL-2 release (filled circles, dotted line), but the maximum release was significantly less than all anti-human CD137 / PD-L1 mAb2. All anti-human CD137 / PD-L1 mAb2 without PD-L1-overexpressing HEK cells for cross-linking show significantly lower mIL-2 release compared to cross-linked mAb2 (data not shown). [Figure 9] Figure 9 shows IL-2 release on day 2 (Figure 9A) or IFN-γ release on day 6 (Figure 9B) from cynomolgus CD4+ T cells cultured with allogeneic cynomolgus monocytes in the presence of titrations of anti-human CD137 / PD-L1 mAb2 FS22-053-008-AA / E12v2 or 172-003-AA / E12v2, or anti-human PD-L1 positive control antibody G1-AA / E12v2, or isotype control antibody G1-AA / HelD1.3. [Figure 10]Figure 10 shows mouse IL-2 release in a DO11.10 mouse CD137 T cell activation assay testing the mouse and human cross-reactive CD137 Fcabs FS22-053-014 and FS22-053-017 in mock mAb2 format when cross-linked with Protein L. FS22-053-014 and FS22-053-017, as well as the anti-mouse CD137 Fcab FS22m-063, all in the HelD1.3 mock mAb2 format, activated CD137 and released mIL-2 when cross-linked with Protein L. The positive control anti-mouse CD137 mAb, Lob12.3, showed increased mIL-2 release, as expected. All anti-CD137 Fcabs in mock mAb2 format without Protein L for cross-linking (dotted line) showed significantly reduced mIL-2 release compared to when cross-linked. FS22-053-017 was less active in this assay (8-fold worse EC50 compared to FS22-053-014), but still showed activity in the assay. [Figure 11] Figure 11 shows the release of mouse IFNγ, indicative of CD8+ T cell activation. Anti-mouse CD137 / PD-L1 mAb2 shows the greatest potency in this assay, compared to either positive control antibody against human CD137 or PD-L1, or the combination of the two. As expected, the FS22m-063-AA Fcab (FS22m-063-AA / HelD1.3) in mock mAb2 format does not show any activity. [Figure 12]Figure 12 shows tumor volume measurements of the CT26 syngeneic tumor model grown subcutaneously in Balb / c mice treated with G1-AA / 4420 (IgG control), G1 / S70 (PD-L1 positive control), G1-AA / Lob12.3 and G1 / Lob12.3 (CD137 positive controls with and without the LALA mutation), a combination of G1 / S70 plus G1-AA / Lob12.3, and FS22m-063-AA / S70 (anti-mouse CD137 Fcab FS22m-063 in a model PD-L1 mAb2 format). Mean tumor volumes plus or minus the 95% confidence interval are plotted. FS22m-063-AA / S70 significantly reduced tumor growth in the CT26 syngeneic tumor model compared to mice treated with the IgG control and the anti-PD-L1 positive control mAb. Statistical significance is shown for pairwise growth rates over the course of the study using mixed model analysis. Mean tumor volumes are presented as geometric or arithmetic means, as appropriate, based on data normality tests. *P≦0.05; **P≦0.01; ***P≦0.001; ****P≦0.0001. [Figure 13]Figure 13 shows the results of a dose-response study of anti-mouse CD137 / PD-L1 mAb2 in the CT26 syngeneic mouse tumor model. A: Tumor volume measurements from the CT26 syngeneic tumor model grown subcutaneously in Balb / c mice treated with three doses of G1-AA / 4420 (IgG control, 10 mg / kg), G1 / Lob12.3 (CD137 positive control, 1 mg / kg), and four different doses (0.1 mg / kg, 0.3 mg / kg, 1.0 mg / kg, and 10.0 mg / kg) of anti-mouse CD137 / PD-L1 mAb2 FS22m-063-AA / S70. Each dose is indicated by a vertical black arrow on the x-axis. The mean tumor volume plus or minus the 95% confidence interval is plotted. FS22m-063-AA / S70 significantly reduces tumor growth in the CT26 syngeneic tumor model compared to mice treated with an IgG control and an anti-PD-L1 positive control mAb. Statistical significance is shown for paired growth rates over the course of the study using mixed-model analysis. Mean tumor volumes are presented as geometric or arithmetic means, as appropriate, based on data normality tests. **P≦0.01; *** ****P≦0.0001. B: Kaplan-Meier plot of the CT26 syngeneic tumor model grown subcutaneously in Balb / c mice treated with three doses of G1-AA / 4420 (IgG control, approximately 10 mg / kg) and four different doses of the anti-mouse CD137 / PD-L1 mAb2 FS22m-063-AA / S70 at 2 μg, 6 μg, 20 μg, and 200 μg (equivalent to approximately 0.1 mg / kg, 0.3 mg / kg, 1.0 mg / kg, and 10.0 mg / kg). FS22m-063-AA / S70 induces a dose-dependent increase in survival in the CT26 syngeneic tumor model compared to mice treated with the IgG control. [Figure 14] Figure 14 shows the dose-dependent increase in CD8+:CD4+ percentage ratios in tumors and blood of mice treated with q2dx3 anti-mouse CD137 / PD-L1 mAb2 FS22m-063-AA / S70 at four different dose levels, shown in panels A and B, and Ki67 expression on CD8+ T cells, shown in panels C and D. [Figure 15]Figure 15 shows tumor volume measurements of the MC38 syngeneic tumor model grown subcutaneously in C57BL / 6 mice treated with G1-AA / 4420 (isotype control), G1-AA / S70 (PD-L1 positive control), G1-AA / Lob12.3 (CD137 positive control), the combination of G1-AA / S70 plus G1-AA / Lob12.3, and FS22m-063-AA / S70 (anti-mouse CD137 Fcab FS22m-063 in model PD-L1 mAb2 format). Mean tumor volume [mm3] plus or minus the 95% confidence interval is plotted. FS22m-063-AA / S70 significantly reduced tumor growth in the MC38 syngeneic tumor model compared to mice treated with the IgG control, the anti-PD-L1 positive control mAb, and the anti-CD137 positive control. Statistical significance is shown pairwise for growth rate over time of the study using mixed model analysis. ****≦0.0001 p-value. [Figure 16] Figure 16 shows tumor volume measurements in the B16.F10 syngeneic tumor model grown subcutaneously in C57BL / 6 mice treated with G1-AA / 4420 (isotype control) and the anti-mouse CD137 / PD-L1 mAb2 FS22m-063-AA / S70. Both compositions were administered at 1 mg / kg. Mean tumor volume [mm3] plus or minus the 95% confidence interval is plotted. FS22m-063-AA / S70 treatment significantly reduced local tumor growth in the B16.F10 syngeneic tumor model compared to mice treated with the IgG control. Statistical significance is shown for paired growth rates over the entire study time period using mixed model analysis. Mean tumor volumes are presented as geometric or arithmetic means, as appropriate, based on a test for data normality. *P≦0.05; **P≦0.01; ***P≦0.001; ****P≦0.0001. [Figure 17]Figure 17 shows spaghetti plots of individual mice in the CT26 syngeneic tumor model grown subcutaneously in Balb / c mice treated with (A) G1-AA / 4420 (IgG control), (C) G1 / S70 (PD-L1 positive control), (B) G1-AA / Lob12.3 and (D) G1 / Lob12.3 (anti-CD137 positive controls with and without the LALA mutation), or (E) the combination of G1 / S70 plus G1-AA / Lob12.3 and (F) FS22m-063-AA / S70 (anti-mouse CD137 Fcab FS22m-063 in a model PD-L1 mAb2 format). FS22m-063-AA / S70 induced significant tumor growth inhibition in the CT26 syngeneic tumor model compared to mice treated with the IgG control. [Figure 18] Figure 18 shows a Kaplan-Meier plot of the CT26 syngeneic tumor model grown subcutaneously in Balb / c mice treated with G1-AA / 4420 (IgG control), the combination of G1 / S70 plus G1-AA / Lob12.3, and FS22m-063-AA / S70 (anti-mouse CD137 Fcab FS22m-063 in model PD-L1 mAb2 format), all at 1 mg / kg. FS22m-063-AA / S70 induced significant survival in the CT26 syngeneic tumor model compared to mice treated with the IgG control. [Figure 19]Figure 19 shows tumor volume measurements of the CT26 syngeneic tumor model grown subcutaneously in Balb / c mice treated with G1-AA / HelD1.3 (IgG control), G1 / S70 (anti-PD-L1 positive control), G1-AA / Lob12.3 (anti-CD137 positive control), and FS22m-063-AA / S70 (anti-mouse CD137 Fcab FS22m-063 in model PD-L1 mAb2 format). Mean tumor volumes plus or minus the 95% confidence interval are plotted. FS22m-063-AA / S70 was able to significantly reduce tumor growth in the CT26 syngeneic tumor model compared to mice treated with the IgG control, the anti-PD-L1 positive control mAb, and the anti-CD137 positive control. Statistical significance is shown pairwise for growth rate over the course of the study using mixed model analysis. Mean tumor volumes are presented as geometric or arithmetic means, as appropriate, based on tests for data normality. *P≦0.05; **P≦0.01; ***P≦0.001; ****P≦0.0001. [Figure 20] Figure 20 shows Kaplan-Meier plots of CT26 syngeneic tumor models grown subcutaneously in Balb / c mice treated with G1-AA / HelD1.3 (IgG control), G1 / S70 (anti-PD-L1 positive control), G1-AA / Lob12.3 (anti-CD137 positive control), and FS22m-063-AA / S70 (anti-mouse CD137 Fcab FS22m-063 in a model PD-L1 mAb2 format). FS22m-063-AA / S70 induces significant survival in the CT26 syngeneic tumor model compared to mice treated with the IgG control and the CD137 positive control. [Figure 21]Figure 21 shows spaghetti plots of individual mice in the MC38 syngeneic tumor model grown subcutaneously in C57BL / 6 mice treated with three doses of (A) G1-AA / 4420 (isotype control), (B) G1-AA / S70 (PD-L1 positive control), (C) G1-AA / Lob12.3 (anti-CD137 positive control), (D) the combination of G1-AA / S70 plus G1-AA / Lob12.3, and (E) FS22m-063-AA / S70 (anti-mouse CD137 Fcab FS22m-063 in a model PD-L1 mAb2 format). FS22m-063-AA / S70 induced complete tumor growth inhibition in the MC38 syngeneic tumor model, resulting in 100% tumor-free mice compared to mice treated with the IgG control. [Figure 22] Figure 22 shows a Kaplan-Meier plot of MC38 syngeneic tumor models grown subcutaneously in C57BL / 6 mice treated with three doses of G1-AA / 4420 (isotype control), G1-AA / S70 (anti-PD-L1 positive control), G1-AA / Lob12.3 (anti-CD137 positive control), a combination of G1-AA / S70 and G1-AA / Lob12.3, and FS22m-063-AA / S70 (anti-mouse CD137 Fcab FS22m-063 in a model PD-L1 mAb2 format). FS22m-063-AA / S70 induces complete survival in the MC38 syngeneic tumor model compared to mice treated with the IgG control. [Figure 23] Figure 23 shows spaghetti plots of individual mice in the B16.F10 syngeneic tumor model grown subcutaneously in C57BL / 6 mice treated with G1-AA / 4420 (isotype control) (Figure 23A) and the anti-mouse CD137 / PD-L1 mAb 2FS22m-063-AA / S70 (Figure 23B). FS22m-063-AA / S70 induced partial tumor growth inhibition in the B16.F10 syngeneic tumor model compared to mice treated with the IgG control. [Figure 24]Figure 24 shows anti-mCD137 / PD-L1 mAb2 binding data to T cells ex vivo as determined by flow cytometry. Mean fluorescence intensity (MFI) values were measured from an anti-human Fc secondary antibody conjugated to Alexa Fluor 488, which detects the human Fc region of cell-bound anti-mCD137 / PD-L1 mAb2. Positive cells with an MFI greater than that of the unstained control sample were identified as positive for anti-mCD137 / PD-L1, and the presented data show the positive population as a percentage of (A) all CD8+ or (B) all CD4+ T cells from blood, or (C) all CD8+ or (D) all CD4+ T cells from tumor. These results demonstrate that anti-mCD137 / PD-L1 mAb2 rapidly binds to both CD8+ and CD4+ T cells present in both tumor and blood, and that the percentage of the positive T cell population decreases over time depending on the dose level. [Figure 25] Figure 25 shows Ki67 expression data by ex vivo T cells as determined by flow cytometry. Mean fluorescence intensity (MFI) values were measured from cell-bound anti-Ki67 antibodies conjugated with PE-Cy7. Positive cells with an MFI greater than that of unstained control samples were identified as positive for Ki67 expression, and the presented data show the positive population as a percentage of (A) all CD8+ or (B) all CD4+ T cells from blood, or (C) all CD8+ or (D) all CD4+ T cells from tumors. These results demonstrate that T cells from mice treated with anti-mCD137 / PD-L1 mAb2 rapidly express Ki67 on both CD8+ and CD4+ T cells in the blood, and that a high percentage of Ki67-positive T cells is already present in samples from the tumor microenvironment. A dose-level-dependent increase in Ki67 expression over time was observed. [Figure 26]Figure 26 shows PD-L1 receptor occupancy compared to time-matched samples from mice administered the control antibody G1-AA / 4420 and spiked ex vivo with 100 nM anti-mCD137 / PD-L1 mAb2 to saturate all PD-L1 receptors, thus representing a 100% PD-L1 receptor occupancy level (triangle symbols and dashed line). Free PD-L1 receptor was detected using the mean fluorescence intensity (MFI) value of a competing anti-mPD-L1 antibody conjugated to Bv605. Positive cells with an MFI greater than the unstained control sample were identified as positive for free PD-L1. Results are shown as the percentage of PD-L1 receptor occupancy compared to 100% saturated samples of (A) CD8+ or (B) CD4+ T cells from blood, or (C) CD8+ or (D) CD4+ T cells from tumors. These results demonstrate that PD-L1 receptor occupancy rapidly reached 100% in the blood, followed by a dose-dependent decline over time. PD-L1 receptor occupancy on T cells was maintained longer in the tumor microenvironment than in the blood. [Figure 27] Figure 27 shows the pharmacokinetic profiles of anti-CD137 / PD-L1 mAb2 at 25, 10, 3, and 1 mg / kg following a single intravenous dose in naive C57BL / 6 mice. The concentration of CD137 / PD-L1 mAb2 in the mice over time is shown. Figure 27 demonstrates that the clearance rate of anti-CD137 / PD-L1 mAb2 at each dose is comparable to the clearance of standard human IgG in mice. [Figure 28]Figure 28 shows that anti-human CD137 / PD-L1 mAb2 FS22-172-003-AA / E12v2 can activate T cells in PBMC T cell activation assays using (A) cynomolgus monkey PBMCs or (B) human PBMCs. IFN-γ release in the PBMC assays was tested in the presence of anti-human CD137 / PD-L1 mAb2 and the anti-human CD137 positive control antibody G1-AA / MOR7480.1 (crosslinked with anti-human CH2 antibody). mAb2 was active in both assays, demonstrating higher activation levels than the positive control antibody. This indicates that PD-L1 blockade and CD137 agonism by the same molecule induces greater T cell activation in both cynomolgus monkeys and humans, likely through PD-L1-based clustering and activation of CD137. DETAILED DESCRIPTION OF THE INVENTION
[0086] Detailed Description Aspects and embodiments of the present invention will now be discussed with reference to the accompanying drawings. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.
[0087] The present invention relates to antibody molecules that bind to both PD-L1 and CD137. Specifically, the antibody molecules of the invention comprise a PD-L1 CDR-based antigen-binding site and a CD137 antigen-binding site located in the constant domain of the antibody molecule. The terms "PD-L1" and "CD137" may refer to human PD-L1 and human CD137, mouse PD-L1 and mouse CD137, and / or cynomolgus PD-L1 and cynomolgus CD137, unless the context requires otherwise. Preferably, the terms "PD-L1" and "CD137" refer to human PD-L1 and human CD137, unless the context requires otherwise.
[0088] The term "antibody molecule" describes an immunoglobulin, whether natural or partially or wholly synthetically produced. The antibody molecule may be human or humanized, preferably human. The antibody molecule is preferably a monoclonal antibody molecule. Examples of antibodies are immunoglobulin isotypes such as immunoglobulin G, and their isotypic subclasses such as IgG1, IgG2, IgG3, and IgG4, and fragments thereof. The antibody molecule may be isolated, in the sense that it is free of contaminants, such as antibodies capable of binding to other polypeptides and / or serum components.
[0089] Thus, the term "antibody molecule" as used herein includes antibody fragments, wherein said fragments comprise the CDR-based antigen-binding site of PD-L1 and the CD137 antigen-binding site located in the constant domain. Thus, unless the context requires otherwise, the term "antibody molecule" as used herein is equivalent to "antibody molecule or fragment thereof."
[0090] With monoclonal and other antibodies, recombinant DNA technology techniques can be used to produce other antibodies or chimeric molecules that retain the specificity of the original antibody. Such techniques can involve transferring CDRs, or variable regions, and / or constant domain sequences that provide the CD137 antigen-binding site, into a different immunoglobulin. Transfer of CDRs from one immunoglobulin into another is described, for example, in EP-A-184187, GB-A-2188638A, or EP-A-239400. Similar techniques can be used for related constant domain sequences. Alternatively, hybridomas or other cells that produce antibody molecules can be subjected to genetic mutations or other changes that may or may not alter the binding specificity of the antibody produced.
[0091] Because antibodies can be modified in many ways, the term "antibody molecule" should be interpreted as covering antibody fragments, derivatives, functional equivalents, and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or wholly or partially synthetic. Chimeric molecules comprising an immunoglobulin binding domain or equivalent fused to another polypeptide are therefore included. Cloning and expression of chimeric antibodies are described in EP-A-0120694 and EP-A-0125023.
[0092] An example of an antibody fragment containing both CDR sequences and a CH3 domain is a minibody containing an scFv linked to a CH3 domain (Hu et al. (1996), Cancer Res., 56(13):3055-61).
[0093] The antibody molecules of the invention bind to PD-L1 and CD137. Binding in this context may refer to specific binding. The term "specific" may refer to a situation in which an antibody molecule does not exhibit significant binding to molecules other than its specific binding partners (here, PD-L1 and CD137). The term "specific" may also apply when the antibody molecule is specific for a particular epitope carried by several antigens, such as an epitope on PD-L1 and CD137, in which case the antibody molecule can bind to a variety of antigens bearing the epitope.
[0094] The inventors have demonstrated that the antibody molecules described herein exhibit a high level of specificity for human PD-L1 and do not exhibit significant binding to other T cell targets PD-L1, CD80, PD-1, or B7-H3 (see Example 9.3). Thus, in a preferred embodiment, the antibody molecule does not bind to, or exhibits no significant binding to, any one, preferably all, of PD-L2, CD80, PD-1, and B7-H3. The inventors have also demonstrated that the CD137 antigen-binding site does not exhibit significant binding to the human TNFRSF receptors CD40, OX40, and GITR (see Example 3.6). Thus, in a more preferred embodiment, the antibody molecule does not bind to, or exhibits no significant binding to, any one, preferably all, of PD-L2, CD80, PD-1, B7-H3, CD40, OX40, and GITR.
[0095] Antibodies and methods for their construction and use are well known in the art and are described, for example, in Holliger & Hudson (2005). With monoclonal and other antibodies, techniques of recombinant DNA technology can be used to produce other antibodies or chimeric molecules that retain the specificity of the original antibody. Such techniques can involve transferring the CDRs or variable regions of one antibody molecule into a different antibody molecule (European Patent Application Publication No. A-184187, British Patent Application Publication No. 2188638A, and European Patent Application Publication No. A-239400).
[0096] A CDR-based antigen-binding site is an antigen-binding site of an antibody variable region. A CDR-based antigen-binding site can be formed by three CDRs, such as three light chain variable domain (VL) CDRs or three heavy chain variable domain (VH) CDRs. Preferably, a CDR-based antigen-binding site is formed by six CDRs, three VL CDRs and three VH CDRs. The contribution of different CDRs to antigen binding can vary among different antigen-binding sites.
[0097] The three VH domain CDRs of an antigen-binding site can be located within an immunoglobulin VH domain, and the three VL domain CDRs can be located within an immunoglobulin VL domain. For example, a CDR-based antigen-binding site can be located in an antibody variable region.
[0098] An antibody molecule may have one, or preferably more than one, e.g., two CDR-based antigen-binding sites for a first antigen. Thus, an antibody molecule may comprise one VH and one VL domain, but preferably comprises two VH and two VL domains, i.e., two VH / VL domain pairs, as in, for example, naturally occurring IgG molecules.
[0099] The CDR-based antigen binding site is derived from antibody E12v2, E05v2, G12v2, or lam-G02v3, preferably antibody E12v2, E05v2, or G12v2, more preferably E12v2 or E05v2, most preferably , three VH CDRs or three VL CDRs, preferably three VH CDRs, of E12v2 It may comprise a R and three VL CDRs.
[0100] The VH and VL domain sequences of these antibodies are listed as follows: (i) The VH and VL domain sequences of antibody E12v2 are shown in SEQ ID NOs: 12 and 14, respectively. Re; (ii) The VH and VL domain sequences of antibody E05v2 are shown in SEQ ID NOs: 23 and 25, respectively. be; (iii) The VH and VL domain sequences of antibody G12v2 are set forth in SEQ ID NOs: 23 and 30, respectively. Shown; (iv) The VH and VL domain sequences of antibody lam-G02v3 are SEQ ID NOs: 23 and 41, respectively. As shown in.
[0101] Those skilled in the art will have no difficulty in determining the CDR sequences from the VH and VL domain sequences of the above antibodies. CDR sequences can be obtained, for example, from Kabat (Kabat, EA et al. (1991). Sequences of Proteins of Immunological Interest, 5th edition, NIH Publication no. 91-3242. US Department of Health and Human Services) or the international ImMunoGeneTics information system (IMGT: Lefranc, M.-P. et al. Nucleic Acids Res. 43, D413-22 (2015)). ) can be determined according to
[0102] The VH domain CDR1, CDR2 and CDR3 sequences of an antibody molecule according to Kabat numbering are , and sequences located at positions 31 to 35, 50 to 65, and 95 to 102 of the VH domain, respectively.
[0103] The VH domain CDR1, CDR2, and CDR3 sequences of an antibody molecule according to the IMGT numbering system may be sequences located at positions 27 to 38, 56 to 65, and 105 to 117, respectively, of the VH domain of the antibody molecule.
[0104] The VL domain CDR1, CDR2 and CDR3 sequences of the antibody molecule according to Kabat numbering are , and sequences located at positions 24 to 34, 50 to 56, and 89 to 97 of the VL domain, respectively.
[0105] The VL domain CDR1, CDR2, and CDR3 sequences of an antibody molecule according to the IMGT numbering system may be sequences located at positions 27 to 38, 56 to 65, and 105 to 117 of the VL domain, respectively.
[0106] The antibody molecule may comprise the sequence of a VH domain CDR1 of SYGIS (SEQ ID NO: 1), a VH domain CDR2 of WISAYSGGTNYAQKLQG (SEQ ID NO: 2), and a VH domain CDR3 of DLFPTIFGVSYYYY (SEQ ID NO: 3), where the CDR sequences are defined according to the Kabat numbering scheme.
[0107] In a preferred embodiment, the antibody molecule contains a polypeptide at position 28 according to the Kabat numbering scheme. Contains phosphorus.
[0108] The antibody molecule may comprise the sequence of a VH domain CDR1 of GYX1FTSYG (SEQ ID NO: 45), a VH domain CDR2 of ISAYSGGT (SEQ ID NO: 8), and a VH domain CDR3 of ARDLFPTIFGVSYYYY (SEQ ID NO: 9); wherein X1 is P or T, preferably X1 is P; Here, the CDR sequences are defined according to the IMGT numbering scheme.
[0109] The antibody molecule is (i) SEQ ID NOs: 7, 8, and 9 [E12v2], respectively; or (ii) SEQ ID NOs: 21, 8, and 9 [E05v2, G12v2, or lam-G02v3], respectively; and the VH domain CDR1, CDR2 and CDR3 sequences of Here, the CDR sequences are defined according to the IMGT numbering scheme.
[0110] The CDRs of the VH domain may be flanked by framework (FW) sequences (HFW1, HFW2, HFW3, and HFW4). The VH domain may comprise the HFW1, HFW2, HFW3, and HFW4 sequences of SEQ ID NOs: 51, 52, 53, and 54, respectively, where the FW and CDR sequences are defined according to the Kabat numbering scheme. Alternatively, the VH domain may comprise The HFW1, HFW2, HFW3 and HFW4 sequences may be those of SEQ ID NOs: 55, 56, 57 and 54, respectively, where the FW and CDR sequences are defined according to the IMGT numbering scheme.
[0111] The antibody molecule may comprise the sequences of the VL domain CDR1 of TGTSSDVGGYNYVS (SEQ ID NO: 34), the VL CDR2 of EVTNRPS (SEQ ID NO: 35), and the VL CDR3 of SSFKRGSTLVV (SEQ ID NO: 36), where the CDR sequences are represented by the Kabat numbering system. The VL domain can be derived from a lambda VL domain. For example, each VL domain CDR can be flanked by framework (FW) sequences (LFW1, LFW2, LFW3, and LFW4) derived from a lambda VL domain. Specifically, the VL domain can comprise the LFW1, LFW2, LFW3, and LFW4 sequences of SEQ ID NOs: 65, 66, 67, and 68, respectively, where the FW sequences are defined according to the Kabat numbering scheme. do.
[0112] The antibody molecule may comprise the sequences of the VL domain CDR1 of RASQSIX2X3RLA (SEQ ID NO: 46), the VL CDR2 of EASX4X5EX6 (SEQ ID NO: 47), and the VL CDR3 of QQSYSX7PX8X9T (SEQ ID NO: 48); wherein X2 is S or G, X3 is N or G; X4 is T or N; X5 is S or L; X6 is T or S; X7 is T or W; X8 is absent or R; X9 is Y, R, or V; wherein the numbering of CDR sequences and positions is defined according to the Kabat numbering scheme .
[0113] Preferably, the antibody molecule comprises the VH domain CDR1 of RASQSIGNRLA (SEQ ID NO: 4), the VL CDR2 of EASTSET (SEQ ID NO: 5), and the VL CDR3 of QQSYSTPYT (SEQ ID NO: 6). CDR3 (SEQ ID NO: 6), wherein the CDR sequences are in accordance with the Kabat numbering scheme. The VL domain may be derived from a kappa VL domain. For example, each VL domain CDR may be flanked by framework (FW) sequences (LFW1, LFW2, LFW3, and LFW4) derived from a kappa VL domain. Specifically, the VL domain may comprise the LFW1, LFW2, LFW3, and LFW4 sequences of SEQ ID NOs: 58, 59, 60, and 61, respectively, where the FW sequences are defined according to the Kabat numbering scheme.
[0114] For example, an antibody molecule may be (i) SEQ ID NOs: 4, 5 and 6 [E12v2], respectively; (ii) SEQ ID NOs: 18, 19 and 20 [E05v2], respectively; (iii) SEQ ID NOs: 18, 19, and 29 [G12v2], respectively; or (iv) SEQ ID NOs: 34, 35 and 36 [lam-G02v3], respectively; and the VL domains CDR1, CDR2 and CDR3 sequences of Herein, the CDR sequences are defined according to the Kabat numbering scheme.
[0115] The antibody molecule may comprise the sequences of VL domain CDR1 of SSDVGGYNY (SEQ ID NO: 37), VL CDR2 of EVT (SEQ ID NO: 38), and VL CDR3 of SSFKRGSTLVV (SEQ ID NO: 36), where the CDR sequences are defined according to the IMGT numbering scheme. The VL domain may be derived from a lambda VL domain. For example, each VL domain CDR may comprise a framework (FW) sequence (LFW1, LFW2) from a lambda VL domain. Specifically, the VL domain may comprise the LFW1, LFW2, LFW3, and LFW4 sequences of SEQ ID NOs: 69, 70, 71, and 68, respectively, where the FW sequences are defined according to the IMGT numbering scheme.
[0116] Alternatively, the antibody molecule may be QSIX 10 X 11VL domain CDR1 of R (SEQ ID NO: 49), VL CDR2 of EAS (SEQ ID NO: 11), and QQSYSX 12 X 13 X 14 X 15 and the sequence of the VL CDR3 of T (SEQ ID NO: 50), where X 10 is G or S; X 11 is N or G; X 12 is absent or T; X 13 is T, W or P; X 14 is P or R; X 15 is Y or R, Here, the numbering of the CDR sequences and positions is defined according to the IMGT numbering scheme.
[0117] Preferably, the antibody molecule comprises the sequences of VH domain CDR1 of QSIGNR (SEQ ID NO: 10), VL CDR2 of EAS (SEQ ID NO: 11), and VL CDR3 of QQSYSTPYT (SEQ ID NO: 6), where the CDR sequences are defined according to the IMGT numbering scheme. The VL domain may be derived from a kappa VL domain. For example, each VL domain CDR may be flanked by framework (FW) sequences (LFW1, LFW2, LFW3, and LFW4) derived from a kappa VL domain. Specifically, the VL domain may comprise the LFW1, LFW2, LFW3, and LFW4 sequences of SEQ ID NOs: 62, 63, 64, and 61, respectively, where the FW sequences are defined according to the IMGT numbering scheme.
[0118] For example, an antibody molecule may be (i) SEQ ID NOs: 10, 11 and 6 [E12v2], respectively; (ii) SEQ ID NOs: 22, 11, and 20 [E05v2], respectively; (iii) SEQ ID NOs: 22, 11, and 29, respectively [G12v2]; or (iv) SEQ ID NOs: 37, 38 and 36 [lam-G02v3], respectively; and the VL domains CDR1, CDR2 and CDR3 sequences of Here, the CDR sequences are defined according to the IMGT numbering scheme.
[0119] The CDR-based antigen binding site is derived from antibody E12v2, E05v2, G12v2, or lam-G02v3, preferably antibody E12v2, E05v2, or G12v2, more preferably E12v2 or E05v2, most preferably , E12v2, VH or VL domains, preferably VH and VL domains.
[0120] The VH domains of antibodies E12v2, E05v2, G12v2, and lam-G02v3 may have the sequences set forth in SEQ ID NOs: 12, 23, 23, and 23, respectively. The VL domains of antibodies E12v2, E05v2, G12v2, and lam-G02v3 may have the sequences set forth in SEQ ID NOs: 14, 25, 30, and 41, respectively.
[0121] The antibody molecule of the present invention comprises a CD137 antigen-binding site located in the constant domain of the antibody molecule. The constant domain may be a CL, CH1, CH2, CH3, or CH4 domain; preferably, the constant domain is a CH1, CH2, or CH3 domain, more preferably a CH2 or CH3 domain, and most preferably a CH3 domain. The CD137 antigen-binding site comprises one or more modified structural loops in the constant domain of the antibody molecule. Engineering of antibody constant domain structural loops to create antigen-binding sites for target antigens is known in the art, and is described, for example, in Wozniak-Knopp G et al. (2010) and WO 2006 / 07292. 620 and WO 2009 / 132876.
[0122] The CD137 antigen-binding site of an antibody molecule may comprise a first and a second sequence, preferably a first and a second sequence, wherein the first and second sequences are, respectively, constant domains of the antibody molecule. , preferably of the CH3 domain, may comprise sequences located in the AB and EF structural loops.
[0123] In a preferred embodiment, the residues at positions 95 and 96 of the CH3 domain of the antibody molecule are wild-type, i.e., preferably arginine (R) and tryptophan (W), respectively. Both of these residues are located in the EF structural loop. Amino acid residue positions are numbered herein according to the ImMunoGeneTics (IMGT) numbering scheme unless otherwise specified. The IMGT numbering scheme is described in Lefranc et al., 2005.
[0124] The first sequence preferably comprises the sequence PPY (SEQ ID NO: 78).
[0125] The PPY sequence may be located between positions 10 and 19, preferably between positions 15 and 17, in the CH3 domain of the antibody molecule. In a preferred embodiment, the PPY sequence is located at positions 16, 16.5, and 16.4 in the CH3 domain. Alternatively, the PPY sequence may be located between positions 16 and 17 in the CH3 domain. In an alternative preferred embodiment, the PPY sequence is located at positions 16.3, 16.2, and 16.1 in the CH3 domain. In the IMGT numbering scheme, inserted residues are numbered according to the direction of the loop in which they are located. If the loop is "up," the inserted residue takes the number of the residue immediately preceding the insertion, and the numbers of the inserted residues within the sequence are indicated in ascending decimal order. For example, residue 16 followed by three mutations is indicated as 16, 16.1, 16.2, and 16.3. If the loop goes "down," the inserted residue takes the number of the residue immediately preceding the insertion, and the inserted residues in the sequence are numbered in descending decimal order. For example, residue 16 followed by three mutations is designated as 16, 16.3, 16.2, and 16.1 (LeFranc et al., 2005, and LeFranc et al. 2015).
[0126] In a preferred embodiment, the AB structural loop comprises an amino acid insertion. The insertion can be 1 to 10, 2 to 9, 3 to 7, 4 to 6, or 5 amino acids in length. Preferably, the insertion is 5 amino acids in length.
[0127] The insertion may be located between positions 10 and 19, preferably between positions 14 and 17, more preferably between positions 16 and 17, in the CH3 domain of the antibody molecule. In a preferred embodiment, the insertion is located at positions 16.5 to 16.1 in the CH3 domain of the antibody molecule. Figure 1 shows an Fcab comprising a CH3 domain in which an insertion is located at positions 16.5 to 16.1 in the CH3 domain.
[0128] The majority of Fcabs identified after affinity maturation contained a leucine (L) residue at position 97 in the CH3 domain. Many of these Fcabs also contained an aspartic acid (D) or glutamic acid (E) residue at position 98 in the CH3 domain. Both of these amino acid changes are located in the EF structural loop. These results suggest that one or both of these residues may be important for CD137 binding. Therefore, the second sequence preferably contains the sequence LD or LE, where the LD or LE sequence is preferably located at positions 97 and 98 in the CH3 domain of the antibody molecule.
[0129] The first sequence and the second sequence are FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-053-010, FS22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, FS22-053, preferably FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017 or FS22-053-014, more preferably FS22-053-008, FS22-053-009, FS22-053-011 or FS22-053-017, even more preferably the first and second sequences of the CH3 domain of specific binding member FS22-053-008.
[0130] The first and second sequences are FS22-053-008, FS22-053-009, FS22-053-011, and FS22-053 -017, FS22-053-014, FS22-053-010, FS22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, FS22-053, FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, or FS22-172, preferably FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-1 The first and second sequences of the CH3 domain of FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, or FS22-172-006, more preferably FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-172-003, FS22-172-002, or FS22-172-004, even more preferably FS22-053-008 or FS22-172-003, and even more preferably FS22-172-003. In an alternatively preferred embodiment, the first and second sequences may be the first and second sequences of the CH3 domain of FS22-053-017.
[0131] FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-053-010, F S22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, FS22-053, FS22-172-003, FS22-17 The CH3 domain sequences of FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, and FS22-172 are set forth in SEQ ID NOs: 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 115, 118, 121, 124, 127, 130, and 132, respectively.
[0132] The first and second sequences of FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-053-010, FS22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, FS22-053, FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, and FS22-172-007 were identified as FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-053-010, FS22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, FS22-053, FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, and FS22-172-007, respectively. FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-053-010, FS22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, FS22-053, FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, and FS22-172.
[0133] Alternatively, the first and second sequences of FS22-053-008, FS22-053-010, FS22-053-011, FS22-053-012, and FS22-053-016 may be sequences between positions 14 and 17, and between positions 92 and 99, of the CH3 domain of FS22-053-008, FS22-053-010, FS22-053-011, FS22-053-012, and FS22-053-016, respectively.
[0134] Alternatively, the first and second sequences of FS22-053-015 may be sequences between positions 14 and 17, and between positions 92 and 98, respectively, of the CH3 domain of FS22-053-015.
[0135] The CD loop sequence of the antibody molecule is preferably unmodified, i.e., wild-type. Thus, the CD loop sequence preferably has the sequence shown in SEQ ID NO: 73. The CD loop sequence is preferably located at positions 43 to 78 of the CH3 domain.
[0136] The first and second sequences can be the complete AB and EF structural loop sequences of FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-053-010, FS22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, FS22-053, FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, or FS22-172, respectively. Determining the location of the AB, CD, and EF structural loops in the CH3 domain sequence can be accomplished by those skilled in the art, for example, according to the IMGT, IMGT exon, EU, or Kabat numbering systems. and described in Hasenhindl et al. (2013). In a preferred embodiment, the AB, CD, and EF structural loops according to the IMGT numbering system are located between positions 10 and 19, 42 and 79, and 91 and 102 of the CH3 domain, respectively. Thus, in a preferred embodiment, the first, second, and third sequences are FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-053- The sequences are sequences between positions 10 and 19, 42 and 79, and 91 and 102 in the CH3 domain of FS22-010, FS22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, FS22-053, FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, or FS22-172.
[0137] Thus, in one preferred embodiment, the first and second sequences of the CD137 antigen binding site are the AB and EF loop sequences set forth in SEQ ID NOs: 171 and 172, respectively [FS22-172-003], or the AB and EF loop sequences set forth in SEQ ID NOs: 173 and 174, respectively [FS22-53-008]. In a further preferred embodiment, the first and second sequences of the CD137 antigen binding site comprise the AB and EF structural loops set forth in SEQ ID NOs: 171 and 172 [FS22-172-003], respectively.
[0138] In an alternatively preferred embodiment, the first and second sequences of the CD137 antigen binding site comprise the AB and EF structural loop sequences set forth in SEQ ID NOs: 173 and 175 [FS22-053-017], respectively.
[0139] In a preferred embodiment, the CD137 antigen binding site is (i) SEQ ID NOs: 79 and 80 [FS22-053-008], respectively; (ii) SEQ ID NOs: 79 and 83 [FS22-053-009], respectively; (iii) SEQ ID NOs: 79 and 86 [FS22-053-011], respectively; (iv) SEQ ID NOs: 79 and 89 [FS22-053-017], respectively; (v) SEQ ID NOs: 79 and 92 [FS22-053-014], respectively; (vi) SEQ ID NOs: 79 and 95 [FS22-053-010], respectively; (vii) SEQ ID NOs: 79 and 98 [FS22-053-012], respectively; (viii) SEQ ID NOs: 79 and 101 [FS22-053-013], respectively; (ix) SEQ ID NOs: 79 and 104 [FS22-053-015], respectively; (x) SEQ ID NOs: 79 and 107 [FS22-053-016], respectively; (xi) SEQ ID NOs: 79 and 110 [FS22-053], respectively; (xii) SEQ ID NOs: 113 and 114, respectively [FS22-172-003]; (xiii) SEQ ID NOs: 117 and 114, respectively [FS22-172-002]; (xiv) SEQ ID NOs: 120 and 114 [FS22-172-004], respectively; (xv) SEQ ID NOs: 123 and 114 [FS22-172-001], respectively; (xvi) SEQ ID NOs: 126 and 114 [FS22-172-005], respectively; (xvii) SEQ ID NOs: 129 and 114, respectively [FS22-172-006]; or (xviii) SEQ ID NOs: 129 and 114 [FS22-172], respectively; wherein the first and second sequences are preferably located between positions 14 and 17, and between positions 91 and 99, respectively, of the CH3 domain of the antibody molecule.
[0140] In an even more preferred embodiment, the antibody molecule comprises: (i) SEQ ID NOs: 79 and 80 [FS22-053-008], respectively; (ii) SEQ ID NOs: 79 and 83 [FS22-053-009], respectively; (iii) SEQ ID NOs: 79 and 86 [FS22-053-011], respectively; (iv) SEQ ID NOs: 79 and 89 [FS22-053-017], respectively; (v) SEQ ID NOs: 113 and 114 [FS22-172-003], respectively; (vi) SEQ ID NOs: 117 and 114, respectively [FS22-172-002]; or (vii) SEQ ID NOs: 120 and 114 [FS22-172-004], respectively; The present invention relates to a method for producing a medicament for the treatment of a heart disease, comprising the steps of:
[0141] In an even more preferred embodiment, the CD137 antigen binding sites of the antibody molecule each comprise The first and second sequences are set forth in SEQ ID NOs: 113 and 114 [FS22-172-003], or the first and second sequences are set forth in SEQ ID NOs: 79 and 80 [FS22-53-008], respectively. In a more preferred embodiment, the CD137 antigen-binding site of the antibody molecule comprises the first and second sequences set forth in SEQ ID NOs: 113 and 114 [FS22-172-003], respectively. For example, the CD137 antigen-binding site may comprise the AB and EF structural loop sequences set forth in SEQ ID NOs: 171 and 172 [FS22-172-003], respectively.
[0142] In one embodiment, the antibody molecule, in particular the antibody molecule comprising the first and / or second, preferably the first and second, sequences set forth in SEQ ID NOs: 129 and 114 [FS22-172-006], may comprise a leucine (L) at position 19 of the CH3 domain of the antibody molecule.
[0143] As an alternative to the IMGT numbering system, amino acid residue positions in the amino acid sequences described herein, including positions of substitutions, deletions, and insertions, may be numbered according to the IMGT exon numbering system (also called sequential numbering), EU numbering, or Kabat numbering system. The agreement between IMGT numbering, IMGT exon numbering, EU numbering, and Kabat numbering of residue positions in the clone is shown in Figure 1. Thus, for example, if the present application Referring to a first sequence located between positions 14 and 17 of the CH3 domain, respectively, where the residue positions are numbered according to the IMGT numbering scheme, the first sequence is located between positions 18 and 21 of the CH3 domain, where the residue positions are numbered according to the IMGT exon numbering scheme as shown in Figure 1. Alternatively, the positions of amino acid residues in the CH3 domain, including the amino acid sequence, substitutions, deletions, and insertions in the CH3 domain as described herein, can be defined by reference to their positions in the wild-type CH3 domain sequence set forth in SEQ ID NO: 75. The correspondence between the IMGT numbering and the wild-type CH3 domain sequence is also shown in Figure 1.
[0144] In one embodiment, the antibody molecule is selected from the group consisting of FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-053-010, FS22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, FS22-0 53, FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, or FS22-172, wherein FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-053-010, FS22-053-01 2, FS22-053-013, FS22-053-015, FS22-053-016, FS22-053, FS22-172-003, FS22-172-002, F The CH3 domain sequences of S22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, and FS22-172 are set forth in SEQ ID NOs: 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 115, 118, 121, 124, 127, 130, and 132, respectively.
[0145] In a preferred embodiment, the antibody molecule comprises a CH3 domain comprising, having or consisting of the CH3 domain sequence of FS22-172-003 or FS22-053-008 set forth in SEQ ID NOs: 115 and 81, respectively. In a more preferred embodiment, the antibody molecule comprises a CH3 domain comprising, having or consisting of the CH3 domain sequence of FS22-172-003 set forth in SEQ ID NO: 115.
[0146] In an alternatively preferred embodiment, the antibody molecule comprises a CH3 domain comprising, having or consisting of the CH3 domain sequence of FS22-053-017 as set forth in SEQ ID NO:90, respectively.
[0147] The CH3 domain of the antibody molecule may optionally comprise an additional lysine residue (K) immediately adjacent to the C-terminus of the CH3 domain sequence.
[0148] Furthermore, the antibody molecules of the present invention may comprise a CH2 domain of an immunoglobulin G molecule, such as a CH2 domain of an IgG1, IgG2, IgG3, or IgG4 molecule. Preferably, the antibody molecules of the present invention comprise a CH2 domain of an IgG1 molecule. The CH2 domain may have the sequence set forth in SEQ ID NO: 76.
[0149] The CH2 domain is known to bind to Fcγ receptors and complement. Binding of the CH2 domain to Fcγ receptors is required for antibody-dependent cell-mediated cytotoxicity (ADCC), while binding to complement is required for complement-dependent cytotoxicity (CDC). The CH2 domain of an antibody molecule preferably contains one or more mutations that reduce or inhibit binding of the CH2 domain to one or more Fcγ receptors, such as FcγRI, FcγIIa, FcγRIIb, and FcγRIII, and / or complement. The inventors hypothesize that reducing or inhibiting binding to Fcγ receptors reduces or eliminates ADCC mediated by the antibody molecule. Similarly, reducing or inhibiting complement binding is expected to reduce or eliminate CDC mediated by the antibody molecule. Without wishing to be bound by theory, this is expected to reduce or avoid liver toxicity when the antibody molecule is administered to a patient. Furthermore, reducing or abolishing binding to Fcγ receptors is expected to be useful when the antibody molecule contains a second antigen-binding site for an immune cell antigen, where killing of the immune cell to which the antibody molecule binds via ADCC and / or CDC should be avoided. Mutations that reduce or abolish binding of the CH2 domain to one or more Fcγ receptors and / or complement are known in the art (Wang et al., 2018). These The mutations include the "LALA mutation" described in Bruhns et al., 2009 and Hezareh et al., 2001. ", which involves substituting the leucine residues at positions 1.3 and 1.2 of the CH2 domain with alanine (L1.3A and L1.2A). Alternatively, the generation of α-glycosylated antibodies through mutation of the conserved N-linked glycosylation site by mutating the asparagine (N) at position 84.4 of the CH2 domain to alanine, glycine, or glutamine (N84.4A, N84.4G, or N84.4Q) is also known to reduce IgG1 effector function (Wang et al., 2018). As a further alternative, complement activation (C 1q binding) and ADCC are known to be reduced by mutating proline at position 114 in the CH2 domain to alanine or glycine (P114A or P114G) (Idusogie et al., 2000; Klein et al., 2016). These mutations reduce ADCC or CD40 binding. They can also be combined to generate antibody molecules with further reduced or no C activity.
[0150] Thus, the antibody molecule may comprise a CH2 domain, wherein the CH2 domain preferably comprises: (i) alanine residues at positions 1.3 and 1.2; and / or (ii) alanine or glycine at position 114; and / or (iii) alanine, glutamine, or glycine at position 84.4; wherein the numbering of amino acid residues is according to the IMGT numbering scheme.
[0151] In a preferred embodiment, the antibody molecule comprises a CH2 domain, wherein the CH2 domain comprises: (i) an alanine residue at position 1.3; and (ii) an alanine residue at position 1.2; wherein the numbering of amino acid residues is according to the IMGT numbering scheme.
[0152] For example, the CH2 domain may have the sequence set forth in SEQ ID NO:77.
[0153] In an alternative preferred embodiment, the antibody molecule comprises a CH2 domain, wherein the CH2 domain comprises: (i) an alanine residue at position 1.3; (ii) an alanine residue at position 1.2; and (iii) alanine at position 114; wherein the numbering of amino acid residues is according to the IMGT numbering scheme.
[0154] For example, the CH2 domain may have the sequence set forth in SEQ ID NO:176.
[0155] In a preferred embodiment, the antibody molecule that binds PD-L1 and CD137 is (a) a CDR-based antigen-binding site of PD-L1; and (b) CD137 antigen-binding site located in the CH3 domain of the antibody molecule wherein the CDR-based antigen-binding site comprises the three VH CDRs and three VL CDRs (CDR1-6) of antibody E12v2, E05v2, or G12v2, preferably E12v2; The CD137 antigen-binding site comprises a first sequence and a second sequence located in the AB, CD, and EF structural loops of the CH3 domain, respectively, and the first and second sequences are set forth in SEQ ID NOs: 113 and 114 [FS22-172-003], or 79 and 80 [FS22-53-008], respectively. Preferably, the first and second sequences have the sequences set forth in SEQ ID NOs: 113 and 114 [FS22-172-003].
[0156] As described in the Examples, an antibody molecule having a CD137 antigen-binding site comprising the first and second sequences set forth in SEQ ID NOs: 79 and 89 [FS22-053-017], respectively, was able to bind to human, cynomolgus monkey, and, unexpectedly, mouse CD137. The inventors demonstrated that this antibody molecule, when cross-linked, was active in human, cynomolgus monkey, and mouse T cell activation assays.
[0157] In an alternatively preferred embodiment, the antibody molecule that binds PD-L1 and CD137 is: (a) a CDR-based antigen-binding site of PD-L1; and (b) CD137 antigen-binding site located in the CH3 domain of the antibody molecule wherein the CDR-based antigen-binding site comprises the three VH CDRs and three VL CDRs (CDR1-6) of antibody E12v2, E05v2, or G12v2, preferably E12v2; The CD137 antigen-binding site comprises a first sequence and a second sequence located in the AB, CD, and EF structural loops of the CH3 domain, respectively, and the first and second sequences have the sequences set forth in SEQ ID NOs: 79 and 89 [FS22-053-017], respectively.
[0158] In some embodiments, the antibody molecule comprises: (a) a CDR-based antigen-binding site of PD-L1; and (b) CD137 antigen-binding site located in the CH3 domain of the antibody molecule wherein the CDR-based antigen-binding site comprises the three VH CDRs and three VL CDRs (CDR1-6) of antibody E12v2, E05v2, or G12v2, preferably E12v2; The CD137 antigen-binding site comprises a first sequence and a second sequence located in the AB, CD, and EF structural loops of the CH3 domain, respectively, and the first and second sequences are set forth in SEQ ID NOs: 113 and 114 [FS22-172-003], or 79 and 80 [FS22-53-008], respectively. and preferably the first and second sequences have the sequences set forth in SEQ ID NOs: 113 and 114 [FS22-172-003], with the proviso that the antibody molecule comprises a C12v2 antibody paired with a CD137 antigen binding site having a first and second sequence set forth in SEQ ID NOs: 79 and 80 [FS22-053-008]. Does not include DR1-6.
[0159] In a further preferred embodiment, the antibody molecule that binds to PD-L1 and CD137 comprises: (a) a CDR-based antigen-binding site of PD-L1; and (b) SEQ ID NO: 115 [FS22-172-003] or 81 [FS22-53-008], preferably SEQ ID NO: No. 115 [FS22-172-003], a CH3 domain comprising, having, or consisting of a sequence set forth in and the CDR-based antigen-binding site comprises the three VH CDRs and three VL CDRs (CDR1-6) of antibody E12v2, E05v2, or G12v2, preferably E12v2.
[0160] In yet an alternatively preferred embodiment, the antibody molecule that binds PD-L1 and CD137 is: (a) a CDR-based antigen-binding site of PD-L1; and (b) a CH3 domain comprising, having, or consisting of the sequence set forth in SEQ ID NO: 90 [FS22-053-017]; and the CDR-based antigen-binding site comprises the three VH CDRs and three VL CDRs (CDR1-6) of antibody E12v2, E05v2, or G12v2, preferably E12v2.
[0161] In an even more preferred embodiment, the antibody molecule that binds PD-L1 and CD137 is (a) a VH domain and a VL domain comprising a CDR-based antigen-binding site of PD-L1; and (b) SEQ ID NO: 115 [FS22-172-003] or 81 [FS22-53-008], preferably SEQ ID NO: No. 115 [FS22-172-003], a CH3 domain comprising, having, or consisting of a sequence set forth in and the VH and VL domains comprise, comprise or consist of the VH and VL domains of antibody E12v2, E05v2, or G12v2, preferably E12v2.
[0162] In an even more preferred embodiment, the antibody molecule that binds PD-L1 and CD137 is (a) a VH domain and a VL domain comprising a CDR-based antigen-binding site of PD-L1; and (b) a CH3 domain comprising, having, or consisting of the sequence set forth in SEQ ID NO: 90 [FS22-053-017]; and the VH and VL domains comprise, comprise or consist of the VH and VL domains of antibody E12v2, E05v2, or G12v2, preferably E12v2.
[0163] In an even more preferred embodiment, the antibody molecule that binds PD-L1 and CD137 is (a) a VH domain and a VL domain comprising the CDR-based antigen-binding site of PD-L1; (b) SEQ ID NO: 115 [FS22-172-003], or 81 [FS22-53-008], preferably SEQ ID NO: No. 115 [FS22-172-003], a CH3 domain comprising, having, or consisting of a sequence set forth in (c) the CH2 domain is (i) an alanine residue at position 1.3; (ii) an alanine residue at position 1.2; a CH2 domain comprising, having or consisting of the sequence set forth in SEQ ID NO: 76; wherein the numbering of amino acid residues is according to the IMGT numbering scheme; The VH and VL domains comprise, comprise or consist of the VH and VL domains of antibody E12v2, E05v2 or G12v2, preferably E12v2.
[0164] In a further embodiment, the antibody molecule that binds PD-L1 and CD137 is: (a) a VH and VL domain comprising a CDR-based antigen-binding site of PD-L1, wherein the CDR-based antigen-binding site comprises CDRs 1-6; and (b) a CD137 antigen-binding site located in a CH3 domain of the antibody molecule, the CD137 antigen-binding site comprising a first sequence and a second sequence located in the AB and EF structural loops of the CH3 domain; wherein CDRs 1 to 6, the first sequence, and the second sequence are (i) SEQ ID NOs: 1, 2, 3, 4, 5, 6, 113, and 114 [FS22-172-003-AA / E12v2], respectively; (ii) SEQ ID NOs: 1, 2, 3, 18, 19, 20, 113, and 114, respectively [FS22-172-003-AA / E05v2]; (iii) SEQ ID NOs: 1, 2, 3, 18, 19, 29, 113, and 114, respectively [FS22-172-003-AA / G12v2]; (iv) SEQ ID NOs: 1, 2, 3, 4, 5, 6, 79, and 80, respectively [FS22-053-008-AA / E12v2]; or (v) SEQ ID NOs: 1, 2, 3, 18, 19, 20, 79 and 80 [FS22-053-008-AA / E05v2], respectively; or The VH domain, the VL domain, the first sequence and the second sequence (i) SEQ ID NOs: 12, 14, 113, and 114 [FS22-172-003-AA / E12v2], respectively; (ii) SEQ ID NOs: 23, 25, 113, and 114, respectively [FS22-172-003-AA / E05v2]; (iii) SEQ ID NOs: 23, 30, 113, and 114 [FS22-172-003-AA / G12v2], respectively ; (iv) SEQ ID NOs: 12, 14, 79, and 80, respectively [FS22-053-008-AA / E12v2]; or (v) SEQ ID NOs: 23, 25, 79, and 80, respectively [FS22-053-008-AA / E05v2]; or The VH domain, VL domain, and CH3 domain are (i) SEQ ID NOs: 12, 14, and 115 [FS22-172-003-AA / E12v2], respectively; (ii) SEQ ID NOs: 23, 25, and 115 [FS22-172-003-AA / E05v2], respectively; (iii) SEQ ID NOs: 23, 30, and 115 [FS22-172-003-AA / G12v2], respectively; (iv) SEQ ID NOs: 12, 14, and 81, respectively [FS22-053-008-AA / E12v2]; or (v) SEQ ID NOs: 23, 25, and 81 [FS22-053-008-AA / E05v2], respectively It has the sequence set forth in
[0165] In an even more preferred embodiment, the antibody molecule that binds PD-L1 and CD137 is the antibody: (i) FS22-172-003-AA / E12v2 set forth in SEQ ID NOs: 134 and 17, respectively; (ii) FS22-172-003-AA / E05v2 set forth in SEQ ID NOs: 137 and 28, respectively; (iii) FS22-172-003-AA / G12v2 set forth in SEQ ID NOs: 140 and 33, respectively; (iv) FS22-053-008-AA / E12v2 set forth in SEQ ID NOs: 143 and 17, respectively; (v) FS22-053-008-AA / E05v2 set forth in SEQ ID NOs: 146 and 28, respectively; or (vi) FS22-053-008-AA / G12v2 set forth in SEQ ID NOs: 149 and 33, respectively The heavy chain comprises, has, or consists of a heavy chain and a light chain of the present invention.
[0166] In an even more preferred embodiment, the antibody molecule that binds PD-L1 and CD137 is the antibody: (i) FS22-172-003-AA / E12v2 set forth in SEQ ID NOs: 134 and 17, respectively; (ii) FS22-172-003-AA / E05v2 set forth in SEQ ID NOs: 137 and 28, respectively; (iii) FS22-172-003-AA / G12v2 set forth in SEQ ID NOs: 140 and 33, respectively; (iv) FS22-053-008-AA / E12v2, as set forth in SEQ ID NOs: 143 and 17, respectively; or (v) FS22-053-008-AA / E05v2 set forth in SEQ ID NOs: 146 and 28, respectively; The heavy chain comprises, has, or consists of a heavy chain and a light chain of the present invention.
[0167] In an even more preferred embodiment, the antibody molecule that binds PD-L1 and CD137 is the antibody: (i) FS22-172-003-AA / E12v2 as set forth in SEQ ID NOs: 134 and 17, respectively; or (iv) FS22-053-008-AA / E12v2 set forth in SEQ ID NOs: 143 and 17, respectively The heavy chain comprises, has, or consists of a heavy chain and a light chain of the present invention.
[0168] In an even more preferred embodiment, the antibody molecule that binds PD-L1 and CD137 comprises the heavy and light chains of antibody FS22-172-003-AA / E12v2 as set forth in SEQ ID NOs: 134 and 17, respectively. The term "antibody" includes a heavy chain, comprising, having or consisting of a chain.
[0169] In an even more alternatively preferred embodiment, the antibody molecule that binds PD-L1 and CD137 is the antibody: (i) FS22-053-017-AA / E12v2 set forth in SEQ ID NOs: 152 and 17, respectively; (ii) FS22-053-017-AA / E05v2 as set forth in SEQ ID NOs: 153 and 28, respectively; or (iii) FS22-053-017-AA / G12v2 set forth in SEQ ID NOs: 154 and 33, respectively The heavy chain comprises, has, or consists of a heavy chain and a light chain of the present invention.
[0170] The antibody molecules of the present invention may also comprise variants of the first, second, or third sequences, AB, CD, or EF structural loop sequences, CH3 domain, CH2 domain, CH2 and CH3 domains, CDRs, FW, VH domain, VL domain, light chain, and / or heavy chain sequences described herein. Suitable variants can be obtained by methods of sequence alteration or mutation and screening. In preferred embodiments, antibody molecules comprising one or more variant sequences retain one or more functional characteristics of the parent antibody molecule, such as binding specificity and / or affinity to PD-L1 and CD137. For example, antibody molecules comprising one or more variant sequences preferably bind to PD-L1 and / or CD137 with the same affinity as, or higher affinity than, the (parent) antibody molecule. The parent antibody molecule is an antibody molecule that does not contain the amino acid substitutions, deletions, and / or insertions incorporated into the variant antibody molecule.
[0171] For example, an antibody molecule of the invention may comprise a first, second or third sequence, an AB, CD or EF structural loop sequence, a CH3 domain, a CH2 domain, a CH2 and CH3 domains, a CDR, a FW, a VH domain, a VL domain, a light chain and / or a heavy chain sequence that has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity to a structural loop, a CH3 domain, a CH2 domain, a CH2 and CH3 domains, a CDR, a FW, a VH domain, a VL domain, a light chain or a heavy chain sequence described herein.
[0172] In a preferred embodiment, the antibody molecule of the invention comprises a CH3 domain sequence having at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% sequence identity to the CH3 domain sequence set forth in SEQ ID NO: 115 [FS22-172-003] or 81 [FS22-053-008], preferably SEQ ID NO: 115 [FS22-172-003].
[0173] In a further preferred embodiment, the antibody molecule has a sequence identity with the CH2 domain sequence set forth in SEQ ID NO: 76 or 77 of at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6% , having or comprising a CH2 domain sequence having at least 99.7%, at least 99.8%, or at least 99.9% sequence identity.
[0174] Sequence identity is generally measured using the algorithm GAP (Wisconsin GCG Package, Accelerys GAP is defined with reference to the Needleman and Wunsch algorithm (http: / / www.ncbi.nlm.nih.gov / pubmed / 2111111). GAP uses the Needleman and Wunsch algorithm to align two complete sequences, maximizing the number of matches and minimizing the number of gaps. Generally, default parameters are used, with a gap creation penalty equal to 12 and a gap extension penalty equal to 4. While the use of GAP is sometimes preferred, other algorithms, such as BLAST (using the method of Altschul et al., 1990), FASTA (using the method of Pearson and Lipman, 1988), or the Smith-Waterman algorithm (Smith and Waterman, 1981), or the TBLASTN program of Altschul et al. (1990), supra, can also be used, generally using default parameters. In particular, the psi-Blast algorithm (Altschul et al., 1997) can be used.
[0175] The antibody molecules of the present invention may also comprise a first, second, or third sequence, AB, CD, or EF structural loop sequence, CH3 domain, CH2 domain, CH2 and CH3 domains, CDR, FW, VH domain, VL domain, light chain, and / or heavy chain having one or more amino acid sequence alterations (additions, deletions, substitutions, and / or insertions of amino acid residues) compared to the first, second, or third sequence, AB, CD, or EF structural loop sequence, CH3 domain, CH2 domain, CH2 and CH3 domains, CDR, FW, VH domain, VL domain, light chain, or heavy chain sequence described herein, preferably no more than 20 alterations, no more than 15 alterations, no more than 10 alterations, no more than 5 alterations, no more than 4 alterations, no more than 3 alterations, no more than 2 alterations, or no more than 1 alteration. In particular, alterations may be made in one or more framework regions of the antibody molecule outside the VH and VL domain sequences and / or in one or more framework regions of the CH3 domain. For example, alterations may occur in the CH3 domain outside of the sequences described herein, as first, second, and third sequences, or as AB, CD, or EF structural loop sequences.
[0176] In a preferred embodiment, an antibody molecule of the invention may comprise a CH3 domain sequence with one or more amino acid sequence alterations (addition, deletion, substitution and / or insertion of amino acid residues) compared to the CH3 domain sequence set forth in SEQ ID NO: 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 115, 118, 121, 124, 127, 130, or 132, preferably no more than 20 alterations, no more than 15 alterations, no more than 10 alterations, no more than 5 alterations, no more than 4 alterations, no more than 3 alterations, no more than 2 alterations, or no more than 1 alteration. In a more preferred embodiment, the antibody molecule of the present invention may comprise a CH3 domain sequence with one or more amino acid sequence alterations (addition, deletion, substitution and / or insertion of amino acid residues), preferably no more than 20 alterations, no more than 15 alterations, no more than 10 alterations, no more than 5 alterations, no more than 4 alterations, no more than 3 alterations, no more than 2 alterations, or no more than 1 alteration, compared to the CH3 domain sequence set forth in SEQ ID NO: 115 [FS22-172-003] or 81 [FS22-053-008], preferably SEQ ID NO: 115 [FS22-172-003].
[0177] In a further preferred embodiment, the antibody molecule comprises a CH2 domain sequence with one or more amino acid sequence alterations (additions, deletions, substitutions and / or insertions of amino acid residues) compared to the CH2 domain sequence set forth in SEQ ID NO: 76 or 77, preferably no more than 20 alterations, no more than 15 alterations, no more than 10 alterations, no more than 5 alterations, no more than 4 alterations, no more than 3 alterations, no more than 2 alterations, or no more than 1 alteration.
[0178] In preferred embodiments where one or more amino acids are substituted with another amino acid, the substitutions may be conservative substitutions, for example according to the following table: In some embodiments, amino acids in the same category in the middle column are substituted for each other, i.e., non-polar amino acids is substituted with another non-polar amino acid, for example. In some embodiments, amino acids on the same line in the rightmost column are substituted for each other.
[0179] [Table 1]
[0180] In some embodiments, substitutions may be functionally conservative, i.e., in some embodiments, the substitution may not affect (or not substantially affect) one or more functional properties (e.g., binding affinity) of an antibody molecule comprising the substitution, compared to a comparable unsubstituted antibody molecule.
[0181] Where the antibody molecule comprises a variant of the first sequence, AB structure loop sequence, CH3 domain, or heavy chain sequence as disclosed herein, preferably the antibody molecule retains a PPY sequence between positions 11 and 19, preferably between positions 15 and 17, in the CH3 domain of the antibody molecule. Further, preferably the antibody molecule retains an insertion, preferably a 5 amino acid insertion, between positions 16 and 17 in the CH3 domain of the antibody molecule. In a further preferred embodiment, the antibody molecule preferably retains a sequence at positions 97 and 98 in the CH3 domain of the antibody molecule.
[0182] Additionally or alternatively, when an antibody molecule comprises a variant of the CH3 domain, CH2 and CH3 domains, light chain, or heavy chain sequence disclosed herein, the variant preferably does not contain amino acid changes in the first and second sequences located in the AB and EF structural loops of the CH3 domain of the antibody molecule. For example, the variant may not contain amino acid changes in the AB and EF structural loops of the CH3 domain of the antibody molecule. Furthermore, the variant may not contain amino acid changes in the CD structural loop of the CH3 domain of the antibody molecule. That is, the variant may not contain amino acid changes in the AB and EF structural loops of the CH3 domain of the antibody molecule.
[0183] Where an antibody molecule comprises a variant of a VH domain, VL domain, light chain, or heavy chain sequence disclosed herein, the antibody molecule preferably does not contain any amino acid changes in the CDR sequences. That is, any amino acid changes present may be present in a FW sequence, e.g., HFW1, HFW2, HFW3, HFW4, LFW1, LFW2, LFW3, and / or LFW4. For example, the variant may not contain amino acid changes in the CDR1, CDR2, CDR3, CDR4, CDR5, and / or CDR6 sequences.
[0184] The antibody molecule preferably binds to human PD-L1 and human CD137. Preferably, the antibody molecule can simultaneously bind to human PD-L1 and human CD137, where human CD137 and human PD-L1 are co-expressed. As used herein, co-expression means that the two targets are expressed on the surface of a single cell, or on the surface of two separate cells. For example, the antibody molecule can bind to human PD-L1 and human CD137 when they are co-expressed on two separate cells, for example, on an immune cell that expresses CD137 and another tumor cell that expresses PD-L1 in the tumor microenvironment. Not only can they bind to human PD-L1 and human CD137, but they may also be able to bind to human PD-L1 and human CD137 when these are co-expressed on a single cell, such as an immune cell.
[0185] The antibody molecule preferably has an affinity (K D ) or with an affinity of 0.3 nM or higher. Preferably, the antibody molecule binds to human PD-L1 with an affinity (K D ) or with higher affinity to human PD-L1.
[0186] Human PD-L1 can, for example, have the sequence set forth in SEQ ID NO: 180. Human PD-L1 can also be expressed as an Avi tag (hPD-L1-Avi-H), available from Acro Biosystems. The recombinant human PD-L1 may be a recombinant human PD-L1 with the PD-L1 (Cat. No.: PD1-H82E5). The recombinant human PD-L1 may be biotinylated.
[0187] The antibody molecule preferably has an affinity (K D ) or with an affinity higher than 2 nM. Preferably, the antibody molecule binds to dimeric human CD137 with an affinity (K D ) or with higher affinity to dimeric human CD137.
[0188] In preferred embodiments, the antibody molecule binds to dimeric CD137 with higher affinity than to monomeric CD137, hi preferred embodiments, the antibody molecule binds to dimeric CD137 with at least 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 110-fold, 120-fold, 130-fold, 140-fold, 150-fold, 160-fold, 170-fold, or 200-fold higher affinity than the antibody molecule for monomeric CD137.
[0189] Human CD137 can, for example, have the sequence shown in SEQ ID NO: 186. Methods for producing dimeric and monomeric CD137 antigens are described in the Examples.
[0190] The antibody molecule preferably binds to cynomolgus PD-L1 and cynomolgus CD137. Preferably, the antibody molecule can bind to cynomolgus PD-L1 and cynomolgus CD137 simultaneously, where cynomolgus PD-L1 and cynomolgus CD137 are expressed on the surface of a single cell or on the surface of two separate cells.
[0191] In preferred embodiments, the antibody molecule may bind to cynomolgus PD-L1 with an affinity (KD) of 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.5 nM, 0.4 nM, or 0.3 nM, or with an affinity of greater than 1 nM.D ) or with higher affinity to cynomolgus PD-L1.
[0192] Cynomolgus monkey PD-L1 may, for example, have the sequence set forth in SEQ ID NO: 184.
[0193] In preferred embodiments, the antibody molecule is capable of binding to dimeric cynomolgus monkey CD137 with an affinity (KD) of 60 nM, 50 nM, 40 nM, 30 nM, 20 nM, 10 nM, 5 nM, 4 nM, 3 nM, or 2 nM, or with an affinity higher than 2 nM. D ) or with higher affinity to dimeric cynomolgus CD137.
[0194] The antibody molecule may bind to human PD-L1 and cynomolgus monkey PD-L1 with similar affinity, and / or may bind to dimeric human CD137 and dimeric cynomolgus monkey CD137 with similar affinity, as demonstrated by efficacy and toxicity studies conducted with the antibody molecule in cynomolgus monkeys. However, it is believed to be useful for ensuring the quality of antibody molecules and predicting efficacy and toxicity in humans.
[0195] Thus, in a preferred embodiment, the antibody molecule binds to cynomolgus PD-L1 with an affinity that is no more than 10-fold, preferably no more than 5-fold less than or greater than the affinity with which it binds to human PD-L1. In a preferred embodiment, the antibody molecule binds to dimeric cynomolgus CD137 with an affinity that is no more than 10-fold, preferably no more than 5-fold less than or greater than the affinity with which it binds to dimeric human CD137.
[0196] The binding affinity of antibody molecules to their cognate antigens, such as human PD-L1, human CD137, cynomolgus PD-L1, or cynomolgus CD137, can be determined using surface protease assays, e.g., Biacore. The concentration can be determined by spectroscopy using plasmon resonance (SPR). Further details of suitable methods are provided in the Examples.
[0197] The ability of an antibody molecule to simultaneously bind two cognate antigens, e.g., human PD-L1 and human CD137, or cynomolgus PD-L1 and cynomolgus CD137, can be assessed using, for example, Biacore Further details of suitable methods are provided in the Examples.
[0198] The antibody molecule may be capable of blocking the interaction between PD-L1 and its receptor PD-1, preferably between human PD-L1 and human PD-1.
[0199] The PD-1 / PD-L1 signaling pathway is known to be important in mediating immunosuppression. Therefore, antibody molecules that can block this pathway are expected to be advantageous in that they can help reduce immunosuppression and increase anti-tumor responses. PD-1 / PD-L1 signaling inhibition and CD137 activation can work in tandem to enhance anti-tumor capabilities.
[0200] The ability of antibody molecules to block the binding of PD-L1 to PD-1 is determined using a bioluminescent cell-based assay, for example, using Promega's PD-1 / PD-L1 Blockade Bioassay product. The ability of an antibody molecule to block the binding of PD-L1 to PD-1 can be determined using ELISA. Further details of these assays are provided in the Examples.
[0201] The ability of an antibody molecule to block the binding of PD-L1 to PD-1, also referred to herein as PD-1 / PD-L1 blocking activity, is determined by the heavy and light chains of antibody 2.14H9OPT, as described in WO 2011 / 066389 A1, respectively, or the heavy and light chains of antibody 2.14H9OPT, as described in SEQ ID NOs: 177 and 178, respectively. Refers to an antibody molecule comprising or consisting of the heavy and light chains of antibody G1 / 280_02_G02 It can be determined by
[0202] For example, the antibody molecule may have a level of PD-1 / PD-L1 blocking activity comparable to or greater than that of an antibody molecule comprising or consisting of the heavy and light chains of antibody 2.14H9OPT described in WO 2011 / 066389 A1, or the heavy and light chains of antibody G1 / 280_02_G02 described in SEQ ID NOs: 177 and 178, respectively.
[0203] The antibody molecule is a clone of antibody 2.14H9OPT described in WO 2011 / 066389 A1. PD-1 / PD-L1 blocking antibody molecules comprising or consisting of the heavy and light chain sequences, or sequences of the heavy and light chains of antibody G1 / 280_02_G02 set forth in SEQ ID NOs: 177 and 178, respectively. It may have PD-1 / PD-L1 blocking activity that is at least 70%, 80%, or 90% of the activity.
[0204] The antibody molecule is a clone of antibody 2.14H9OPT described in WO 2011 / 066389 A1. PD-1 / PD-L1 blocking antibody molecules comprising or consisting of the heavy and light chain sequences, or sequences of the heavy and light chains of antibody G1 / 280_02_G02 set forth in SEQ ID NOs: 177 and 178, respectively. It may have a PD-1 / PD-L1 blocking activity that is between 70% and 130%, 80% and 120%, or 90% and 110% of the activity.
[0205] As described above, the antibody molecules of the invention are capable of binding to PD-L1 and CD137 simultaneously, resulting in the activation (agonism) of CD137. In a preferred embodiment, the antibody molecules are capable of binding to both human PD-L1 and human CD137 simultaneously, where such binding causes the activation of human CD137. In a further preferred embodiment, the antibody molecules are capable of binding to both cynomolgus PD-L1 and cynomolgus CD137 simultaneously, where such binding causes the activation of cynomolgus CD137. Exemplary methods for testing simultaneous binding and activation include T cell activation assays, as described in more detail below.
[0206] The ability of antibody molecules to activate T cells can be measured using T cell activation assays. Upon activation, T cells release IL-2. Therefore, T cell activation assays can measure IL-2 release to determine the level of T cell activation induced by antibody molecules.
[0207] For example, the ability of an antibody molecule to activate T cells can be determined by measuring the concentration of the antibody molecule required to achieve half-maximal release of IL-2 by T cells in a T cell activation assay. This is hereinafter referred to as EC 50 It is called.
[0208] In a preferred embodiment, the antibody molecule has an EC value in a T cell activation assay that is higher than the EC value of FS22-172-003-AA / E12v2 in the same assay. 50 50 times, 40 times, 30 times, 20 times, 10 times EC within 2x, 5x, 4x, 3x, or 2x 50 wherein FS22-172-003-AA / E12v2 consists of a heavy chain of SEQ ID NO: 134 and a light chain of SEQ ID NO: 17.
[0209] For example, the antibody molecule has an EC50 of 30 nM or less, 25 nM or less, 20 nM or less, 14 nM or less, 10 nM or less, 5 nM or less, 4 nM or less, 3 nM or less, 2 nM or less, 1.5 nM or less, 1 nM or less, 0.4 nM or less, 0.4 nM or less, or 0.3 nM or less, preferably 1 nM or less, and more preferably 1.5 nM or less when the antibody molecule is crosslinked. 50 may have:
[0210] Additionally, or alternatively, the ability of an antibody molecule to activate T cells may be measured by measuring the maximum concentration of IL-2 (E) released by T cells in a T cell activation assay in the presence of the antibody molecule. max ) can be determined by measuring
[0211] The antibody molecule may have a maximum concentration of IL-2 released by T cells in a T cell activation assay in the presence of the antibody molecule of at least 1500 pg / ml, 2000 pg / ml, 2500 pg / ml, 3000 pg / ml, or 3250 pg / ml or more, preferably 2500 pg / ml or more.
[0212] In a preferred embodiment, the maximum concentration of IL-2 released by T cells in a T cell activation assay in the presence of the antibody molecule is 20%, or 10% or more of the maximum concentration of IL-2 released by T cells in the presence of FS22-172-003-AA / E12v2 in the same assay. wherein FS22-172-003-AA / E12v2 has a heavy chain of SEQ ID NO: 134 and a heavy chain of SEQ ID NO: 17 It consists of light chains.
[0213] T cell activation assays preferably include CD137-expressing T cells and cells expressing PD-L1; for example, HEK293 cells overexpressing human PD-L1 (HEK.hPD-L1) can be prepared and used as described in the Examples. Alternatively, or in addition, cells expressing different levels of PD-L1 can be used, such as human breast adenocarcinoma cell line MDA-MB-231 (ATCC HTB-26) cells and / or SKBR3 cells. As described in the Examples, HEK.hPD-L1 express high levels of human PD-L1, MDA-MB-231 cells express intermediate levels of human PD-L1, and SKBR3 cells express low levels of PD-L1.
[0214] In a preferred embodiment, the T cell activation assay does not include any agents capable of cross-linking antibody molecules other than CD137- and PD-L1-expressing cells. Examples of agents capable of cross-linking antibody molecules include anti-human CH2 antibodies, as described in the Examples.
[0215] The T cell activation assay can be a T cell assay as described herein, such as a pan T cell assay as described in this example.
[0216] For example, the T cell activation assay can be an IL-2 release assay based on T cells isolated from human peripheral blood mononuclear cells (PBMCs). For example, the T cell activation assay can include isolating human PBMCs from a leukocyte depletion cone. Methods for isolating PBMCs are known in the art and are described in this example. T cells can then be isolated from the PBMCs. Methods for isolating T cells (total T cells) from PBMCs are known in the art and are described in this example.
[0217] Activation assays can involve preparing the required number of T cells in experimental medium, such as T cell medium. The required number of T cells is 1.0 x 10 6 The isolated T cells can be prepared at a concentration of 2.0 x 10 cells / ml. The T cells can then be stimulated using an appropriate T cell activation reagent that provides the signals necessary for T cell activation. For example, the T cell activation reagent can be a reagent containing CD3 and CD28, such as beads containing CD3 and CD28. The isolated T cells can be incubated overnight with the T cell activation reagent to activate the T cells. Following this, the activated T cells are washed to separate the T cells from the T cell activation reagent, and then diluted to 2.0 x 10 cells. 6 The activated T cells can then be added to a plate coated with an anti-human CD3 antibody.
[0218] Cells (e.g., HEK.hPD-L1 cells) are plated at a density of, e.g., 2 x 10 per well onto tissue culture plates coated with anti-CD3 antibody in T cell culture medium. 5 After, e.g., 4 hours of incubation, all T cell culture medium can be removed and T cells can be plated at, e.g., 5.0 x 10 5 Replace with 100 μl of T cell culture medium containing 5.0 x 10 cells / ml 4 Cells / well may be obtained.
[0219] Appropriate dilutions of each test antibody molecule can be prepared and added to the wells. T cells can then be incubated with the test antibody for 24 hours at 37°C, 5% CO2. The supernatant can be collected and assayed to measure the concentration of IL-2 in the supernatant. Methods for determining the concentration of IL-2 in a solution are known in the art and are described in this example. The concentration of human IL-2 can be plotted against the logarithmic concentration of the antibody molecule. The resulting curve can be fitted using the log(agonist) vs. response equation.
[0220] The antibody molecule may be conjugated to a biologically active molecule or a detectable label, in which case the antibody molecule may be referred to as a conjugate. Such conjugates find use in the treatment of diseases such as those described herein.
[0221] For example, the bioactive molecule can be an immune system modulator, such as a cytokine, preferably a human cytokine. For example, the cytokine can be a cytokine that stimulates the activation and / or proliferation of T cells. Examples of cytokines for conjugation to antibody molecules include IL-2, IL-10, IL-12, IL-15, IL-21, GM-CSF, and IFN-γ.
[0222] Alternatively, the bioactive molecule may be a ligand trap, such as a ligand trap for a cytokine, eg, TGF-beta or IL-6.
[0223] Alternatively, the biologically active molecule can be a therapeutic radioisotope.
[0224] Radioimmunotherapy is used, for example, in the treatment of cancer. Suitable therapeutic radioisotopes for radioimmunotherapy are known in the art and include yttrium-90, iodine-131, bismuth-213, astatine-211, lutetium-177, rhenium-188, copper-67, actinium-225, and iodine-125 and terbium-161.
[0225] Suitable detectable labels that can be conjugated to antibody molecules are known in the art and include radioisotopes such as iodine-125, iodine-131, yttrium-90, indium-111, technetium-99, and the like; fluorescent dyes such as fluorescein, rhodamine, phycoerythrin, Texas Red, and cyanine dye derivatives (e.g., Cy7 and Alexa750); chromogenic dyes such as diaminobenzidine; latex beads; enzyme labels such as horseradish peroxidase; fluorophores or laser dyes with spectrally resolved absorption or emission properties; and chemical moieties such as biotin that can be detected via binding to a specific cognate detectable moiety (e.g., labeled avidin).
[0226] The antibody molecule can be conjugated to the biologically active molecule or detectable label by any suitable covalent or non-covalent bond, such as a disulfide or peptide bond. When the biologically active molecule is a cytokine, the cytokine can be attached to the antibody molecule by a peptide linker. Suitable peptide linkers are known in the art and can be 5 to 25 amino acids, 5 to 20 amino acids, 5 to 15 amino acids, 10 to 25 amino acids, 10 to 20 amino acids, or 10 to 15 amino acids in length.
[0227] In some embodiments, the biologically active molecule may be conjugated to the antibody molecule via a cleavable linker. The linker may enable release of the biologically active molecule from the antibody molecule at the therapeutic site. The linker may include an amide bond (e.g., a peptide linker), a disulfide bond, or a hydrazone. For example, a peptide linker may be cleaved by a site-specific protease, a disulfide bond may be cleaved by the reducing environment of the cytosol, and a hydrazone may be cleaved by acid-mediated hydrolysis.
[0228] The present invention also provides isolated nucleic acid molecules or molecules encoding the antibody molecules of the present invention. A person skilled in the art will have no difficulty in preparing such nucleic acid molecules using methods well known in the art.
[0229] The one or more nucleic acid molecules can include, for example, the sequence set forth in SEQ ID NOs: 82, 85, 88, 91, 94, 97, 100, 103, 106, 109, 112, 116, 119, 122, 125, 128, 131, or 133, which are set forth in FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, respectively. , FS22-053-010, FS22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, FS22-053, FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, and the CH3 domains of FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, and FS22-172-007. Preferably, the one or more nucleic acid molecules comprise the sequence set forth in SEQ ID NO: 116 or 82, which encode the CH3 domain of FS22-172-003 or FS22-053-008, respectively. More preferably, the one or more nucleic acid molecules comprise the sequence set forth in SEQ ID NO: 116, which encodes the CH3 domain of FS22-172-003.
[0230] The one or more nucleic acid molecules may encode the VH and / or VL domains, preferably the VH and VL domains, of antibody E12v2, E05v2, G12v2, or lam-G02v3, preferably antibody E12v2, E05v2, or G12v2, more preferably E12v2 or E05v2, and most preferably E12v2. The VH and VL domain sequences of these antibodies are described herein.
[0231] For example, the nucleic acid molecule may be (i) the VH domain nucleic acid sequence of antibody E12v2 set forth in SEQ ID NO: 13, and / or SEQ ID NO: 1 5. The nucleic acid sequence of the VL domain of antibody E12v2 according to claim 5; or (ii) the VH domain nucleic acid sequence of antibody E05v2 set forth in SEQ ID NO: 24, and / or SEQ ID NO: 26. The nucleic acid sequence of the VL domain of antibody E05v2 according to claim 26; (iii) the VH domain nucleic acid sequence of antibody G12v2 set forth in SEQ ID NO: 24, and / or SEQ ID NO: No. 31; or the nucleic acid sequence of the VL domain of antibody G12v2. (v) the VH domain nucleic acid sequence of antibody lam-G02v3 set forth in SEQ ID NO: 24, and / or SEQ ID NO: Nucleic acid sequence of the VL domain of antibody lam-G02v3 described in No. 42 may include:
[0232] The one or more nucleic acid molecules may be selected from the group consisting of antibody FS22-172-003-AA / E12v2, FS22-172-003-AA / E05v2, FS22-172-003-AA / G12v2, FS22-053-008-AA / E12v2, FS22-053-008-AA / E05v2, or FS22-053-008-AA / G12v2, preferably antibody FS22-172-003-AA / E12v2, FS22-172-003-AA / E05v2, FS22-172-003-AA / G12v2, FS22-053-008-AA / E12v2, or FS22-053-008-AA / E05v2, more preferably Alternatively, the heavy chain and / or the light chain, preferably the heavy chain and the light chain, of the antibody FS22-172-003-AA / E12v2. The heavy and light chain sequences of these antibodies are described herein.
[0233] For example, the nucleic acid molecule may be (i) the heavy chain nucleic acid sequence of antibody FS22-172-003-AA / E12v2 set forth in SEQ ID NO: 32 or 135, and and / or the light chain nucleic acid sequence of antibody FS22-172-003-AA / E12v2 set forth in SEQ ID NO: 39 or 136; or (ii) the heavy chain nucleic acid sequence of antibody FS22-172-003-AA / E05v2 set forth in SEQ ID NO: 138, and / or is the light chain nucleic acid sequence of antibody FS22-172-003-AA / E05v2 set forth in SEQ ID NO: 139; (iii) the heavy chain nucleic acid sequence of antibody FS22-172-003-AA / G12v2 set forth in SEQ ID NO: 141, and / or or the light chain nucleic acid sequence of antibody FS22-172-003-AA / G12v2 set forth in SEQ ID NO: 142; (iv) the heavy chain nucleic acid sequence of antibody FS22-053-008-AA / E12v2 set forth in SEQ ID NO: 144, and / or is the light chain nucleic acid sequence of antibody FS22-053-008-AA / E12v2 set forth in SEQ ID NO: 145; (v) the heavy chain nucleic acid sequence of antibody FS22-053-008-AA / E05v2 set forth in SEQ ID NO: 147, and / or The light chain nucleic acid sequence of antibody FS22-053-008-AA / E05v2 set forth in SEQ ID NO: 148; or (vi) the heavy chain nucleic acid sequence of antibody FS22-053-008-AA / G12v2 set forth in SEQ ID NO: 150, and / or is the light chain nucleic acid sequence of antibody FS22-053-008-AA / G12v2 set forth in SEQ ID NO: 151; may include:
[0234] When a nucleic acid encodes the VH and VL domains, or the heavy and light chains, of an antibody molecule of the invention, the two domains or chains may be encoded on two separate nucleic acid molecules.
[0235] Isolated nucleic acid molecules may be used to express the antibody molecules of the invention. The nucleic acid is generally provided in the form of a recombinant vector for expression. Thus, another aspect of the invention is A vector containing the nucleic acid as described above is provided. Suitable vectors can be selected or constructed containing appropriate regulatory sequences, including promoter sequences, transcription termination fragments, polyadenylation sequences, enhancer sequences, marker genes, and other sequences as needed. Preferably, the vector contains appropriate regulatory sequences for driving expression of the nucleic acid in a host cell. The vector can be a plasmid, a viral vector, e.g., a phage, or a phagemid, as needed.
[0236] The nucleic acid molecules or vectors described herein can be introduced into host cells. Techniques for introducing nucleic acids or vectors into host cells are well established in the art, and any suitable technique can be used. A variety of host cells suitable for the production of recombinant antibody molecules are known in the art and include bacterial, yeast, insect, or mammalian host cells. Preferred host cells are mammalian cells such as CHO, NS0, or HEK cells, e.g., HEK293 cells.
[0237] Another aspect of the present invention provides a method for producing an antibody molecule of the present invention, comprising expressing a nucleic acid encoding the antibody molecule in a host cell and, optionally, isolating and / or purifying the antibody molecule so produced. Methods for culturing host cells are well known in the art. The method may further comprise isolating and / or purifying the antibody molecule. Techniques for purifying recombinant antibody molecules are well known in the art and include, for example, HPLC, FPLC, or affinity chromatography (e.g., using Protein A or Protein L). In some embodiments, purification may be performed using an affinity tag on the antibody molecule. The method may also comprise formulating the antibody molecule, optionally with a pharmaceutically acceptable excipient or other substance as described below, into a pharmaceutical composition.
[0238] PD-L1 is known to be expressed on many cancer cells and is expressed on cells of the immune system. CD137 is expressed on T cells, especially CD8 + It is expressed on cells of the immune system, including T cells, B cells, NK cells, and tumor-infiltrating lymphocytes (TILs). + At lower levels than T cells, CD4 + Expressed on T cells, but not on CD4 + It has also been shown to be involved in inducing the proliferation and activation of some subsets of T cells.
[0239] Activation of CD137 inhibits CD8 + T cell proliferation, survival and cytotoxic effector function, and CD8 +T cell differentiation and memory CD8 + It has been shown to play a role in enhancing T cell maintenance. Activation of CD137 has also been demonstrated to enhance NK cell-mediated ADCC, as well as B cell proliferation, survival, and cytokine production.
[0240] As described in detail herein, the inventors have demonstrated that the antibody molecules of the present invention can simultaneously bind to PD-L1 and CD137 to induce CD137 agonism. Thus, the antibody molecules autonomously drive agonism based on the expression of PD-L1 and CD137, without the need for an additional cross-linking agent. Because PD-L1 is expressed on many cancer cells and CD137 is expressed on immune cells and has a known role in enhancing immune cell proliferation and survival, the antibody molecules of the present invention are expected to be able to enhance immune responses where PD-L1 is expressed, for example, in the tumor microenvironment. Furthermore, the inventors have shown that the use of antibody molecules with these properties is effective in suppressing tumor growth in syngeneic mouse models of cancer, and that such antibody molecules are more effective than the administration of two binding molecules that bind to PD-L1 and CD137, respectively.
[0241] Thus, the antibody molecules described herein may be useful in therapeutic applications, particularly in the treatment of cancer.
[0242] The antibody molecules described herein may be used in methods of treatment of the human or animal body. (i) an antibody molecule as described herein for use as a medicament; (ii) an antibody molecule as described herein for use in a method for treating a disease or disorder; (iii) use of an antibody molecule described herein in the manufacture of a medicament for use in the treatment of a disease or disorder; and (iv) a method for treating a disease or disorder in an individual, the method comprising administering to the individual a therapeutically effective amount of an antibody molecule described herein. to provide.
[0243] The individual may be a patient, preferably a human patient.
[0244] Treatment can be any procedure or therapy that achieves some desired therapeutic effect, such as inhibiting or slowing the progression of a condition, including slowing the rate of progression, stopping the rate of progression, improving the condition, curing or ameliorating (partially or totally) the condition, preventing, ameliorating, delaying, alleviating, or arresting one or more symptoms and / or signs of the condition, or extending the survival of an individual or patient beyond that expected in the absence of treatment.
[0245] Treatment as a preventative measure (i.e., prophylaxis) is also included. For example, an individual susceptible to or at risk of developing or recurring a disease, such as cancer, can be treated as described herein. Such treatment can prevent or delay the development or recurrence of the disease in the individual.
[0246] The treatment methods described may include administering at least one additional treatment to an individual in addition to the antibody molecule. Thus, the antibody molecules described herein may be administered to an individual alone or in combination with one or more other treatments. When the antibody molecule is administered to an individual in combination with another treatment, the additional treatment may be administered to the individual simultaneously with, sequentially with, or separately from the administration of the antibody molecule. When the additional treatment is administered simultaneously with the antibody molecule, the antibody molecule and the additional treatment may be administered to the individual as a combined preparation. For example, the additional treatment may be a known treatment or therapeutic agent for the disease being treated.
[0247] Although antibody molecules can be administered alone, they are usually administered in the form of a pharmaceutical composition, which may contain at least one component in addition to the antibody molecule. Accordingly, another aspect of the present invention provides a pharmaceutical composition comprising the antibody molecule described herein. Methods are also provided that include formulating the antibody molecule into a pharmaceutical composition.
[0248] In addition to the antibody molecule, the pharmaceutical composition may include pharmaceutically acceptable excipients, carriers, buffers, stabilizers, or other materials known to those skilled in the art. As used herein, the term "pharmaceutically acceptable" refers to compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of a subject (e.g., a human) without undue toxicity, irritation, allergic response, or other problem or complication, within the scope of sound medical judgment, commensurate with a reasonable benefit / risk ratio. Each carrier, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation. The precise nature of the carrier or other material will depend on the route of administration, which may be by infusion, injection, or other suitable route, as discussed below.
[0249] For parenteral, e.g., subcutaneous or intravenous, administration (e.g., by injection), a pharmaceutical composition containing the antibody molecule may be in the form of a parenterally acceptable aqueous solution that is pyrogen-free and has appropriate pH, isotonicity, and stability. Those skilled in the relevant art will readily appreciate that suitable solutions can be prepared using, for example, isotonic vehicles such as sodium chloride injection, Ringer's injection, lactated Ringer's injection, etc. It is possible to prepare a solution containing buffers such as phosphoric acid, citric acid, and other organic acids; antioxidants such as ascorbic acid and methionine; preservatives (octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3'-pentanol; and m-cresol); low molecular weight polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; glycolic acid; glycerol; PEG; PEG-100; PEG-1500; PEG-10 ... Preservatives, stabilizers, buffers, antioxidants and / or other additives may be used as needed, including amino acids such as lysine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™, PLURONICS™, or polyethylene glycol (PEG).
[0250] In some embodiments, the antibody molecule may be provided in lyophilized form for reconstitution prior to administration, for example, lyophilized antibody molecules may be reconstituted with sterile water and mixed with saline prior to administration to an individual.
[0251] The amount administered may be a "therapeutically effective amount," which is sufficient to show benefit to the individual. The actual amount administered, as well as the rate and time course of administration, will depend on the nature and severity of the condition being treated, the particular individual being treated, the individual's clinical condition, the cause of the disorder, the site of delivery of the composition, the type of antibody molecule, the method of administration, the schedule of administration, and other factors known to physicians. Prescribing treatment, e.g., determining dosage, is within the responsibility of general practitioners and other physicians and may depend on the severity of the symptoms and / or the progression of the disease being treated. Appropriate dosages of antibody molecules are well known in the art (Ledermann et al., (1991) Int. J. Cancer 47: 659-664; and Bagshawe et al., (1991 Antibody, Immunoconjugates and Radiopharmaceuticals 4: 915-922). The dosages described herein or in the Physician's Desk Reference 10 ... (2003) may be used. A therapeutically effective amount of an antibody molecule or an appropriate Dosages can be determined by comparing in vitro and in vivo activity in animal models. Methods for extrapolating effective dosages in mice and other test animals to humans are known. The exact dose will depend on many factors, including the size and location of the area to be treated, and the precise nature of the antibody molecule.
[0252] Typical antibody doses range from 100 μg to 1 g for systemic administration and from 1 μg to 1 mg for local administration. An initial higher loading dose may be administered, followed by one or more lower doses. This is the dose for a single treatment of an adult individual and can be adjusted proportionally for children and infants, and for other antibody formats proportionally based on molecular weight.
[0253] Treatments may be repeated daily, twice weekly, once weekly, or once monthly, at the physician's discretion. An individual's treatment schedule may depend on the pharmacokinetic and pharmacodynamic properties of the antibody composition, the route of administration, and the nature of the condition being treated.
[0254] Treatment can be periodic, with the period between administrations being about 2 weeks or more, e.g., about 3 weeks or more, about 4 weeks or more, about monthly or more, about 5 weeks or more, or about 6 weeks or more. For example, treatment can be every 2 to 4 weeks, or every 4 to 8 weeks. Suitable formulations and routes of administration are described above.
[0255] In a preferred embodiment, the antibody molecules described herein may be for use in methods of treating cancer.
[0256] Cancer can be characterized by the abnormal proliferation of malignant cancer cells. When referring to a specific type of cancer, such as breast cancer, this refers to the abnormal proliferation of malignant cells in related tissues, such as breast tissue. A secondary cancer that is located in the breast but is the result of the abnormal proliferation of malignant cells in another tissue, such as ovarian tissue, is not breast cancer as referred to herein, but ovarian cancer.
[0257] The cancer may be a primary cancer or a secondary cancer. Accordingly, the antibody molecules described herein may be for use in methods of treating cancer in an individual, wherein the cancer is a primary tumor and / or tumor metastasis.
[0258] Cancer tumors treated using the antibody molecules described herein may contain TILs that express CD137, for example, on their cell surface. In one embodiment, the tumor may be one that has been determined to contain TILs that express CD137. Methods for determining antigen expression on the cell surface are known in the art and include, for example, flow cytometry.
[0259] For example, cancers that may be treated using the antibody molecules described herein include leukemias such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL); lymphomas such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, and multiple myeloma; and sarcomas (e.g., soft tissue sarcoma), skin cancer (e.g., Merkel cell carcinoma), melanoma, bladder cancer (e.g., urothelial carcinoma), brain cancer (e.g., glioblastoma multiforme), breast cancer, uterine / endometrial cancer, ovarian cancer (e.g., ovarian serous carcinoma). and solid cancers such as ovarian cancer, ...
[0260] In a preferred embodiment, the cancer to be treated using the antibody molecules described herein is a solid tumor.
[0261] More preferably, the cancer to be treated using the antibody molecules described herein is a solid tumor selected from the group consisting of melanoma, bladder cancer, brain cancer, breast cancer, ovarian cancer, prostate cancer, lung cancer, colorectal cancer, cervical cancer, liver cancer, head and neck cancer, pancreatic cancer, renal cancer, gastric cancer, and gastrointestinal stromal tumor (GIST).
[0262] In a further preferred embodiment, the cancer treated using the antibody molecules described herein may be a cancer that responds to treatment with one or more checkpoint inhibitors, such as antibodies that bind to PD-1, PD-L1, or CTLA4. Such tumors are likely to have higher TIL levels and / or higher tumor mutation burden than tumors that are not sensitive to checkpoint inhibitor treatment. Such tumors are also referred to as warm or hot tumors.
[0263] Examples of such tumors include head and neck squamous cell carcinoma (HNSCC), melanoma, lung cancer (such as squamous cell lung carcinoma, lung adenocarcinoma, non-small cell lung cancer [NSCLC], or small cell lung cancer [SCLC]), prostate cancer, cervical cancer (such as cervical squamous cell carcinoma or endocervical adenocarcinoma), bladder cancer, breast cancer, thyroid cancer, renal cancer, colorectal cancer (MSI or MSS, e.g., colorectal adenocarcinoma), esophageal cancer, non-Hodgkin's lymphoma (NHL), gastric cancer, endometrial cancer, pancreatic cancer, ovarian cancer, hepatocellular carcinoma, mesothelioma, urothelial carcinoma, Merkel cell carcinoma, and gastric adenocarcinoma. In a preferred embodiment, the cancer is HNSCC. The cancer further has not been previously treated with a chemotherapeutic or radiotherapeutic agent. It may be cancer, i.e., the individual being treated may be a cancer patient who has not been treated with a chemotherapy or radiotherapy agent for the cancer in question.
[0264] Alternatively, the cancer to be treated using the antibody molecules described herein may be a cancer, such as pancreatic or prostate cancer, that does not respond to treatment with one or more checkpoint inhibitors, such as antibodies that bind to PD-1, PD-L1 or CTLA4. Thus, individuals treated with the antibodies of the invention may be cancer patients, such as pancreatic or prostate cancer patients, who have previously shown an inadequate response to one or more checkpoint inhibitors, such as anti-PD-L1 or anti-PD-L1 antibodies.
[0265] Tumors that do not respond to treatment with one or more checkpoint inhibitors are also called cold tumors. Without wishing to be bound by theory, it is believed that treatment of cancers that do not respond to treatment with one or more checkpoint inhibitors alone with chemotherapy, radiation therapy, immunotherapeutic agents such as immunostimulants, or anti-tumor vaccines causes cancer cell death, resulting in an increase in TILs within the tumor and increased expression of immunosuppressive receptors, thereby making the cancer responsive to treatment with checkpoint inhibitors, i.e., converting the cold tumor into a warm tumor. Thus, the antibody molecule of the present invention can be used in a method for treating cancer in an individual, where the cancer is unresponsive or resistant to treatment with one or more checkpoint inhibitors alone, and the method comprises administering the antibody molecule to the individual in combination with a chemotherapeutic agent, radiation therapy agent, or immunostimulant, or an anti-cancer vaccine. Also contemplated are methods of treating cancer in an individual, wherein the cancer is unresponsive or resistant to treatment with one or more checkpoint inhibitors alone, and the method comprises administering to the individual the antibody molecule in combination with a chemotherapeutic, radiotherapeutic, or immunostimulatory agent, or an anti-cancer vaccine.
[0266] In cancer, treatment can include inhibiting cancer growth, including complete cancer remission, and / or inhibiting cancer metastasis and inhibiting cancer recurrence. Cancer growth generally refers to any of a number of indicators that indicate a change in cancer to a more advanced form. Thus, indicators for measuring inhibition of cancer growth include reduced cancer cell survival, a decrease in tumor volume or morphology (e.g., as determined using computed tomography (CT), ultrasound, or other imaging methods), slowed tumor growth, destruction of tumor vasculature, improved performance in delayed-type hypersensitivity skin tests, increased activity of anti-cancer immune cells or other anti-cancer immune responses, and reduced levels of tumor-specific antigens. Activating or enhancing an individual's immune response to a cancerous tumor can improve the individual's ability to resist cancer growth, particularly the growth of cancer already present in the subject, and / or reduce the individual's propensity for cancer growth.
[0267] In the treatment of cancer, the antibody molecules described herein may be administered to an individual in combination with another anti-cancer therapy or therapeutic agent, such as an anti-cancer therapy or therapeutic agent that has been shown or may be suitable for treating the cancer in question. For example, the antibody molecule may be administered to an individual in combination with a chemotherapeutic agent, radiation therapy, radionuclides, immunotherapeutic agents, anti-tumor vaccines, oncolytic viruses, adoptive cell transfer (ACT) therapy such as adoptive NK cell therapy, or treatment with chimeric antigen receptors (CARs), TILs, or gamma / delta T cells, or an agent for hormonal therapy.
[0268] Without wishing to be bound by theory, it is believed that the antibody molecules described herein may act as adjuvants in anti-cancer treatments. Specifically, it is believed that administration of the antibody molecules to an individual in combination with, for example, chemotherapy or radiation therapy, elicits a greater immune response against the cancer than is achieved with chemotherapy or radiation therapy alone.
[0269] One or more chemotherapeutic agents for administration in combination with an antibody molecule as described herein The agent may be selected from the group consisting of taxanes, cytotoxic antibiotics, tyrosine kinase inhibitors, PARP inhibitors, B-Raf enzyme inhibitors, MEK inhibitors, c-MET inhibitors, VEGFR inhibitors, PDGFR inhibitors, alkylating agents, platinum analogs, nucleoside analogs, antifolates, thalidomide derivatives, anti-cancer chemotherapeutic agents, etc. Taxanes include docetaxel, paclitaxel, and nab-paclitaxel; cytotoxic antibiotics include actinomycin, bleomycin, and anthracyclines such as doxorubicin, mitoxantrone, and valrubicin; tyrosine kinase inhibitors include erlotinib, gefitinib, axitinib, PLX3397, imatinib, cobemitinib, and trametinib; PARP inhibitors include pilaparib. B-Raf enzyme inhibitors include vemurafenib and dabrafenib; alkylating agents include dacarbazine, cyclophosphamide, and temozolomide; platinum analogs include carboplatin, cisplatin, and oxaliplatin; nucleoside analogs include azacitidine, capecitabine, fludarabine, fluorouracil, and gemcitabine; and antifolates include methotrexate and pemetrexed. Other chemotherapeutic agents suitable for use in the present invention include defactinib, entinostat, eribulin, irinotecan, and vinblastine.
[0270] Preferred therapeutic agents for administration with the antibody molecules described herein are doxorubicin, mitoxantrone, cyclophosphamide, cisplatin, and oxaliplatin.
[0271] Radiation therapy for administration in combination with an antibody molecule as described herein can be external beam radiation therapy or brachytherapy.
[0272] Radionuclides for administration with the antibody molecules described herein may be selected from the group consisting of yttrium-90, iodine-131, bismuth-213, astatine-211, lutetium-177, rhenium-188, copper-67, actinium-225, iodine-125 and terbium-161.
[0273] The immunotherapeutic agent for administration in combination with the antibody molecule described herein may be a therapeutic antibody molecule, a nucleotide, a cytokine, or a cytokine-based therapeutic agent. For example, the therapeutic antibody molecule may bind to an immunomodulatory molecule, such as an inhibitory checkpoint molecule or an immune co-stimulatory molecule, a receptor of the innate immune system, or a tumor antigen, such as a cell surface tumor antigen or a soluble tumor antigen. Examples of immunomodulatory molecules to which the therapeutic antibody molecule may bind include CTLA-4, LAG-3, TIGIT, TIM-3, VISTA, PD-L1, PD-1, CD47, CD73, CSF-1R, KIR, CD40, HVEM, IL-10, and CSF-1. Examples of receptors of the innate immune system to which the therapeutic antibody molecule may bind include TLR4, TLR7, TLR9, RIG-I-like receptors (e.g., RIG-I and MDA-5), and STING. Examples of tumor antigens to which therapeutic antibody molecules may bind include HER2, EGFW, EGFR, CD20 and TGF-beta.
[0274] The nucleotide for administration in combination with an antibody molecule as described herein may be an siRNA.
[0275] The cytokine or cytokine-based therapy may be selected from the group consisting of IL-2, a prodrug of conjugated IL-2, GM-CSF, IL-7, IL-12, IL-9, IL-15, IL-18, IL-21, and type I interferon.
[0276] Antitumor vaccines for the treatment of cancer are being implemented in the clinic and are being discussed at length in the scientific literature (e.g., Rosenberg, S. 2000 Development of Cancer Vaccines). In addition, the use of these cells as a vaccination method, both with and without granulocyte-macrophage colony-stimulating factor (GM-CSF), has been shown to be effective in the treatment of autologous or allogeneic leukemia. These include strategies that stimulate the immune system to respond to various cell markers expressed by cancer cells in the system. GM-CSF elicits a strong response in antigen presentation and works particularly well when used in these strategies.
[0277] The features disclosed in the foregoing description, the following claims, or the accompanying drawings, and appropriately expressed in their specific form or in terms of means for performing a disclosed function or a method or process for obtaining a disclosed result, may be utilized separately or in any combination of such features to realize the invention in various of its forms.
[0278] While the present invention has been described in conjunction with the above exemplary embodiments, many equivalent modifications and variations will be apparent to those skilled in the art given this disclosure. Accordingly, the exemplary embodiments of the invention set forth above are considered to be illustrative and not limiting. Various modifications to the described embodiments can be made without departing from the spirit and scope of the invention.
[0279] For the avoidance of doubt, any theoretical explanations provided herein are provided for the purpose of enhancing the understanding of the reader, and the inventors do not wish to be bound by any of these theoretical explanations.
[0280] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0281] Throughout this specification, including the claims that follow, unless the context requires otherwise, the words "comprise" and "include," as well as variations such as "comprises," "comprising," and "including," are used interchangeably. It is understood that the term "inclusive" means the inclusion of a recited integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps.
[0282] As used in this specification and the appended claims, the singular forms "a," "an," and "the" only includes plural referents unless the context clearly indicates otherwise. It should be understood that, as used herein, ranges may be expressed as from "about" one particular value and / or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment. The term "about" in connection with numerical values is optional and means, for example, + / - 10%. [Example]
[0283] Example Example 1: Antigen selection and characterization mAb that binds to both PD-L1 and CD137 and can agonize CD137 2 The selection and screening methods used to identify these tumors involve the use of various PD-L1 and CD137 antigens, the production of which is described in more detail below.
[0284] 1.1 Recombinant CD137 antigen Tumor necrosis factor receptor superfamily (TNFRSF) members, such as CD137, are known to have a tendency to form clustered multimers when bound to their cognate ligand (Croft, M. 2003). This tendency to aggregate for their function has been shown to be useful for use in in vitro selections such as phage and yeast display, and for the analysis of selected proteins. This makes it difficult to produce soluble recombinant proteins that do not aggregate in solution for characterization.
[0285] Several commercially available recombinant antigens were tested, and most were found to be unsuitable for use with these selections due to the level of aggregates present. Among those tested, biotinylated human secreted CD137, hFc fusion protein (BPS Biosciences) Only hCD137-hFc-Avi-BPS (Cat. No. 71171) (hereinafter referred to as "hCD137-hFc-Avi-BPS") exhibited sufficiently low aggregation. It is quite suitable and has been used for selection, but with limited success (see Example 2).
[0286] Since the majority of commercially available antigens were deemed unsuitable, the following recombinant dimeric and monomeric CD137 antigens (see Table 1) were produced in-house for use in the selections.
[0287] [Table 2]
[0288] Monomeric antigens were produced by cloning DNA encoding the extracellular domain of human (SEQ ID NO: 186) or mouse CD137 (SEQ ID NO: 188) along with the Avi sequence and six C-terminal histidine residues into a modified pFUSE vector (Invivogen catalog no. pfuse-mg2afc2) using EcoRI-HF and BamHI-HF restriction enzymes. The vectors were transfected into HEK293-6E cells (National Research Council of Canada). The expressed CD137 was isolated by HisTrap™ excel nickel column (GE LifeSciences). , 29048586) and size exclusion chromatography (SEC) to ensure that the antigen was a single species and free of aggregates.
[0289] To produce dimeric antigens, DNA constructs encoding the extracellular domains of human, mouse, or cynomolgus CD137 fused to the mIgG2a Fc domain along with the Avi sequence were cloned into a modified pFUSE vector and transfected into HEK293-6E cells. Recombinant CD137 was purified using a MabSelect SuRe™ Protein A column (GE Healthcare, 11003494) and size exclusion chromatography (SEC) to confirm that the antigen was a single molecule. Ensure seeds and no aggregates.
[0290] The dimeric and monomeric antigens were biotinylated using a BirA biotin-biotin protein ligase reaction kit (Avidity LLC, BirA500) to produce monomeric CD137 antigen labeled with a single biotin molecule and dimeric CD137 antigen labeled with two biotin molecules, one for each of the two monomers. Three milligrams of antigen was mixed with 7.8 μl of BirA enzyme mix at an enzyme-to-substrate molar ratio of 1:50. Additives were then added according to the manufacturer's recommendations (142 μl Biomix A, 142 μl Biomix B, 142 μl biotin), and the reaction mixture was incubated at room temperature for 2 hours. To maintain the integrity of the biotinylated protein, the reaction mixture was immediately filtered using an Amicon 30 μm filter (Merck Millipore UFC503096). The buffer was exchanged into DPBS (Life Technologies 14190-169).
[0291] The protein was further purified by SEC to ensure the removal of BirA enzyme and the generation of a final high-quality, monodisperse protein preparation free of high-molecular-weight aggregates. More specifically, materials from the same production lot were mixed and analyzed for stability and purity by size-exclusion high-performance liquid chromatography (SE-HPLC), SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and size-exclusion chromatography with multi-angle light scattering detection (SEC-MALS). Complete biotinylation of the protein was confirmed by streptavidin-shift SDS-PAGE gels. Recombinant human and mouse antigens were analyzed in vitro by surface plasmon resonance (SPR) against anti-CD137 positive control antibodies (20H4.9 (U.S. Patent No. 7,288,638) and Lob12.3 (University of Southampton), respectively), and IgG. Binding to human and mouse CD137 ligand-expressing DO11.10 cells was confirmed by flow cytometry. After incubation of cells with CD137 antigen for 1 hour, cell binding was detected using a fluorescently labeled anti-mouse Fc fragment antibody. Recombinant cyno antigen was confirmed to bind to DO11.10 cells (National Jewish Health) expressing cynoCD137 ligand by flow cytometry as described above. To ensure the highest possible purity for the material used in the selection protocol, thorough protein characterization of the antigen was performed to ensure that the presence of protein aggregates did not exceed 2%.
[0292] 1.2 Cell-expressed CD137 antigen DO11.10 cells (National Jewish Health) expressing full-length murine CD137 (SEQ ID NO: 187) or human CD137 (SEQ ID NO: 185), designated "DO11.10.mCD137" and "DO11.10.hCD137," respectively, were produced to present antigen in a membrane-bound conformation most similar to its native form for selection and further characterization of selected Fcabs as listed in Table 2.
[0293] Lentiviral transduction was used to generate these DO11.10 cells overexpressing the human or mouse CD137 receptor using the Lenti-X HTX Packaging System (Clontech, Catalog No. 631249). The Lenti-X expression vector (pLVX) (Clontech, Catalog No. 631253) containing cDNA encoding human CD137 (SEQ ID NO: 185) or mouse CD137 (SEQ ID NO: 187) was cotransfected with the Lenti-X HTX Packaging Mix into the Lenti-X 293T Cell Line (Clontech, Catalog No. 632180) to generate virus. The DO11.10 cell line was then transduced with these lentiviral vectors.
[0294] Expression of human or mouse CD137 on these cells was confirmed by flow cytometry by binding of the 20H4.9 and Lob12.3 anti-CD137 positive control antibodies, respectively. After incubating cells with the human or mouse positive control antibodies for 1 hour, cell binding was detected using a fluorescently labeled anti-human Fc detection antibody (Stratech Scientific Ltd, catalog number 109-546-098-JIR).
[0295] DO11.10 cells expressing cynomolgus monkey CD137 (SEQ ID NO: 189, designated "DO11.10.cCD137") were also generated using the same lentiviral transduction method and used to test the cross-reactivity of cynomolgus monkey CD137 with anti-human CD137 Fcabs. Cynomolgus monkey CD137 expression was confirmed by flow cytometry analysis of the cells with an anti-CD137 positive control antibody (MOR7480.1, U.S. Patent Application Publication No. 2012 / 0237498) as previously described. This was confirmed by the combination of the two strains (A1).
[0296] [Table 3]
[0297] 1.3 CD4 + and Fc-tagged mouse and human PD-L1 Fusion proteins containing human and mouse PD-L1 antigens have been generated for use in antibody selection and screening. The antigens contain a C-terminal His tag and a monomeric rat CD4 + , domains 3 and 4 (rCD4) tag (Brown and Barclay, 1994), dimeric human IgG The Fc domain or human PD-L1 alone was expressed with either an Avi tag, resulting in hPD-L1-rCD4-His (SEQ ID NO: 195), hPD-L1-Fc-His (SEQ ID NO: 196), mPD-L1-rCD4-His (SEQ ID NO: 197), mPD-L1-Fc-His (SEQ ID NO: 198), and hPD-L1-His-Avi (SEQ ID NO: 199). Producing the antigen in different formats allowed for removal of tag binders during successive rounds of antibody phage display panning. Expression plasmids encoding the antigen were transfected into HEK293 cells as described in Chapple et al., 2006. The supernatant was collected 5 days after transfection, and the secreted antigen was purified by Ni-NTA Sepharose affinity chromatography (Schofield et al., 2007). rCD4 and Fc-containing PD-L1 antigen were biotinylated using EZ-link Sulfo-NHS-Biotin Reagent (Thermo Fisher Scientific, product code 21326) according to the manufacturer's recommendations. The biotinylated reaction product was subjected to gel filtration, and the monomer fraction was collected. The monomer fraction was used for all solution-phase phage display selections. The average biotin content per molecule was determined using a fluorescent biotin quantitation kit (Thermo Fisher Scientific, product code 46610). The number of biotins ranged from 1 to 3 per PD-L1 monomer.
[0298] Example 2: Selection and characterization of anti-human CD137 Fcabs 2.1 Naive selection of anti-human CD137 Fcabs To select Fcabs that bind to human CD137, we employed yeast and phage display selection campaigns to maximize the diversity of identified Fcabs. Cell surfaces displaying both human CD137 and recombinant dimeric human CD137 were used to provide various antigen formats to exert avidity-driven selection pressure against dimeric or multimeric CD137 proteins. Obtaining Fcabs that bind strongly to the CD137 complex rather than with high affinity to monomeric CD137 was considered beneficial because such Fcabs would preferentially target activated and primed T cells, where CD137 upregulation occurs after T cell stimulation. Without wishing to be bound by theory, we hypothesized that T cells with very low or negligible levels of CD137 membrane expression are more likely to have monomeric CD137, unlike activated T cells with highly upregulated CD137, where the majority of the protein is in dimeric, trimeric, or higher multimeric forms. As a result of avidity-driven selection, Fcabs bind preferentially to activated T cells and poorly to naive T cells that express only monomeric CD137. Selecting for CD137 Fcabs with high avidity reduces potential off-target T cell activation and associated toxicity.
[0299] Six naive phage libraries displaying the CH3 domain of human IgG1 were Six libraries were used for selection by page display. All six libraries consisted of a randomized AB loop (containing residues at positions 14–18 according to the IMGT numbering) and a randomized EF loop (containing residues at positions 92–101 according to the IMGT numbering). One of the libraries consisted of clones with either two or four amino acids (encoded by two or four NNK codons) inserted at position 101 of the EF loop (the inserted residues were at positions 101.4–101.1 according to the IMGT numbering).
[0300] 3230 phage clones were screened by phage ELISA for binding to dimeric recombinant hCD137 antigen, with recombinant Fc used as a negative control. 1140 phage clones were screened by phage FACS for specific binding to DO11.10.hCD137 cells. Individual hits were then sequenced, and the resulting 76 unique sequences were assigned Fcab clone identifiers and identified as mAbs. 2 To express the Fcab clones in this format, they were subcloned into the pTT5 expression vector (National Research Council of Canada) containing the HelD1.3 IgG1 heavy chain expression cassette (as performed See Example 3.2).
[0301] Four naive yeast libraries displaying the CH1 to CH3 domains of human IgG1 were used for yeast display selection. All four libraries consisted of a randomized AB loop (containing residues 14 to 18 according to the IMGT numbering) and a randomized EF loop (containing residues 92 to 101 according to the IMGT numbering) of the CH3 domain. Two of the libraries further contained a five-amino acid residue insertion at position 16 of the AB loop of the CH3 domain (residues 16.5 to 16.1 according to the IMGT numbering).
[0302] The 2784 yeast single clones identified from the library selection were screened for antigen binding using a flow cytometry antigen-binding assay, which involved incubating cells with biotinylated recombinant dimeric human antigen or mouse Fc fragment and distinguishing yeast clones that bound to the Fc portion of the recombinant hCD137 antigen. To increase the number of hits, selection was repeated under various antigen concentrations and conditions, such as increasing the induction temperature, decreasing the selection stringency, or reducing the number of rounds. Hit sequences revealed fairly low output diversity, with only nine Fcab clones with identified unique sequences: FS22-053, FS22-172, FS22-173, FS22-174, FS22-175, FS22-176, FS22-177, FS22-178, and FS22-179.
[0303] 2.2 "Mock" mAb 2 Preparation of anti-human CD137 Fcab in the format "Mock" mAbs consisting of IgG1 molecules containing 76 anti-human CD137 Fcab clones isolated from phage and 9 clones isolated from yeast selection 2 The antibody is a mAb 2 Mock mAb was produced to allow characterization of Fcabs in a 24-well format. 2 was prepared by substituting a portion of the CH3 domain Fcab, including the AB, CD, and EF loops, for the corresponding region of the CH3 domain of the anti-hen egg lysozyme antibody HelD1.3. The generation of the HelD1.3 antibody is described in Tello et al. 1993. The heavy and light chain sequences of the antibody HelD1.3 are shown in SEQ ID NOs: 191 and 159, respectively. Mock mAb 2 The molecules were produced by transient expression in HEK293-6E cells. To assess the amount of protein produced, a protein A quantitative biosensor from PALL (18-5021) was used. Using the Octet QKe platform, which incorporates Protein content was quantified. Proteins were purified by protein A affinity chromatography using a mAb SelectSure column. 53 phage-derived CD137 mAb 2 The protein measured below the detection threshold and was therefore deemed unsuitable for further analysis. 2 The column was loaded onto a mAb Select SuRe Protein A column (GE Healthcare, Purified using 11003494).
[0304] Next, these mAbs 2 Select from a wide range of biomedical applications using the Octet QKe platform. Using blue light interferometry (BLI), human recombinant antigen (biotinylated hCD137-mFc-A) was detected. vi) were tested for binding to 12 mAbs. 2 19 did not bind to the CD137-coated sensor (FS22-007, FS22-033, FS22-042, FS22-049, FS22-050, FS22-052, FS22-053, FS22-054, FS22-169, FS22-172, FS22-173, FS22-174, FS22-179, FS22-180, FS22-181, FS22-183, FS22-187, FS22-194, and FS22-195).
[0305] 2.3 Selected anti-CD137 mock mAbs in human NF-κB reporter assays 2 Activity of Multimerization and clustering are required for TNFR signaling (Bitra et al., 2017). CD137 is involved in the NF-κB signaling pathway when it interacts with its NF-κB cognate ligand, CD137L. , which clusters and activates the NF-κB signaling pathway. Agonist molecules mimic ligands that promote CD137 clustering and activation, thereby activating the NF-κB signaling pathway. Some agonistic antibodies, such as urelumab, can inherently induce CD137 clustering upon binding, while others, such as utomilumab, require additional cross-linking of the antibody itself to induce CD137 clustering (Fisher et al., 2012). Fc gamma receptors on cells are known to induce such cross-linking in vivo, but this is inefficient and can occur far from the site of therapeutic interest. Because dose-limiting toxicities are associated with urelumab but not with utlimumab, we chose to select anti-CD137-binding Fcabs that have no inherent agonizing capacity, but only those that require additional cross-linking to induce CD137 clustering. We therefore developed an assay that can detect activation of the intracellular NF-κB signaling pathway by clustering cell-surface-expressed CD137 with a cross-linking antibody, but that shows little activity when the antibody is not cross-linked. This assay was then tested against a mock mAb, regardless of whether the Fcabs were found to bind to the recombinant antigen by BLI. 2 27 anti-CD137 Fcab clones and anti-CD20 mAb in the format 2 This was used to test the agonistic functional activity of six anti-CD137 Fcab clones in a ELISA format.
[0306] This can be measured by activation of the NF-κB signaling pathway in the assay. 2 Cross-linking was promoted and NF-κB activation was measured.
[0307] The cDNA encoding human CD137 (SEQ ID NO: 185) was subcloned into the pMSCV-neomycin vector (Takara Clontech, Cat. 634401) using EcoRI-HF and XhoI restriction enzymes. RetroPack PT67 cell line (Clontech, Cat. 631510) was used to produce retroviral particles according to the manufacturer's protocol. This retrovirus was then used to transfect Qiagen Cignal Lenti NFkB Reporter (luc) (Qiagen, Cat. No. 336851) lentivirus, which contains an NF-κB-sensitive promoter controlling the expression of luciferase. The virus was used to transduce HEK.FRT.luc cells, which had been previously generated by transducing the Flp-In T-REx 293 HEK cell line (Life Technologies, R780-07). These HEK.FRT.luc.hCD137 cells were used to transduce a mock mAb containing the CD137 binders identified in the selection. 2 was screened.
[0308] Each mock mAb 2 Prepare a 2 μM dilution of in DPBS (Life Technologies, 14190169) The reporter cells were cultured in a medium containing DMEM (Gibco, Cat. 61965-026); 10% FCS (Gibco, Cat. 10270-106); 1 x PennStrep (Gibco, Cat. 15140-122); 15 μg / mL of blasticidin. The mAbs were further diluted 1:3 in 100 μg / ml (Melford Laboratories Ltd, Cat. B1105); puromycin 5 μg / ml (Life technologies, Cat. A11113803); zeocin 100 μg / ml (InvivoGen, Cat. 11006-33-0); geneticin 500 μg / ml (Life Technologies, Cat. 10131-027). Protein L (Life Technologies, 21189) was used as an artificial crosslinker to crosslink the mAbs. 2The cells were mixed with the molecule at a 1:4 molar ratio. After 24 hours of incubation, cells were treated with 100 μl of Promega Bio-Glo™ Luciferase Assay Reagent (Promega catalog number G7941) according to the manufacturer's instructions, and luminescence was measured using a plate reader equipped with Gen5 Software, BioTek, with a 0.5-second integration time. Luminescence values are a measure of luciferase produced in response to activation of the NF-κB signaling pathway by crosslinked Fcab-induced CD137 clustering. Luminescence values were plotted against the logarithmic concentration of Fcab, and the resulting curve was fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0309] Hits were identified by at least a 10-fold increase in luciferase signal when cross-linked with protein L compared to uncross-linked. These clones were determined to be capable of inducing CD137 clustering and subsequent activation of downstream signaling pathways. Of all clones tested, two, FS22-053 and FS22-172, were able to induce this 10-fold increase in luciferase upon cross-linking, but not EC 50 Neither could be determined. Both were selected for further characterization in the DO11.10 T cell activation assay. Surprisingly, despite binding to the CD137 target by BLI, the remaining cross-linked clones showed no observed activity, indicating that they likely bound to unrelated epitopes on CD137 or that the affinity of such clones was not sufficient to bind CD137 strongly enough to initiate the NF-κB signaling cascade.
[0310] Overall, over 30 Fcabs were tested, and only two Fcabs (FS22-053 and FS22-172) were identified from naive selection that exhibited the desired function in the NF-κB reporter assay when cross-linked and had little activity when not cross-linked.
[0311] 2.4 Selected anti-CD137 mock mAbs in the DO11.10 T cell activation assay 2 activity Agonist molecule-mediated CD137 clustering on activated T cells induces T cell activation and downstream signaling, resulting in, but not limited to, IL-2 production. Because FS22-053 and FS22-172 were confirmed to be active in NF-κB reporter assays, their ability to activate CD137 was tested in a T cell activation assay. DO11.10 T cell activation assay was developed using DO11.10 T cells engineered to overexpress human CD137, and T cell activation was assessed by measuring IL-2 release.
[0312] DO11.10 T cells (National Jewish Health) were transduced with lentiviral vectors designed to overexpress mouse or human CD137 as previously described. As well as FS22-053 and FS22-172, the following clones were tested in this DO11.10 T cell activation assay: FS22-007, FS22-033, FS22-042, FS22-049, FS22-050, FS22-052, and FS22-054 (all "mock" HelD1.3 mAb). 2 format). mAb 2 or 20H4.9 positive control mAb was prepared by dilution with or without recombinant protein L (Life Technologies, 21189) crosslinker and placed in a 96-well round-bottom plate coated overnight with 0.1 μg / ml anti-CD3 antibody (clone 17A2, BioLegend, 100208) containing DO11.10.hCD13. After 18 hours of incubation, the supernatant was collected and diluted according to the manufacturer's instructions. The mIL-2 concentrations were assayed using a mouse IL-2 ELISA kit (eBioscience, 88-7024-86) using a plate reader equipped with Gens Software, BioTek. The plates were read at 450 nm using a plate reader equipped with Gens Software, BioTek. The absorbance values at 570 nm were subtracted from the absorbance values at 450 nm (corrected). The standard curve for calculating cytokine concentrations was based on a four-parameter logistic curve fit (Gens Software, BioTek). The concentrations of mIL-2 were calculated using the mAb 2 or bench The logarithm of the concentration of the marker mAb was plotted against the logarithm of the concentration, and the resulting curve was fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0313] Clones FS22-053 and FS22-172 showed significantly enhanced activity in this assay when cross-linked to protein L. FS22-053 had an activity of 126 nM uncross-linked and 21 nM cross-linked (a 6-fold improvement), and FS22-172 had an activity of 950 nM uncross-linked and 44 nM cross-linked (a 22-fold improvement). Consequently, both clones were selected for affinity maturation.
[0314] Example 2.4 shows that FS22-053 and FS22-172 are the mAbs tested. 2 These results demonstrate that cross-linking by the form of protein L can promote the clustering and activation of CD137 on the surface of DO11.10 T cells.
[0315] Example 3: Affinity maturation of anti-human CD137 Fcabs and subsequent characterization Two clones (FS22-053 and FS22-172) were selected for affinity maturation based on their functional properties in the NF-κB reporter assay, DO11.10 T cell activation assay, as previously described.
[0316] 3.1 Affinity maturation of FS22-053 and FS22-172 Four yeast display libraries were constructed from the FS22-053 and FS22-172 Fcab clones. Seven residues (positions 15–16.1 by IMGT) were randomized in the AB loop of the CH3 domain of each clone using the ELLA primer, generating libraries FS22-053AB and FS22-172AB. Five residues (positions 92–94 and 97–98 by IMGT) were randomized in the EF loop of the CH3 domain using the ELLA primer, generating libraries FS22-053EF and FS22-172EF.
[0317] For libraries FS22-053AB and FS22-053EF, as well as FS22-172AB and FS22-172EF, three or four selection rounds were performed on the yeast library to select for affinity-matured clones using dimeric hCD137-mFc-Avi antigen or monomeric hCD137-Avi-His antigen. Monomeric antigen was alternated with dimeric antigen to ensure that clones retained affinity for the antigen and did not bind solely via avidity. The use of monomeric or dimeric antigen and the concentration used were empirically determined during each round by flow cytometry, depending on whether enrichment for monomeric or dimeric antigen was observed in the previous round. Whenever possible, a sorting gate above the parent molecule was used to isolate affinity-matured clones compared to the parent molecule. Selection pressure was increased up to 1 nM of dimeric antigen. During each selection round, individual clones were spotted onto agar plates to assess the progress of the selection. Each clone was individually expanded and induced, and its binding and structural parameters were then determined by flow cytometry using biotinylated dimeric antigen and anti-CH2 structural markers, as previously described. Following this screening cascade, successful selection was determined based on a sample of clones from the selection output, allowing for early screening of individual clones that could then be produced as soluble proteins.
[0318] A total of 1,152 yeast single clones were screened for binding to biotinylated recombinant antigen by antigen-binding flow cytometry as described previously. Selection in the FS22-053EF library enriched for 138 unique loop sequences. Similarly, 30 unique loop sequences were isolated from the FS22-172AB library. Libraries FS22-053AB and FS22-172EF did not contain clones that showed improved binding over the parental clones. Sequence analysis of the best-binding clones from the FS22-053EF and FS22-172AB libraries revealed a conserved PPY sequence pattern within the AB loop.
[0319] The presence of the conserved PPY motif may facilitate the formation of an extended binding region by introducing a more rigid or exposed loop based on the limited flexibility of proline residues. Alternatively, because proline-rich sequences have been demonstrated to bind to aromatic sequences in SH3 domain proteins, the PPY sequence may represent a specific conserved motif involved in the binding of these clones. Furthermore, because the PPY conserved sequence was independently selected in two different Fcab lineages, it may be important for epitope binding to CD137. Furthermore, the conserved LE or LD sequence patterns in the EF loop of the CH3 domain of both the FS22-053 and FS22-172 lineages suggest that this amino acid motif in the EF loop is required for improved binding.
[0320] To assess whether the mutated AB and EF loops needed to be recombined as the selection progressed and among affinity-matured clones, the top five unique clones from the FS22-053EF library (FS22-053-008, FS22-053-009, FS22-053-010, FS22-053-011, and FS22-053-012) showed specific binding to 10 nM dimeric human antigen (greater than 30% APC-positive cells in a flow cytometry binding assay). The top six unique clones from the FS22-172AB library (FS22-172-001, FS22-172-002, FS22-172-003, FS22-172-004, FS22-172-005, and FS22-172-006, all showing >10% APC-positive cells when screened with 10 nM dimeric human antigen in a similar assay) were then compared with mock mAb to assess functional and kinetic improvements of the randomized loops. 2 (HelD1.3) and model mAb 2 (PD-L1).
[0321] 3.2 "Mock" and "Model" mAbs 2 Construction of anti-human CD137 Fcab in a 2D format Sixteen affinity-matured clones derived from the parental FS22-053 clone (FS22-053-001 to FS22-053-016) and six affinity-matured clones derived from the parental FS22-172 clone (FS22-172-001 to FS22-172-006) were used as "mock" and "model" mAbs. 2 Clones FS22-053-001 to FS22-053-007 were prepared in a mAb format at levels that allowed for downstream purification for further testing and characterization. 2 As it was not expressed in this manner, it was not pursued further.
[0322] "Mock" mAb containing anti-human CD137 Fcab in HelD1.3 2 The antibody is a mAb 2 Affinity-matured Fcabs of this format were prepared for further characterization.2 was prepared as described in Example 2.2.
[0323] A "model" mAb containing an anti-human CD137 Fcab and a PD-L1-binding Fab region (clone YW243.55.S70 from U.S. Patent No. 8,217,149 B2). 2 too These were also produced by replacing portions of the CH3 of the AB, CD, and EF loop-containing anti-PD-L1 binding antibodies with the corresponding regions of Fcab, as described in Example 2.2. These PD-L1 model mAbs were prepared in a similar manner to those described above. 2 The antibody contained a LALA mutation in the CH2 domain (AA). Introduction of the LALA mutation into the CH2 domain of human IgG1 is known to reduce Fcγ receptor binding (Bruhns, P., et al. (2009) and Hezareh M., et al. (2001)).
[0324] CD137 / HelD1.3 "mock" and CD137-AA / PD-L1 "model" mAbs 2 HEK293-6 Transiently expressed in E cells and purified using a mAb Select SuRe Protein A column. Purified.
[0325] 3.3 Mock mAb in human NF-κB reporter cell assay 2 Human Fcab activity in various formats Enumerated mock mAb 2 Affinity-matured anti-human CD137 F in (HelD1.3) format The functional activity of cab was tested in a similar NF-κB luciferase assay described in Example 2.3. A 0.5 second integration time was used on a plate reader equipped with Gen5 Software, BioTek. Luminescence was measured between 100 and 1000 s. As expected, the Fcabs showed no activity without protein L crosslinking (-XL). All affinity-matured CD137 Fcabs showed significant improvement over the parental CD137 Fcab and were positive in this assay, but not in the EC 50 It was not possible to calculate the value (see Example 2.3). FS22-053-008 and FS22-172-003 had the lowest EC when cross-linked with protein L (+XL). 50 (26.34 nM and 32.64 nM, respectively), showing the highest activity from each family.
[0326] 3.4 Model mAbs in the human DO11.10 T cell activation assay 2 Activity of formally affinity-matured human Fcabs Model mAb 2 Functional activity of affinity-matured human Fcabs in the (PD-L1 LALA) format was tested in a DO11.10 T cell activation assay similar to the assay described in Example 2.4.
[0327] HEK.mPD-L1 cells were generated by subcloning cDNA encoding mouse PD-L1 (SEQ ID NO: 187) into the pcDNA5FRT vector (Life Technologies) using the KpnI and NotI restriction sites and transforming it into the Flp-In T-REx 293 cell line (Life Technologies, R780-07) using Lipofectamine 2000 (Life Technologies, 11668-019). Cells were cultured in 10% FBS, 100μg / ml hygromycin B (Melford Laboratories Ltd, Z2475), and 15μg / ml blastocyst. Stably transformed cells were cultured in DMEM containing lysine (Melford Laboratories Ltd, B1105). The cells were grown for 3–4 weeks until colonies formed, which were expanded in the presence of 1 μg / ml doxycycline (Sigma Aldrich, D9891) and tested for PD-L1 expression using a PE-conjugated anti-mouse PD-L1 (MIH5) antibody (BD Biosciences, 558091).
[0328] Dissociate the cells using cell dissociation buffer, wash once with PBS, and then plate 2 x 10 cells. 5 Cells were plated in wells of a 96-well plate and then incubated with antibodies diluted 1:20 in PBS for 1 hour at 4°C. Cells were washed once with PBS and then incubated with Accuri C6 cytomegalovirus (C6) for 1 hour at 4°C. The data were analyzed using FlowJoX. -L1 expression was confirmed again.
[0329] CD137 / PD-L1 mAb 2 In this study, 15 clones generated in Example 3.2 were tested in this DO11.10 T cell activation assay. 2 or prepare dilutions of the positive control mAb, DO11.10.hCD137 (7.5x10 3 cells / well) and HEK.mPD-L1 cells (2 x 10 4 cells / well) or DO11.10.hCD137 (7.5x10 3 cells / well) and HEK cells not transfected to express mPD-L1 ( 2x10 4 Cells / well) were added to a 96-well flat-bottom plate coated overnight with 0.1 μg / ml anti-CD3 antibody (clone 17A2, BioLegend, 100208). After incubation, supernatants were collected and assayed with a mouse IL-2 ELISA kit (eBioscience, 88-7024-86) according to the manufacturer's instructions. Plates were read at 450 nm using a plate reader equipped with Gens Software, BioTek. Absorbance values at 570 nm were subtracted from absorbance values at 450 nm (corrected). Standard curves for calculating cytokine concentrations were generated using a four-parameter logistic curve fit (Gens Software, BioTek). The concentration of mIL-2 was based on the mAb 2 or the logarithmic concentration of the benchmark mAb, and the resulting curves were fitted using the log(agonist) vs. response equation in GraphPad Prism. T cell activation was detected by measuring the release of mIL-2.
[0330] Without cross-linking by binding to PD-L1-expressing cells, no T cell activation was observed. 2 showed high levels of mIL-2 and subnanomolar EC 50 All clones except FS22-053-009 and FS22-172-005 showed potent T cell activity as seen by the release of EC 50 The minimum E was less than 0.3 nM and therefore as good, if not better, than the positive control (anti-human CD137 mAb, G1-AA / 20H4.9). This is a measure of maximal T cell activation and may be associated with greater T cell antitumor activity in vivo. max was 7758 pg / ml, which was higher than that of the positive control (anti-human CD137 mAb, G1-AA / 20H4.9).
[0331] 3.5 Primary human CD8 + T cell activation assay The ability of Fcabs to activate CD137 on T cells overexpressing CD137 is shown in Example 3.3. To test the activity of Fcabs on cells not engineered to overexpress CD137, a primary human T cell assay was required. Activated cytotoxic CD8 + T cells are involved in the direct killing of cancer cells and express CD137 on their cell surface (Ye et al., 2014). CD137 clustering is involved in downstream signaling and further NaruCD8 + It is known to be essential for the induction of T cell activation. + Use T cell activation assays to identify Fcabs (mAbs detailed below) 2 We assessed the ability of CD8 (CD137) to drive CD137 clustering and downstream signaling. + T cell activation was detected by measuring the release of hIL-2.
[0332] To isolate T cells, peripheral blood mononuclear cells (PBMCs) were collected from leukocyte-depleted cones, a by-product of platelet donation. Briefly, the contents of the leukocyte cones were washed with PBS and layered on a Ficoll (Sigma-Aldrich, 1440-02) gradient. PBMCs were collected by centrifugation, and cells that did not pass through the Ficoll gradient were collected. PBMCs were further washed with PBS, and remaining red blood cells were lysed by adding 10 ml 1X red blood cell lysis buffer (eBioscience, 00-4300-54) according to the manufacturer's instructions. CD8 + T cells, CD8 + T cell isolation PBMCs present in the eluate were isolated using Kit II (Miltenyi Biotec Ltd, 130-096-495) according to the manufacturer's instructions.
[0333] Incubation with anti-CD3 antibody was used as an initial signal to promote early T cell activation. 96-well flat-bottom tissue culture plates were coated with 8 μg / ml anti-CD3 antibody (clone UCHT1, R&D Systems, MAB100-SP) in PBS overnight at 4°C. The plates were then washed three times with 200 μl of PBS.
[0334] PD-L1 model mAb 2 For cell-based cross-linking of affinity-matured human CD137 Fcab in a 3′-CELL format, HEK293 cells overexpressing human PD-L1 (HEK.hPD-L1) were generated by subcloning a cDNA encoding the human PD-L1 sequence (SEQ ID NO: 185) in place of mouse PD-L1, as described in Example 5.3. HEK.hPD-L1 cells were cultured at 2 × 10 5 Cells were plated at 100 μl per well onto a 96-well flat-bottom plate coated with anti-CD3 antibody (8 μg / ml) in 100 μl of T cell culture medium (RPMI medium (Life Technologies, 61870-044) containing 10% FBS (Life Technologies), 1X penicillin-streptomycin (Life Technologies, 15140122), 1 mM sodium pyruvate (Gibco, 11360-070), 10 mM Hepes (Sigma-Aldrich, H0887), 2 mM L-glutamine (Sigma-Aldrich, G7513), and 50 μM 2-mercaptoethanol (Gibco, M6250)). Once HEK.hPD-L1 cells or HEK cells not transduced to express hPD-L1 had attached after 4 hours of incubation, all T cell culture medium was removed and 5.0 x 10 cells were resuspended in 100 μl of T cell culture medium containing T cells. 5 Substitute at a concentration of 5.0 x 10 cells / ml 4 cells / well.
[0335] mAb 2 was diluted in T cell medium at 2x the final concentration starting at 500 nM and a 1:3 titration was performed. 2The titration was added to the cells for a total assay volume of 200 μl and 1x antibody concentration.
[0336] A positive control anti-CD137 antibody (G1-AA / 20H4.9) and a negative control isotype IgG antibody (G1-AA / HelD1.3) were each diluted in T cell medium at 2x final concentrations starting at 500 nM containing 500 nM crosslinker (anti-human CH2, manufactured in-house ( Jefferis et al., 1985 and Jefferis et al., 1992 ) (mG1 / MK1A6)) to perform a 1:3 titration. 100 μl of the diluted positive control antibody / crosslinker mixture or negative control IgG antibody / crosslinker mixture was added to the cells for a total assay volume of 200 μl and a 1x antibody concentration.
[0337] The assay was incubated at 37°C, 5% CO2 for 72 hours. Supernatants were collected and assayed with the Human IL-2 ELISA Ready-SET-Go! Kit (eBioscience, Cat. No. 88-7025-88) according to the manufacturer's instructions. A plate reader equipped with Gen5 Software, BioTek was used. Plates were read at 450 nm using a chromatogram. Absorbance values at 630 nm were subtracted from absorbance values at 450 nm (corrected). Standard curves for calculating cytokine concentrations were based on four-parameter logistic curve fitting (Gen5 Software, BioTek). The concentration of human IL-2 (hIL-2) was plotted against the log concentration of antibody, and the resulting curve was fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0338] The positive control anti-human CD137 mAb, 20H4.9, was compared with the anti-hCH2 antibody (mG1 / MK1A6 ) cross-linking, EC 50 All clones were active in the assay, with most exhibiting subnanomolar EC 50 showed good efficacy. Fcab-containing mAb 2FS22-053-007, FS22-053-008, FS22-053-010, FS22-053-011, FS22-053-012, FS22-172-003, FS22-172-004, and FS22-172-005 had the lowest EC in the range of 0.19–0.49 nM. 50 induced the greatest T cell response. 2 A subset of Fcabs (FS22-053-008, FS22-053-011, FS22-053-014, FS22-173-003, and FS22-172-004) were also tested without cross-linking by PD-L1 expressed on HEK cells and, as expected, showed no activity in this assay, confirming the activity seen in the NF-kB assay and DO11.10 T cell activation assay.
[0339] 3.6 Determining the specificity of anti-human CD137 Fcab by surface plasmon resonance (SPR) The specificity of the anti-human CD137 Fcabs for human CD137 compared to other related TNFSFR family members was tested. Eight of the Fcabs were tested against a mock mAb 2 (HelD1.3) format and by SPR on a Biacore T200 (GE Healthcare) by testing binding to other human TNFRSF receptors: CD40, OX40, and GITR. Amine coupling (amine coupling kit, GE Healthcare, BR-1000-50) was used to measure the ATP concentration on a Biacore CM5 chip (GE Healthcare, catalog number 291496 Human CD40, GITR, and OX40 were coated with 03) at approximately 1000 RU. Mock mAb starting at 1 μM 2Dilutions of anti-human CD137 Fcabs in the following formats (FS22-053-008 / HelD1.3, FS22-053-009 / HelD1.3, FS22-053-010 / HelD1.3, FS22-053-011 / HelD1.3, FS22-053-012 / HelD1.3, FS22-053-014 / HelD1.3, FS22-172-003 / HelD1.3, FS22-172-004 / HelD1.3) were prepared in HBS-EP+ buffer (BR100669) and injected at 30 μl / min for 3 min, followed by 4 min of dissociation in buffer. The chip was regenerated by injecting 10 mM glycine pH 2.5 at 30 μl / min for 12 s. Antibodies specific for different TNFRSF members were used as positive controls to validate the Biacore chip coating. Fcab was double-reference subtracted and analyzed using BIAevaluation3.2 software. , did not bind to any of the TNFRSF receptors tested, demonstrating specificity for CD137. Consequently, Fcabs or mAbs containing antigen-binding sites from these Fcabs 2 is not expected to induce non-target binding to anything other than CD137.
[0340] 3.7 Mock mAb against human, cynomolgus monkey and mouse CD137 by SPR 2 Binding affinity of anti-human CD137 Fcab in the format and generation of FS22-053-017 Mock mAb against human, cynomolgus monkey (cyno) and mouse CD137 2The affinity of anti-human CD137 Fcabs (FS22-053-008, FS22-053-011, FS22-053-014, FS22-172-004, FS22-172-004) in the format (see Example 3.2) was measured by SPR to determine whether the Fcabs could be useful for testing in animal studies. Anti-human Fab capture antibodies were immobilized on all four flow cells of a CM5 Series S chip (GE Healthcare #BR-1005-30) according to the manufacturer's recommendations (GE Healthcare, Human Fab Capture Kit, #28958325) to an average surface density of 6000 RU. Immobilization at 25°C and a flow rate of 10 μl / min achieved an average final response of 6000 RU. Each mAb 2 is mAb diluted in HBS-EP+ buffer (GE Healthcare #BR1006-69). 2 A 3 μg / ml solution of The capture was performed up to approximately 150 RU. Next, different concentrations of human, cyno, or mouse CD137 antigen (non-biotinylated human, cyno, or mouse CD137-mFc-Avi or human CD137-Avi-His) in HBS-EP+ buffer were flowed over the chip at 60 μl / min for 3 minutes, followed by a 10-minute dissociation period. After each antigen concentration, the chip was regenerated by injecting 10 mM glycine pH 2.1 at a flow rate of 30 μl / min for 30 seconds. HBS-EP+ buffer was injected before the highest and after the lowest antigen concentration for reference subtraction, with each random concentration repeated twice. Binding kinetics were fitted to a 1:1 Langmuir model to determine equilibrium binding (K ) for each sample. D ) were generated. Data analysis was performed using BiaEvaluation software version 3.2. The results are shown in Table 3.
[0341] Analysis of the results revealed improved binding to both human and cynomolgus monkey CD137 by all affinity-matured clones compared with their respective parental molecules. The binding affinity for the monomeric human CD137 antigen was weaker (at least 100-fold) than for the dimeric human and cynoFc fusion antigens. As discussed in Example 2.1, the Fcabs were selected to preferentially bind to the dimeric over the monomeric form of CD137, and this data confirms the success of the selection strategy. This kinetic behavior reduces the likelihood of binding to monomeric CD137, which is expressed at minimal levels on unstimulated T cells, thereby reducing the risk of liver or systemic toxicity associated with some anti-CD137 monoclonal antibody therapies.
[0342] The data also show that anti-human CD137 Fcab bound to cynomolgus monkey dimeric CD137 with an affinity comparable to that of human dimeric CD137.
[0343] [Table 4]
[0344] Mock mAb that binds to mouse dimeric CD137 2 The ability of Fcabs in this format was also tested. Clone FS22-053-014 had a K of 24 nM against mouse antigen. D All clones were found to have the mouse antigen (N / A in the table indicates K) except for clone FS22-053-014, which was surprisingly found to have the mouse antigen (N / A in the table indicates K). D This was unexpected, as mouse CD137 and human CD137 share less than 57% sequence homology.
[0345] Sequence analysis of FS22-053-014 revealed a sequence responsible for a potential post-translational aspartate isomerization at position 98 of the EF loop of its CH3 domain. The aspartate (D) at position 98 was inserted by site-directed mutagenesis using the QuickChange II mutagenesis kit (Agilent, catalog no. 200523) according to the manufacturer's recommendations. This was mutated to glutamic acid (E), resulting in clone FS22-053-017.
[0346] Next, experiments were performed to confirm that this mutation did not negatively affect the binding affinity or functional activity of the FS22-053-017 clone compared to the FS22-053-014 clone.
[0347] Fcab clone FS22-053- was analyzed by SPR using a Biacore T200 system with human CD137-mFc-Avi antigen and mouse PD-L1-mFc-Avi. The equilibrium dissociation constant (K D ) was compared with that of clone FS22-053-014. The results showed that both Fcab clones had very similar kinetic profiles with the human antigen, thereby demonstrating that mutating the aspartic acid at position 98 to glutamic acid had no negative effect on binding to the human antigen. The results showed that FS22-053-017 showed a two-fold decrease in binding strength to the mouse CD137 antigen.
[0348] Fcab clone FS22-053-017 was subcloned to generate the HelD1.3 "mock" mAb 2 (see Example 2.2) and then expressed as HelD1.3 mAb in the human CD137DO11.10 T cell activation assay described in Example 2.4. 2 The mAb was compared with the FS22-053-014 clone of the same format. G1-AA / 20H4.9 was used as an anti-CD137 positive control, and G1-AA / HelD1.3 was used as an IgG control. 2 of , Protein L was tested without cross-linking or cross-linked with Protein L at a ratio of 1:4.
[0349] The results showed that in the same DO11.10 T cell activation assay, when crosslinked with Protein L, the mock mAb 2 Format FS22-053-17 Fcab and mock mAb 2 Both forms of FS22-053-014 were shown to have equivalent activity. Therefore, the mutagenesis performed did not negatively affect functional activity. 2 Both clones in this format had no activity without cross-linking.
[0350] 3.8 Overview of affinity maturation and characterization of anti-human CD137 Fcabs In summary, we generated affinity-matured anti-CD137 Fcabs and mAbs 2 These mAbs containing the CD137 antigen-binding domain in the CH3 domain were prepared in various formats and subsequently characterized. 2 showed high levels of activity in human NF-κB reporter cell assays, and this activity was shown to be cross-linking dependent. mAbs containing antigen-binding domains from FS22-053-008 and FS22-172-003 Fcabs 2 showed the best activity in this assay.
[0351] Furthermore, mAbs 2 When prepared from these Fcabs, mAbs containing the CD137 antigen-binding domain and the PD-L1-binding Fab region, as well as the LALA mutation in the CH2 domain, were shown to reduce or abrogate binding to Fcγ receptors, and then 2 It was shown that the mAb has potent T cell activity in the human DO11.10 T cell activation assay, and this activity is dependent on cross-linking by binding to PD-L1-expressing cells. 2 is primary human CD8 + These affinity-matured CD137 antigen-binding domain-containing mAbs were also shown to have cross-linking-dependent activity in T cell activation assays. 2provided further evidence that CD137 agonism can be effectively induced and that this agonistic activity is conditional on cross-linking.
[0352] Anti-human CD137 antigen-binding domain-containing mAb 2 It was also shown to be specific for CD137 and not to bind to other TNFRSF members. 2 were shown to preferentially bind to the dimeric human CD137 antigen over the monomeric human CD137 antigen. 2 was shown to bind to dimeric cynomolgus monkey CD137 with an affinity comparable to that of dimeric human CD137.
[0353] One Fcab clone, FS22-053-014, was surprisingly found to also bind to mouse CD137. Sequence analysis of FS22-053-014 revealed potential sequence trends that were modified by lateral mutagenesis to generate the FS22-053-017 clone. Characterization of FS22-053-017 revealed that it retained similar binding properties and exhibited similar functional activity in the human CD137 DO11.10 T cell activation assay as FS22-053-014.
[0354] Anti-human CD137 antigen-binding domain-containing mAb 2 demonstrated that CD137 requires cross-linking for clustering and activation, our next goal was to identify mAbs that bind human PD-L1 in addition to CD137. 2 The aim of this study was to prepare a mAb directed against human PD-L1 via its Fab arm. 2 It was hypothesized that binding of PD-L1 causes cross-linking of the antibody molecules, resulting in the clustering and activation of CD137, and that this activation should be dependent on the presence of human PD-L1 expression.
[0355] mAb that binds human PD-L1 in addition to CD137 2To prepare these antibodies, it was first necessary to generate mAbs capable of binding to PD-L1. The generation of these mAbs is described below.
[0356] Example 4: Isolation of naive anti-PD-L1 mAb 280_02_G02 4.1 Selection Using the "IONTAS 1" human antibody phage display library (IONTAS Ltd.) Anti-PD-L1 clones were selected. The antibody genes used for construction of the IONTAS 1 library were derived from human lymphocytes (42 buffy coat donations) and one tonsil tissue sample. Both the buffy coat and tonsil tissue were obtained under the approval of the Local Research Ethical Committee.
[0357] Direct coating onto polystyrene Nunc tubing as described in Schofield et al., 2007 Using the labeled antigen, three rounds of antibody screening were performed with the IONTAS1 antibody phage display library. Solid-phase selection of the antibodies was performed using human PD-L1-Fc-His, mouse PD-L1-rCD4-His, and human PD-L1-Fc-His in the first, second, and third selection rounds, respectively (see Example 1.3 for antigen details).
[0358] The selected variable heavy (VH) anti-PD-L1 antibody population was shuffled with a naive variable light (VL) antibody population, and this shuffled and rescued antibody phage display population was used in solution-phase selections as described in Dyson et al., 2011. Briefly, panning was performed with human PD-L1-rCd4-His (10 nM), human PD-L1-rCd4-His (200 pM), and mouse PD-L1-rCd4-His (10 nM) in the first, second, and third rounds, respectively, resulting in an output anti-PD-L1 scFv population referred to as "selection 280." This scFv population contained human and mouse anti-PD-L1 binding scFvs and showed minimal cross-reactivity with human PD-1 or rCd4 or the Fc tag, as determined by phage polyclonal ELISA performed as described in Dyson et al., 2011.
[0359] 4.2 Screening: ELISA, recombinant blocking assays, cell-based blocking assays 4.2.1 Monoclonal scFv ELISA The selected 280 scFv population from Example 4.1 was screened by ELISA to identify clones with the best binding to human PD-L1. The scFv population was subcloned into the soluble scFv vector pSANG10, and Escherichia coli (E. coli) cultures containing soluble scFv were prepared as described (Martin et al., 2006; Studier, 2005). The soluble scFv were then used in a monoclonal ELISA using immobilized human PD-L1-rCd4-His as described by Schofield et al., 2007. Nunc Maxisorp plates (Thermo Fisher Scientific, 437111) were filled with human PD-L1-rCd4-His. The cells were coated overnight with rCd4-His (5 μg / ml, PBS), blocked with 2% MPBS for 1 hour, and then E. coli culture supernatant (diluted 1:2 with 2x 2% MPBS) was added. The scFv was allowed to bind for 1 hour at room temperature. Bound scFv was detected with europium-labeled anti-FLAG M2 antibody (Sigma, F1804). A total of 470 clones were screened. This identified 346 anti-PD-L1 clones with PD-L1 binding signals at least 10-fold higher than background compared to "empty" blocked wells containing no antigen. The 192 best anti-human PD-L1 clones, as assessed by primary ELISA signals, were selected for further analysis.
[0360] 4.2.2 Screening of scFvs in an ELISA-based PD-L1 / PD-1 blocking assay To identify clones that blocked the interaction between PD-L1 and PD-1, ELISA was performed to screen for blocking scFv. Briefly, Nunc Maxisorp plates (437111, Thermo Fisher Scientific) were coated with anti-rCd4 ( Main 3 and 4) Coat with antibodies (MCA1022, OX-68, Bio-Rad) overnight in 3% MPB The plates were blocked with PBS and incubated with human PD-1-rCd4-His (5 μg / ml in 3% MPBS) for 1 hour at room temperature. Human PD-L1-Fc-His (50 μl, 0.2 nM) was premixed with E. coli culture supernatant containing scFv. Nunc 96-well plates were washed three times with PBS, 0.1% Tween™-20 (PBS-T) and three times with PBS, after which the human PD-L1-Fc-His / scFv mix was added and incubated for 1 hour at room temperature. The plates were washed, and the bound human PD-L1-Fc-His was removed with goat anti-Fc-biotin (Jackson ImmunoResearch, 109-065-098, Laboratories, 0.1 μg / ml). l, 3% MPBS) and Streptavidin-Europium (Perkin Elmer, 1244-360), followed by the DELFIA enhancement solution (Perkin The 192 clones screened were detected using a PCR product (Elmer, 4001-0010). Of these, 183 demonstrated at least 90% blocking activity compared to the medium control. The 183 identified anti-PD-L1 scFv clones were further screened for mouse PD-L1 cross-reactivity in a primary ELISA, as described above in Example 4.2.1, but using immobilized mouse PD-L1-rCD4-His instead of human PD-L1. This identified 50 mouse cross-reactive anti-PD-L1 clones that were candidates for conversion to an IgG1 format.
[0361] 4.2.3 Conversion of Blocking Anti-PD-L1 scFv Clones to IgG1 Format Anti-PD-L1 scFv clones that blocked the interaction between PD-L1 and PD-1 were converted to IgG1 format by subcloning the VL and VH genes into the IgG1 expression plasmid pINT3-IgG1 and expressed at a 4 ml scale in HEK293 as described in Chapple et al., 2006. The antibody was purified using Protein A Sepharose beads (PC-A100) and Proteus "One-Step Batch" Midisu™ gel per the manufacturer's instructions. Batch affinity purification was performed using pin columns (Generon, GEN-1SB08). Purified antibodies were dialyzed into GeBAflex Maxi tubing (Generon, D045) with an 8 kDa cutoff. If necessary, antibodies were concentrated to 2 μM by ultrafiltration.
[0362] 4.2.4 Screening for PD-L1-PD-1 Blocking Activity in the Jurkat NFAT Reporter Co-culture Assay The functional activity of the purified anti-PD-L1 mAb was then assessed in a co-culture reporter assay screen. The assay was performed according to the manufacturer's instructions using Jurkat cell line (Promega, CS187102) and thawed and used PD-L1 cells (Promega, CS178103). PD-L1 cells were seeded in HAM'S-F12 medium containing 10% FBS. The next day, the medium was removed and, in parallel, PD-1 Jurkat reporter cells (Promega, CS187102) were resuspended in assay medium (90% RPMI 4000). The cells were resuspended in 1% FBS (Promega, G7940, 1% FBS). To the plate containing the adherent PD-L1 cells, 40 μl of assay medium containing different antibodies at 2x concentration (200 nM) was added, followed by 40 μl of the PD-1 cell mixture. The plate was incubated at 37°C with 5% CO2 for 6 hours. BioGlo reagent (Promega, G7940, 80 μl) was added to each well, and luciferase output was read using a BMG pherastar plate reader. Antibody G1 / 280_02_G02 was identified, which was able to block the interaction between PD-1 and PD-L1 in a co-culture assay by increasing luciferase activity compared to a control without antibody. This activity was confirmed in a dose-response co-incubation assay (doubling concentration range: 200 to 1.56 nM) and was found to be 50% effective at a calculated half-maximal effective concentration (EC 50 ) was 4.2 nM.
[0363] 4.3 Array Optimization Preliminary analysis of the G1 / 280_02_G02 antibody sequence identified potential deamidation sites in VH-CDR2. A NG motif was identified at positions 54 and 55, specifically Kabat positions 54 and 55. The NG motif is not a NA, NS, or S motif, as this could potentially affect binding. Mutant clones were generated in which the NS modification was changed to either G or GG. These modifications did not result in a significant decrease in affinity for recombinant PD-L1 or potency of PD-L1 blocking activity, and a mutant clone containing the NS modification, designated G1 / 280_02_G02_NS, was selected for use in light chain shuffling.
[0364] 4.4 Naive Selection Overview A phage selection strategy identified over 50 anti-human PD-L1 binding clones with potent in vitro PD-1 / PD-L1 blocking activity and mouse PD-L1 cross-reactivity. Notably, G1 / 280_02_G02 showed strong activity in a cell-based PD-L1 reporter assay. It showed activity and was therefore selected for further optimization.
[0365] Example 5: Generation and characterization of kappa light chain-containing anti-PD-L1 clones The G1 / 280_02_G02_NS antibody has lambda light chains. Most monoclonal antibodies used in clinical settings have kappa light chains (Jain et al., 2017). Using a flushing campaign, we sought to generate a clone containing the heavy chain of the G1 / 280_02_G02_NS antibody, but paired with a kappa light chain that retained affinity for human PD-L1 and cross-reactivity with the mouse PD-L1. The phage display plasmid pIONTAS-1 (kappa light chain) A light chain shuffle library of scFv clones containing the heavy chain of the G1 / 280_02_G02_NS antibody combined with light chain variants was prepared using the IONTAS™ kappa light chain library from Brilliant.
[0366] 5.1 Phage selection and screening strategies A number of phage display solutions were selected in three rounds using biotinylated human PD-L1-rCD4-His and mouse PD-L1-rCD4-His antigens (see Example 1.3 for antigen details). Selections were performed by decreasing the antigen concentration in every round (varying from 100 to 0.02 nM), and a "no antigen" control was used in each round of selection.
[0367] Six selection outputs were selected for screening using the soluble scFv expression system as described in Section 4.2.1: two from round 2 (nos. 871 and 872) and four from round 3 (nos. 887, 890, 891, and 894). A total of 1692 soluble scFv clones were screened for binding to immobilized antigen by ELISA (hu-PD-L1-rCD4-His antigen was coated onto Maxisorb plates at 3 μg / mL in 50 μl Dulbecco's PBS) using the assay described in Example 1.3.1 above using DELFIA enhancement solution.
[0368] Of the 1692 clones screened, 1029 produced a signal of over 2000 RFU in the DELFIA assay, representing a success rate of approximately 61%. The top 736 clones were then selected and analyzed using a secondary assay (affinity ranking) using three concentrations of hPD-L1-rCD4-His antigen (1.0 nM, 0.2 nM, and 0.04 nM). From the 736 clones screened, 48 clones that showed the highest signals were selected for cloning and expression in IgG1 format. The clones were cultured in Expi293F™ (Fisher Scientific catalog number 13479756) cells at an 800 μl scale. and culture supernatants were harvested 5 days post-transfection for further screening in IgG1 format.
[0369] 5.2 SPR screening All 48 antibodies were affinity ranked using SPR (Biacore T200 instrument). For ranking, diluted supernatants (1X PBS and 0.002% Tween A 1:10 mixture of rCD4-His (prepared with 1000kJ / mL IgG) and rCD4-His (prepared with 1000kJ / mL IgG) was immobilized on a Protein A chip (GE healthcare, product code: 29127556) and human PD-L1-rCD4-His was flowed over the prepared surface at a concentration of 50 nM. The binding (k) generated using this single injection was 0.01%. a ) and dissociation (k d ) rate constant to calculate the dissociation constant (K D ) was determined. D The values were compared to those of clone G1 / 280_02_G02_NS in an Ig1 format. Ten clones with unique sequences were identified that showed higher affinity for human PD-L1 than clone G1 / 280_02_G02_NS and were therefore subjected to full kinetic analysis alongside clone G1 / 280_02_G02_NS.
[0370] Briefly, SPR experiments were performed using a BIAcore T200 instrument. Antibodies from the culture supernatant were transferred to a Protein A chip (GE Healthcare, 29127556) on an FC2. Capture was performed at a flow rate of 0 μl / min with a contact time of 60 seconds. Typically, this results in capture of 500-800 RU of antibody. Two-fold dilutions of PD-L1-rCd4-His were injected from 50 nM on FC1 and FC2 at a flow rate of 30 μl / min (concentration range: 50 nM-0.05 nM). Binding was measured over 180 seconds, and dissociation was measured over 300 seconds. All measurements were performed in PBS, pH 7.4, 0.05% Tween™-20 at 25°C. Kinetic parameters were calculated by subtraction of reference cells and fitting of sensogram experimental data assuming a 1:1 interaction using BIAevaluation software (GE, BR-1005-97). The data obtained were filtered using BIAevaluation software. The corresponding k a , k d , and K D Of the 10 clones tested, four antibodies, designated "G1 / 887_04_E12," "894_08_A05," "G1 / 894_08_E05," and "G1 / 887_04_G12," exhibited subnanomolar K D This shows the value of K per G1 / 280_02_G02_NS. D The affinity data obtained under the described screening conditions were showed that by kappa light chain shuffling as described in Example 5.1, the heavy chain of the G1 / 280_02_G02_NS antibody was paired not only with a lambda light chain but also with a kappa light chain to produce an antibody with good, and indeed improved, affinity for recombinant human PD-L1.
[0371] 5.3: Characterization of kappa clones in IgG1 format 5.3.1 Cell-Based PD-1 / PD-L1 Blocking Assays Anti-PD-L containing kappa light chain, G1 / 887_04_E12, G1 / 894_08_E05, and G1 / 887_04_G12 The ability of the G1 / 280_02_G02_NS clone to block the interaction between PD-1 and PD-L1 was assessed in a bioluminescent cell-based assay using the PD-1 / PD-L1 Blockade Bioassay product (Promega, J1250 / J1255) according to the manufacturer's recommendations. Blocking activity was compared with that of the G1 / 280_02_G02_NS clone.
[0372] Briefly, all antibodies were purified as described in Example 4.2.3 and tested in duplicate at 3-fold dilutions from 100 nM to 35 pM (8 concentrations). All clones tested were shown to be potent inhibitors of the PD-1 / PD-L1 interaction, including clones G1 / 887_04_E12, G1 / 894_08_E05, and G1 / 884_04_G12, which contain three kappa light chains. showed even better IC than the lambda light chain-containing clone G1 / 280_02_G02_NS 50 The values were shown.
[0373] 5.3.2 Affinity Recombinant human anti-PD-L1 mAbs G1 / 887_04_E12, G1 / 887_04_G12, and G1 / 894_08_E05 Binding to human (biotinylated hPD-L1-Avi-His, Acro Biosystems, PD1-H82E5), cynomolgus monkey (cPD-L1-His, Acro Biosystems, PD1-C52H4), and mouse (mPD-L1-His, Acro Biosystems, PD1-M5220) was measured by SPR using a Biacore T200 processing unit (GE Healthcare). The affinity was compared to the 280_02_G02_NS clone in IgG1 format (G1-AA / 280_02_G02_NS; the "AA" in this clone name indicates that this clone also contained the "LALA" mutation in the CH2 domain).
[0374] Briefly, diluted to 2 μg / ml in HBS-EP buffer (GE Healthcare, BR100188). The purified anti-PD-L1 mAb was injected individually into flow cells 2, 3, and 4 of a Protein A chip (GE Healthcare, 29127556) at 30 μl / min, achieving a final response of approximately 110 RU. Recombinant human, cynomolgus monkey, and mouse PD-L1-His antigens diluted in HBS-EP buffer were injected into flow cells 1, 2, 3, or 4, as appropriate, at 3-fold dilutions ranging from 81 nM to 0.037 nM at 75 μl / min for 4 minutes, followed by dissociation in buffer for 10 minutes. Regeneration was performed by injecting 10 mM glycine-HCl pH 1.5 (GE Healthcare, Human Antibody Capture Kit, BR00356) at 30 μl / min for 30 seconds. Subtracted data (flow cell 2 - flow cell 1, flow cell 3 - flow cell 1, or flow cell 4 - flow cell 1) were analyzed using BIAevaluation 3.2 software (GE Healthcare) to identify binding using a model 1:1 binding with mass transfer at a refractive index (RI) constant of 0. To determine the affinity of the mouse PD-L1 binding curves, the Rmax of the corresponding human binding profile was used.
[0375] Binding data showed that the G1-AA / 280_02_G02_NS clone and the G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12 clones bound to human and cynomolgus PD-L1 with low single-digit nanomolar or subnanomolar affinities, demonstrating complete human / cynomolgus cross-reactivity. Compared to the G1-AA / 280_02_G02_NS clone, the binding affinities of the G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12 clones were approximately 1.8- to 4.8-fold higher for human and 2.7- to 4.7-fold higher for cynomolgus PD-L1. The affinity of the clones for recombinant mouse PD-L1 was low, with K D Values ranged from 38 to 225 nM, with the highest affinity observed for the G1 / 887_04_E12 clone. These data demonstrate that the heavy chain of the G1-AA / 280_02_G02_NS antibody can be paired with both lambda and kappa light chains to produce antibodies with good (and subnanomolar in the case of kappa light chain pairing) affinity for recombinant human and cynomolgus monkey PD-L1, and at least some affinity for recombinant mouse PD-L1.
[0376] 5.3.3 Binding of anti-PD-L1 mAb to cell-expressed PD-L1 Anti-human PD-L1 mAb, G1 / 894_08_E05, G1 / 887_04_E12 and G1 / 887_04_G12, were then Binding to HEK293 cells expressing human PD-L1 (HEK.hPD-L1 cells) was tested using flow cytometry. Nonspecific binding was also assessed by testing binding to parental HEK293 cells lacking human PD-L1 (Flp-In T-Rex 293 cell line, Life Technologies, R780-07).
[0377] cDNA encoding the human PD-L1 sequence (SEQ ID NO: 185) was cloned into the pcDNA™5 / FRT vector (ThermoFisher Scientific, Cat. ID 185) using the KpnI and NotI restriction sites. The vector was then subcloned into a Flp-In T-REx 293 cell line (Life Technologies, R780-07) using Lipofectamine 2000 (Life Technologies, 11668-019). The cells were cultured in DMEM containing 10% FBS, 100 μg / ml hygromycin B (Melford Laboratories Ltd, Z2475), and 15 μg / ml blasticidin (Melford Laboratories Ltd, B1105) to form colonies of stably transformed cells. The cells were grown for 3–4 weeks until colonies formed. These colonies were expanded in the presence of 1 μg / ml doxycycline (Sigma Aldrich, D9891) and tested for PD-L1 expression using a PE-conjugated anti-human PD-L1 (MIH1) antibody (BD Biosciences, 557924). Cells were detached using cell dissociation buffer, washed once with PBS, and plated at 2 × 10 cells per well of a 96-well plate. 5 Cells were plated and incubated with antibodies diluted 1:20 in PBS for 1 hour at 4°C, then washed again with PBS and measured using an Accur iC6 cytometer (BD Biosciences). Data were analyzed using FlowJoX software. Human PD-L1 expression was detected in the cell lines.
[0378] G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12 clones were EC 50 The value is 0.26 They were found to bind to cell surface human PD-L1 in the range of ~0.29 nM. No binding to parental HEK293 cells was observed, demonstrating specificity of binding. Thus, all mAb clones tested specifically bound to PD-L1, with no nonspecific binding observed.
[0379] 5.3.4 Activity of anti-PD-L1 mAbs in mixed lymphocyte reaction assays The activity of anti-PD-L1 mAbs was tested in a mixed lymphocyte reaction (MLR) assay. The MLR assay measures the cellular immune response that occurs between two allogeneic lymphocyte populations (same species but genetically distinct). This assay uses CD4+ T cells from one donor and monocyte-derived dendritic cells (iDCs) from another donor. Because immune cells contain physiological levels of immune checkpoint regulators, the MLR assay can be used to confirm that T cell activation is enhanced by the mAb in a human system.
[0380] CD4 expansion culture + Generation of T cells PBMCs were isolated from leukocytes by Ficoll gradient separation. + T cells were isolated using the Human CD4+ T Cell Isolation Kit (Miltenyi Biotec Ltd, 130-096-533) according to the manufacturer's instructions. Human T-activator CD3 / CD28 Dynabeads (Life Technologies, 11131D) were resuspended by vortexing. The beads were placed in a sterile 15 ml tube. Transfer to a tube and add 10 ml RPM containing 10% FBS (Life Technologies, 10270106). Dynabeads were washed by adding I (Life Technologies, 61870044) and 1x penicillin streptomycin (Life Technologies, 15140122). The supernatant was discarded. 1.0 x 10 Dynabeads were collected in RPMI supplemented with 10% FBS and 1x penicillin streptomycin solution. 6 CD4 cells / ml + T cells and 50 IU / ml recombinant human IL-2 (Peprotech, 200-02-50 μg) with a 3:1 bead-to-cell ratio were transferred to a T75 flask (Greiner Bio-one, 690195) and incubated at 37°C + 5% CO2. After 3 days, cells were gently resuspended and counted. Cell densities were adjusted to 0.8–1 × 10 by adding fresh medium (RPMI-10% FBS + 1X penicillin-streptomycin solution + 50 IU / ml rhuIL-2) as needed. 6 On day 7 or 8, CD3 / 28 beads were removed and CD4+ T cells were resuspended at 1 x 10 cells / ml in fresh medium RPMI-10% FBS + 1X penicillin-streptomycin solution with reduced 10 IU / ml rhuIL-2. 6 The cells were incubated overnight at 1000x1000 cells / ml. The cells were frozen and stored until needed.
[0381] iDC differentiation Naive monocytes were isolated from human PBMCs using the Human Pan Monocyte Isolation Kit (Miltenyi Biotec Ltd, 130-096-537) according to the manufacturer's instructions. Monocytes were cultured using Human Mo-DC Differentiation Medium (Miltenyi Biotec Ltd, 130-094-812) according to the manufacturer's instructions. DCs were differentiated.
[0382] The expanded T cells were thawed one day before the experiment, washed with AIM V medium (GIBCO, 12055-091), and incubated overnight in AIM V medium at 37°C and 5% CO2. Anti-human PD-L1 mAbs, G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12, were plated in a 96-well plate. In a round-bottom plate (VWR, 734-1797), 3 Anti-FITC antibody designated 4420 containing the LALA mutation (Bedzyk et al., 1989 and Bedzyk et al., 1990) was included as a negative control. A 3-fold dilution series from 30 nM to 0.002 nM was tested. 1 x 10 cells suspended in 50 μl of AIM V medium were used. 4 iDC cells, and 1 x 10 suspended in 100 μl of AIM V medium 5 Both expanded CD4+ T cells were added to antibody dilutions and incubated for 5 days at 37°C + 5% CO2. The following controls were included: CD4+ T cells alone, iDCs alone, CD4+ T cells + iDCs, and AIMV medium alone. Supernatants were collected, samples were diluted (1:25), and interferon gamma (IFN-γ) concentrations were measured using a human IFN gamma ELISA Ready-SET-Go! kit (Life Technologies, 88-7316-77). Plates were read at 450 nm using a plate reader equipped with Gen5 Software, BioTek. The absorbance values at 630 nm were subtracted from the absorbance values at m (corrected). The standard curve for calculating cytokine concentrations was based on a four-parameter logistic curve fit (Gen5 Software, BioTek). The concentration of human IFN-γ was plotted against the log concentration of the antibody, and the resulting values were used to calculate the cytokine concentrations. The resulting curves were fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0383] Anti-human PD-L1 mAbs G1 / 894_8_E05, G1 / 887_4_E12, and G1 / 887_4_G12 were used in EC 50 values less than 0.030 nM, and IFN-γ (E max ) showed potent activity in the MLR assay with a maximum level exceeding 10,000 pg / ml. 50 indicates the concentration of mAb at which half of the response is achieved, while E maxis an absolute value indicating the maximum concentration of IFN-γ achieved in the assay. As expected, no activity was observed with the negative control G1-AA / 4420 mAb.
[0384] 5.4 Activity of anti-PD-L1 mAbs in the murine DO11.10 T cell activation assay Because the anti-human PD-L1 mAbs G1 / 887_04_E12, G1 / 887_4_G12, and G1 / 894_08_E05 were shown to exhibit weak cross-reactivity with mouse PD-L1 (see Example 5.3.2), their functional activity against mouse PD-L1 was investigated in an interleukin-2 (IL-2) release assay based on DO11.10 OVA T-lymphocyte and LK35.2 B-lymphocyte hybridoma cell lines. IL-2 release is a marker of T cell activation. T cells expressing endogenous mouse PD-1 were transfected with an empty vector (pLVX). B-cells were transfected with mouse PD-L1 constructs.
[0385] 5.4.1 Generation of T cell lines using empty vectors Lentiviral transduction using the Lenti-X HTX packaging system (Clontech DO11.10 cells (National Jewish Health) containing the empty lentiviral vector pLVX were generated using the Lenti-X expression vector (pLVX) (catalog no. 631249). Virus was generated by co-transfecting the Lenti-X293T cell line (catalog no. 632180) with the Lenti-X HTX packaging mix. The DO11.10 cell line was transduced using lentiviral particles produced with the Lenti-X HTX packaging system.
[0386] 5.4.2 Generation of antigen-presenting cells that overexpress PD-L1 Lenti-X HTX Packaging System (Catalog) using lentiviral transduction LK35.2 B cell lymphoma cells (ATCC, HB-98) overexpressing mouse PD-L1 were generated using the Lenti-X expression vector (pLVX) (Cat. No. 631249). The Lenti-X expression vector (pLVX) (Cat. No. 631253) containing the cDNA encoding mouse PD-L1 (SEQ ID NO: 187) was co-transfected with the Lenti-X HTX packaging mix into the Lenti-X293T cell line (Cat. No. 632180) to generate virus. The LK35.2 cell line was transfected with the Lenti-X HTX packaging mix. They were transduced using lentiviral vectors generated in the caging system.
[0387] 5.4.3 Mouse DO11.10 T Cell Activation Assay Dilutions of anti-PD-L1 mAbs G1 / 887_04_E12, G1 / 887_4_G12, and G1 / 894_08_E05 or anti-FITC negative control mAb (G1-AA / 4420) were prepared in experimental medium (DMEM (Gibco, 61965-026), 10% FBS (Gibco, 10270-106), 1 mM sodium pyruvate (Gibco, 11360-070)). 2.46 μM OVA peptide (H-ISQAVHAAHAEINEAGR-OH (SEQ ID NO: 192) (Pepscan)) (100 μL LK35.2mPD-L1). mAbs were cultured in the presence of 4 × 10 L1 cells (B cell hybridomas transduced with a lentiviral vector containing mPD-L1 to overexpress mouse PD-L1) / mAb mixtures per well of a 96-well round-bottom plate. 5 2 × 10 cells / ml of LK35.2mPD-L1 cells were mixed 1:1 in experimental medium and incubated at 37°C, 5% CO2 for 1 hour. 5DO11.10 pLVX cells (DO11.10 T cell hybridoma transduced with an empty lentiviral vector) were added to 100 μl of the LK35.2mPD-L1 / (mAbs) mixture. The cells were then mixed and incubated at 37°C, 5% CO for 24 hours. The supernatant was collected and analyzed using a Mouse IL-2 ELISA kit (eBioscience, 88-7024-88 or R&D Science, Inc.) according to the manufacturer's instructions. The assay was performed using a plate reader equipped with Gen5 Software, BioTek. Plates were read at 450 nm using a 570 nm absorbance value subtracted from the 450 nm (corrected) absorbance value. Standard curves for calculating cytokine concentrations were based on a four-parameter logistic curve fit (Gen5 Software, BioTek). Mouse I The concentration of L-2 was plotted against the log concentration of mAb, and the resulting curve was fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0388] The anti-human PD-L1 mAb showed significant activity in mouse T cell activation assays and potency (EC 50 ) ranged from 1 to 4.4 nM. As expected, no activity was observed with the negative control mAb. Of the three clones tested, G1 / 887_04_E12, which showed the highest affinity for recombinant murine PD-L1, was also the most potent clone in the T cell activation assay. The difference in potency was lower than the measured affinity, likely due to overexpression of murine PD-L1 on LK35.2 cells in this assay.
[0389] 5.5 Overview of characterization of kappa clones in IgG1 format The selected kappa light chain-containing anti-PD-L1 mAbs G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12 showed cross-reactivity with cynomolgus monkey and mouse PD-L1 and were expressed on cell surfaces. The clone showed specific binding to PD-L1 expressed on the surface of the IgG1 / 280_02 antibody, and showed even higher affinity for recombinant human and cynomolgus monkey PD-L1 than the lambda light chain-containing clone G1 / 280_02_G02. Anti-PD-L1 mAbs G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12 were used in vivo. It was shown in vitro to be a potent activator of human T cells and to have functional mouse cross-reactivity.
[0390] Example 6: Sequence optimization of PD-L1 mAb 6.1 Identification and removal of potential protein deamidation sites Analysis of the G1 / 280_02_G02_NS clone sequence identified the H-CDR2 loop (Kabat positions 54-5). The sequence NSNT in 7) was identified as a potential deamidation site that could affect binding if deamidated. Because the heavy chain of this clone was retained in all kappa light chain-containing clones obtained by the chain shuffling campaign described in Example 5, this potential deamidation site was also present in clones G1 / 887_04_E12, G1 / 894_08_A05, G1 / 894_08_E05, and G1 / 887_4_G12. The specific sequence closest to the germline sequence Using primers, the NSNT sequence was changed to either GGST, SGGT, or SGNA in four kappa light chain-containing clones by site-directed mutagenesis to generate identified mutant clones. This potential deamidation site was removed, as well as the G1 / 887_04_E12 clone, which was unintentionally introduced into the sequence of this antibody during kappa light chain shuffling. The role of the proline residue at Kabat position 28 in the VH region of the G1 / 280_02_G02_NS clone The affinities of the clones to human and cynomolgus PD-L1-rCD4-His were determined by SPR using culture supernatants collected 5 days after transfection. Cyno PD-L1-rCD4-His was generated as described in Example 1.3. G1 / 887_04_E12 clone With the exception of the mutant clone derived from , all mutant clones retained subnanomolar affinity for human and cynomolgus PD-L1 compared to their respective parental clones.
[0391] Modified clones derived from the G1 / 894_08_A05, G1 / 894_08_E05, and G1 / 887_04_G12 parent clones All clones showed subnanomolar affinity for human and cynomolgus PD-L1 comparable to their respective parental clones, suggesting that the GGST, SGGT, and SGNA substitutions were well tolerated. The significant decrease in affinity of the G1 / 929_01_A03 clones was due to the G The presence of GST, SGGT and SGNA substitutions was associated with the presence of a promoter in the VH region at Kabat position 28. This protease activity in the G1 / 887_04_E12 clone was likely due to its removal. It was surprising that the ribonucleotide residues appeared to be important for affinity to PD-L1. Three mutants derived from the parent clones G1 / 887_04_E12, G1 / 894_08_E05, and G1 / 887_04_G12, which contained SGGT substitutions in H-CDR2 (positions 54–57), namely, The lines G1 / 929_01_A02, G1 / 929_01_A08, and G1 / 929_01_A11 show that this SGGT substitution is present in the germline. were selected for further characterization based on their closest match to the series sequence.
[0392] Using site-directed mutagenesis, a potential deamidation site within the H-CDR2 loop of the G1 / 280_02_G02_NS clone (NSNT at Kabat positions 54 to 57) was also modified to SGGT. Furthermore, the clone was identified at Kabat positions 31 to 32 in CDR1 of the lambda light chain. An additional potential deamidation site (NS motif) is the substitution of serine 32 (Kabat numbering) for a tyrosine, as found at this position in several germline sequences, including IGLV2-8-01, IGLV2-8-02, IGLV2-8-03, IGLV2-11-01, IGLV2-11-02, IGLV2-11-03, and IGLV2-14-01, IGLV2-14-02, IGLV2-14-03, IGLV2-14-04. The combination of these modifications resulted in the lambda light chain-containing clone G1 / lam-G02v3, which was also selected for further characterization.
[0393] Example 7: Characterization of mAbs 7.1 Cloning and Production of Clones in mAb Format The threonine residue at Kabat position 28 in the VH region of the G1 / 929_01_A02 "SGGT" mutant clone identified in Example 6 was mutated to proline as present at the same position in the parent clone G1 / 887_04_E12 in order to improve affinity for human and cynomolgus PD-L1. Transient expression in EK293-6E cells and mAb Select SuRe Protein A column were used. Purification using this modified mutant clone, as well as three other "SGGT" mutant clones identified in Example 6 with an IgG1 format and LALA mutation (G1 / 929_01_A08, G1 / 929_01_A11, and G1 / lam-G02v3), allowed testing of functional activity in the absence of effector function. The resulting mAbs were designated G1-AA / E12v2, G1-AA / E05v2, G1-AA / G12v2, and G1-AA / lamG02v3 (referred to as G1-AA / lamG02v3 or G1-AA / lambdav3). The heavy and light chain sequences are SEQ ID NO: 16 and SEQ ID NO: 17 for G1-AA / E12v2, respectively. , as shown in SEQ ID NO: 27 and SEQ ID NO: 28 for G1-AA / E05v2, SEQ ID NO: 27 and SEQ ID NO: 33 for G1-AA / G12v2, and SEQ ID NO: 27 and SEQ ID NO: 44 for G1-AA / lam-G02v3. There are.
[0394] 7.2 Affinity of mAbs to human and cynomolgus monkey PD-L1 G1-AA / lam-G02v3 (i.e., NSNT to SGGT in VH-CDR2, VL- NS to NY and LALA mutations in CDR1) and additional sequence modifications present in kappa light chain-containing mAbs G1-AA / E12v2, G1-AA / E05v2, and G1-AA / G12v2 (i.e., LALA mutation, and G1-AA / E12v2 alone, threonine to proline at Kabat position 28 in the VH region). The affinities of these anti-PD-L1 mAbs for human and cynomolgus PD-L1 were determined as described in Example 5.3.2 to determine whether the binding kinetics of mAbs G1-AA / lam-G02v3, G1-AA / E05v2, G1-AA / E12v2, and G1-AA / G12v2 exhibited affinities for human and cynomolgus PD-L1 similar to that observed in Example 5.3 for mAbs G1-AA / 280_02_G02_NS, G1 / 894_08_E05, G1 / 887_04_E12, and G1 / 887_04_G12. 2 It was demonstrated that the binding affinity of G1-AA / E12v2 mAb was not affected by modification of the potential deamination site or introduction of the LALA mutation. G1-AA / E12v2 mAb had the lowest K among all four mAbs tested. D values were shown (human PD-L The results are shown in Table 4.
[0395] The VH of G1-AA / E12v2 mAb differs from the G1 / 929_01_A02 region (Example 6) by one residue: E12v2 retains a proline at Kabat position 28, while G1 / 929_01_A02 retains a threonine at this position. G1 / 929_01_A02 showed over 10-fold lower affinity for both human and cynomolgus PD-L1 when compared to G1-AA / E12v2. This data supports the VH of clone E12v2. The proline residue at position 28 (Kabat nomenclature) in This indicates that the affinity for the
[0396] [Table 5]
[0397] 7.3 Activity of anti-human PD-L1 mAb in MLR Anti-PD-L1 mAbs G1-AA / E05v2, G1-AA / E12v2, and G1-AA / G05v2 were prepared as described in Example 5.3 The antibodies were tested in a mixed lymphocyte reaction (MLR) assay as described in .4. G1-AA / 4420 was used as a negative control. The results are shown in Table 5. mAbs G1-AA / E05v2, G1-AA / E12v2, and G1-AA / G12v2 had an EC of less than 0.054 nM. 50 and IF >600 pg / ml. Maximum level of N-γ (E max ) showed potent activity in the MLR assay (Table 5). 50 , especially E max The values were significantly different from those described in Example 5.3.4. This difference is believed to be due to donor variability, as the response relies on an alloreactivity between T cells from one donor and monocyte-derived dendritic cells from another donor. The potencies of the anti-human PD-L1 mAbs, as well as the clones ranked in order of potency, were consistent with the data described in Example 5.3.4. As expected, no activity was observed for the negative control G1-AA / 4420 mAb.
[0398] [Table 6]
[0399] 7.4 Expression, Purification, and Analytical Characterization of Anti-PD-L1 mAbs mAbs G1-AA / E05v2, G1-AA / E12v2, and G1-AA / G12v2 were produced at lab scale and It was characterized by standard analytical methods of EC and differential scanning calorimetry (DSC).
[0400] 7.4.1 Lab-scale expression and purification of anti-PD-L1 mAb DNA sequences encoding mAbs G1-AA / E05v2, G1-AA / E12v2, and G1-AA / G12v2 were transfected into HEK293 6E (National Research Council Canada) cells using PEIpro (Polyplus, France). After 5 days, the cell culture medium The eluate was collected and purified on a MabSelect Protein-A pre-packed column (both GE Healthcare, Uppsala, Sweden) using an AKTAxpress instrument. Column equilibration was performed using The resin was washed with 50 mM Tris, pH 7.0, 250 mM NaCl, followed by loading with harvested cell culture fluid. The resin was washed with 50 mM Tris, pH 7.0, 250 mM NaCl, and the mAb was subsequently eluted using a buffer with a pH below 3.5.
[0401] 7.4.2 Analysis by SE-UPLC After purification, SE-UPLC was performed using an Acquity H-Class Bio UPLC (Waters Corp, UK). The purification was performed within 24 hours to determine the percentage of monomer (the material was stored at 4°C). An Acquity UPLC BEH200 SEC 1.7 mm column (4.6 x 150 mm) was used. The mobile phase consisted of 250 mM sodium phosphate, 100 mM L-arginine, pH 6.8. Quantification of monomeric, low-molecular-weight, and high-molecular-weight species was performed using Empower software (Waters Corp, UK).
[0402] 7.4.3 Thermal stability The melting temperatures (T m ) was measured using a Microcal VP capillary differential scanning calorimeter (DSC). G1-AA / lam-G02v3 is a kappa light A lambda light chain-containing mAb was included to assess the difference between the Fab and lambda light chain-containing mAb. Samples were measured at a concentration of 0.2 mg / ml in sample buffer. The scan rate was set at 60 °C / h, and data were collected between 35 °C and 100 °C. Data analysis was performed using Origin 7.0 software. The DSC peaks of Fab and CH3 overlapped. Therefore, one value was reported.
[0403] [Table 7]
[0404] A summary of the results is shown in Table 6. Three mAbs: G1-AA / E05v2, G1-AA / E12v2, and G1-AA / G12v2 showed good analytical characterization parameters. The monomer purity after Protein A was 98%. %, and the thermal stability (Tm) of the Fab transition was confirmed at the upper end of the transition typically reported for IgG1, with G1-AA / E12v2 appearing to be the most thermally stable (Fab / CH 3 Tm = 81.484.1°C). The lambda light chain mAb G1-AA / lamG02v3 had a lower Tm than the three kappa light chain-containing mAbs.
[0405] Example 8: Anti-human CD137 / PD-L1 mAb 2 Production and characterization of 8.1 Anti-human CD137 / PD-L1 mAb 2 Production of CD137 / PD-L1 mAb consisting of an IgG1 molecule comprising three anti-human CD137 Fcab clones FS22-053-008, FS22-053-017, and FS22-172-003 (see Example 3). 2 Produce antibodies, mAb 2 This allows for characterization of Fcabs in a format similar to that of CD137 / PD-L1 mAb. 2 The CH3 domain of one of three anti-PD-L1 binding antibodies (G1-AA / E05v2, G1-AA / E12v2, G1-AA / G12v2, see Example 7.1) All resulting mAbs were prepared by replacing part of the CH3 domain of Fcab, including the AB, CD, and EF loops, with the corresponding regions of the Fcab. 2 contained the LALA mutation. CD137 / PD-L1mAb 2 was transiently expressed in HEK293 6E (NRCC, Canada) cells using PEIpro (Polyplus, France). After 5 days, the cell culture medium was harvested and purified on a MabSelect Protein-A pre-packed column (both GE Healthcare, Uppsala, Sweden) using an AKTAxpress instrument. The column was equilibrated with 50 mM Tris-HCl, pH 7.0, 250 mM NaCl, followed by loading with the harvested cell culture medium. The resin was then washed with 50 mM Tris-HCl, pH 7.0, 250 mM NaCl, followed by elution with a pH <3.5 buffer. 2 was eluted.
[0406] To assess the amount of protein produced, a protein A quantitative assay was performed using PALL (18-5021). Biolayer interferometry was performed using an Octet QKe (ForteBio) equipped with a biosensor. The IgG protein content was quantified using a mAbSelectSure column. Nine mAbs were purified by protein A affinity chromatography. 2 was purified using a mAb Select SuRe Protein A column (GE Healthcare, 11003494). The results are shown in Table 7.
[0407] [Table 8]
[0408] 9 CD137 / PD-L1mAbs 2All antibodies were produced by transient expression in HEK2936E, with titers and Protein A purified yields within the typical range expected at lab scale. FS22-172-003-AA-Iam / G02v3 was also expressed and submitted for further testing. Refined.
[0409] 8.2 Size Exclusion Chromatography (SEC) and SDS-PAGE of mAbs 2 Biophysical characterization of 8.2.1 Analysis by SE-HPLC The mobile phase was 20 mM sodium phosphate, 200 mM sodium chloride, pH 6.8, and purified using an Agilent 1100 series HPLC (Agilent, UK) equipped with a TSK-GEL SUPERSW 3000 4.6 mm ID x 30.0 cm column (Tosoh Bioscience). C. Quantification of the proportion of monomer was performed using Chemstation software (Agilent, UK).
[0410] 8.2.2 Analysis by CE-SDS CE-SDS analysis was performed on a 2100 Bioanalyzer capillary electrophoresis system (Agilent, UK) according to the manufacturer's instructions. For reducing conditions, DTT was added and the samples were incubated for 70 min. Denature at 5°C for 5 minutes.
[0411] [Table 9]
[0412] A summary of the analytical results is shown in Table 8. All mAbs except FS22-053-008-AA / G12v2 2 demonstrated high purity post-purification using Protein A; % monomer post-Protein A >95%, and low levels of soluble aggregation and fragmentation as demonstrated by high purity as demonstrated by reduced CE-SDS (>95%, combined heavy and light chain %). FS22-053-008-AA / G12v2 was purified using Protein A. A showed aggregation after purification and as a result was not progressed further.
[0413] Example 9: mAbs 2 Characterization of binding 9.1 SPR analysis of human and cynomolgus monkey PD-L1 using anti-human CD137 / PD-L1 mAb 2 binding affinity Next, anti-human CD137 / PD-L1 mAb 2 Binding of FS22-172-003-AA / lam-G02v3, FS22-172-003-AA / E05v2, FS22-053-008-AA / E05v2, FS22-172-003-AA / E12v2, FS22-053-008-AA / E12v2, and FS22-172-003-AA / G12v2 to recombinant human and cynomolgus PD-L1 antigens was measured by SPR using a Biacore T200 processing unit (GE Healthcare).
[0414] Briefly, 2 μg / ml in HBS-EP buffer (GE Healthcare, BR100188) Anti-human CD137 / PD-L1 mAb diluted in 2 was injected separately into flow cells 2, 3, and 4 of a Protein A chip (GE Healthcare, 29127556) at 30 μl / min, and approximately 11 A final response of 0 RU was achieved. Two different recombinant human PD-L1 antigens were used: hPD-L1-His-Avi (see Example 1.3 for antigen details) and biotinylated hPD-L1-Avi-His (Acrobiosystems, PD-1-H82E5). Human and cynomolgus PD-L1-His (Acrobiosystems, PD-1-C52H4) antigens diluted in HBS-EP buffer were injected in 3-fold dilutions over the concentration range of 81 nM to 0.037 nM at 75 μl / min for 4 minutes, followed by 10 minutes of dissociation in buffer. Regeneration was achieved by injecting 10 mM glycine-HCl pH 1.5 (GE Healthcare, Human Antibody Capture Kit, BR00356) for 30 seconds at a rate of 30 μl / min. The subtracted data (flow cell 2-flow cell 1, flow cell 3-flow cell 1, or flow cell 4-flow cell 1) were analyzed using BIAevaluation3.2 software (GE Healthcare), and binding was determined using a model 1:1 binding with mass transfer at a refractive index (RI) constant of 0.
[0415] [Table 10]
[0416] Binding data are for each anti-human CD137 / PD-L1 mAb 2 All mAbs bind to human and cynomolgus PD-L1 with low to subnanomolar affinity and demonstrate human / cynomolgus cross-reactivity (Table 9). 2 The clones bound equally well to human and cynomolgus PD-L1 with equivalent KD values for each antigen.
[0417] 9.2 SPR of human and cynomolgus monkey CD137 using anti-human CD137 / PD-L1 mAb 2 binding affinity Anti-human CD137 / PD-L1 mAb 2Binding of to recombinant dimeric human and cynomolgus CD137 antigens was also measured by SPR using a Biacore T200 processing unit (GE Healthcare).
[0418] Briefly, 20 μg / ml of anti-human Fab antibody (GE Healthcare, Human Fab Capture kit 28958325) was applied to a Biacore sensor S chip CM5 (GE Healthcare, BR100530 The antibody was coated onto flow cells 1, 2, 3, and 4 of the 1000-well plate, achieving a final response of approximately 5000 RU. The antibody was diluted to 2-5 μg / ml in HBS-EP buffer (GE Healthcare, BR100188). mAb 2 Clones were injected individually into flow cells 2, 3, and 4 at 30 μl / min, achieving a response of approximately 70 RU (200 RU for FS22-172-003-AA / E12v2). Recombinant dimeric antigens, human CD137-mFc-Avi or cynomolgus CD137-mFc-Avi (see Example 1.1 for antigen details) diluted in P buffer were injected onto flow cells 1, 2, 3, or 4 at 3-fold dilutions ranging from 81 nM to 0.037 nM at 70 μl / min for 4 min, followed by dissociation in buffer for 10 min. Regeneration was performed with 30 μl of 10 mM glycine pH 2.1 (GE Healthcare, Human Fab Capture kit 28958325). This was achieved by injecting for 60 seconds at a rate of 1 / min. Data analysis was performed as described in Example 9.1.
[0419] [Table 11]
[0420] Binding data are for anti-human CD137 / PD-L1 mAb 2The clones demonstrated that they bound dimeric human or cynomolgus CD137 with low nanomolar affinity and were human / cynomolgus cross-reactive (Table 10). As expected, these results were comparable to those of the "mock" mAb. 2 The binding data was similar in format to the reported binding data for these Fcab clones (Table 3, Example 3.7). The highest affinity for dimeric CD137 was observed with FS22-172-003-AA / E12v2, followed by the binding of monomeric CD137-His- The affinity of FS22-172-003-AA / E12v2 to Avi was also tested. No binding to CD137 was detected, and anti-human CD137 / PD-L1 mAb 2 The Fcab binding region of FS22-053-008 CD137 Fcab was shown to have low affinity for monomeric CD137. These results were similar to those observed for the FS22-053-008 CD137 Fcab, and the Fcab mAb 2 These results show that conversion to the IgG format resulted in little change in binding to CD137.
[0421] 9.3 Anti-human CD137 / PD-L1 mAb by SPR 2 specific decision 9.3.1 Specificity of human PD-L1 Anti-human CD137 / PD-L1 mAb 2 To analyze the specificity of six mAbs 2 The binding of mAbs (FS22-172-003-AA / lam-G02v3, FS22-172-003-AA / E05v2, FS22-053-008-AA / E05v2, FS22-172-003-AA / E12v2, FS22-053-008-AA / E12v2, and FS22-172-003-AA / G12v2) to other T cell targets was tested using SPR. 2 However, mAbs against PD-L2, CD80, PD-1, and B7-H3 antigens at a concentration of 1 μM 2 The objective of this study was to demonstrate specificity by showing no binding of the antibody.
[0422] Flow cells on a CM5 chip were immobilized with approximately 1000 RU of human PD-L2-Fc (R&D Biosystems, 1224-PL), CD80-Fc (R&D Biosystems, 140-B1), PD-1-His (R&D Biosystems, 8986-PD), B7-H3-His (F-star in-house production, SEQ ID NO: 193), PD-L1-Fc (R&D Biosystems, 156-B7), and PD-L1-His (Acrobiosystems, PD1-H83F3). Flow cell 1 was reserved for immobilization of a blank mAb. 2 was diluted to 1 μM and 1 nM in 1×HBS-EP buffer (GE Healthcare, product code BR100188) and flowed over the chip for 3 minutes, then The dissociation was allowed to continue for 4 min. A 30-s injection of 10 mM glycine pH 1.5 was used for regeneration. Positive control antibodies were injected at 50–100 nM to demonstrate coating of each antigen. Binding levels were determined at the end of the association phase and compared.
[0423] Tested mAbs 2 demonstrated a high level of specificity, with binding responses ranging from 105 RU to 570 RU detected at 1 nM for either human PD-L1-Fc or PD-L1-His, and four antigen-binding mAbs detected at 1 μM. 2 is less than 10RU These results suggest that anti-human CD137 / PD-L1 mAb against PD-L1 2 demonstrated a high level of specificity for , but did not bind to the other T cell targets listed.
[0424] 9.3.2 Specificity of human CD137 CD137 / HelD1.3mAb 2 CD137 / PD-L1 mAb compared with 2 It is predicted that the specificity of the CD137 Fcab binding site is maintained in The specificity of FS22-172-003-AA / E12v2 for the TNFR family members OX40, GITR, CD40, and DR6 (R&D Biosystems) was confirmed in Example 3.6. Analyzed by SPR similarly as described in 9.3.1. At a concentration of 1 μM, FS22-172-003-AA / E12v2 had 278 RU for human CD137-mFc, whereas The binding to human OX40, GITR, CD40, and DR6 was less than 7 RU. 2 demonstrated a high level of specificity Ta.
[0425] 9.4 Anti-human CD137 / PD-L1 mAb by SPR 2 Simultaneous binding of human PD-L1 and human CD137 FS22-172-003-AA / E12v2 mAb simultaneously binds human CD137 and human PD-L1-His Avi (see Example 1.3 for antigen details) 2 The capacity of Biacore T200 Human PD-L1His was immobilized at a surface density of approximately 1100 RU on a CM5 sensor S chip (GE Healthcare, BR100530) at 10 μg / ml diluted in sodium acetate buffer pH 5.0 (GE Healthcare, 18-1069). One flow cell was activated and deactivated without immobilized protein to eliminate background. Antibodies diluted to 5 μg / ml in HBS-EP buffer were captured at a flow rate of 30 μl / min to a density of approximately 200-300 RU. Binding of human CD137-mFc-Avi was tested at 0 and 100 nM for 5 min at 30 μl / min, followed by a 2.5 min dissociation step. The sensor chip was regenerated after each cycle with 20 mM NaOH at a flow rate of 30 μl / min for 60 s. FS22-172-003-AA / E12v2 binds human PD-L1 and Both antibodies were able to simultaneously bind to both human CD137 and human PD-L1, whereas the control G1 / S70 only bound to human PD-L1.
[0426] 9.5 Anti-human CD137 / PD-L1 mAb against cell surface-expressed human or cynomolgus monkey PD-L1 by flow cytometry 2 Binding affinity of Anti-human CD137 / PD-L1 mAb 2 HEK293 cells overexpressing human PD-L1 were generated to assess binding of PD-L1 to cell surface human and cynomolgus PD-L1. HEK293 cells overexpressing human PD-L1 (HEK.hPD-L1) were generated as described in Example 5.3.3. cDNA encoding cynomolgus PD-L1 (SEQ ID NO: 189) was inserted into the pcDNA™5 / FRT vector in place of the human PD-L1 sequence. HEK293 cells overexpressing cynomolgus PD-L1 (HEK.cPD-L1) were also generated as described in Example 5.3.3, except that they were subcloned.
[0427] Next, anti-human CD137 / PD-L1 mAb 2 ,FS22-172-003-AA / E12v2 is flow Binding to HEK293 cells expressing human or cynomolgus PD-L1 was tested using immunocytometry. Non-specific binding was also assessed by testing binding to parental HEK293 cells lacking human PD-L1 (Flp-In T-Rex 293 cell line, Life Technologies, R780-07). Binding affinity was assessed using the positive control antibody G1-AA / E12v2 (heavy and light chain specific antibodies, respectively). The variable domains were cloned and expressed in a human IgG1 format (G1-AA format) containing the LALA mutation in the CH2 domain.
[0428] HEK293, HEK.hPD-L1 and HEK.cPD-L1 suspensions were prepared in FACS buffer (DPBS (Gibco, 14190-094) containing 0.5% BSA (Sigma, A7906)). , 1x10 5 100 μl cells / well in a round-bottom 96-well plate (VWR, 734-1797) The cells were washed once in FACS buffer. 2 FS22-172-003-AA / E12v2 , mock mAb 2 FS22-172-003-AA / HelD1.3, mAbG1-AA / E12v2, and negative control mAbG1-AA / 4420 were diluted in 100 μl of FACS buffer (400 nM to 0.005 nM, 5-fold dilution). Washed cells were resuspended in the diluted antibody mixture and incubated at 4°C for 30 minutes, followed by a single wash with FACS buffer. Next, 100 μl / well of secondary antibody (goat anti-human IgG Alexa Fluor 647-labeled antibody, Invitrogen, A21445) was added in FACS buffer for 1 minute. After incubation at 4°C for 20 minutes, the cells were washed again with FACS buffer and resuspended in 100 μl of PBS containing 7AAD (1:1000, Biotium, 40043), followed by analysis using a Canto II flow cytometer (BD Bioscience). Dead cells were excluded and fluorescence was measured in the APC channel (638 nm 660 / 20). Geometric mean fluorescence intensity (GMFI) values were plotted against the log concentration of antibody, and the resulting curves were fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0429] FS22-172-003-AA / E12v2mAb 2 and G1-AA / E12v2 antibodies, EC 50 to cell surface human PD-L1 with values ranging from 3.1 to 3.7 nM, and EC 50 The FS22-172-003-AA / E12v2 mAb tested was found to bind to cell surface cynomolgus monkey PD-L1 with binding values ranging from 0.6 to 0.7 nM (see Table 11). No binding was observed to HEK293 cells lacking PD-L1 overexpression, demonstrating specificity of binding. 2 No nonspecific binding was observed, and P These results demonstrate that the specificity for human and cynoPD-L1 observed for the PD-L1 mAb (see Example 5.3.3) is retained.
[0430] [Table 12]
[0431] 9.6 Anti-human CD137 / PD-L1 mAb against cell surface-expressed human or cynomolgus CD137 by flow cytometry 2 Binding affinity of DO11.10 cells (National Jewish Health) expressing full-length human (SEQ ID NO: 185) or cynomolgus monkey CD137 (SEQ ID NO: 189) were designated "DO11.10.hCD137" and "DO11.10.cCD137," respectively, and the selected anti-human CD137 / PD-L1 mAb 2 For further characterization, DO11.10.hCD137 and DO11.10.cCD137 cells were produced to present the antigen in a membrane-bound conformation most similar to its native form. Details of the production and expression confirmation of DO11.10.hCD137 and DO11.10.cCD137 cells are described in Example 1.2.
[0432] Anti-human CD137 / PD-L1 mAb 2 FS22-172-003-AA / E12v2 was used for flow cytometry. The antibodies were tested for binding to cells expressing human or cynomolgus monkey CD137 (DO11.10.hCD137 or DO11.10.cCD137) using a ELISA. Nonspecific binding was also assessed by testing binding to DO11.10 cells, which lack CD137 expression. The variable domains of MOR7480.1 (U.S. Patent Application Publication No. 2012 / 0237498) were cloned and expressed in a human IgG1 format (G1-AA format) containing the LALA mutation in the CH2 domain and used as a positive control.
[0433] Briefly, DO11.10, DO11.10.hCD137 and DO11.10.cCD137 suspensions were prepared in FACS buffer (DPBS (Gibco, 14190-094) containing 0.5% BSA (Sigma, A7906)) and diluted to 1x10 5 Cells were seeded in a round-bottom 96-well plate (VWR, 734-1797) at 100 μl / well. The cells were washed once with FACS buffer and then incubated with mAb 2 FS22-172-003-AA / E12v2, mock mAb 2 FS22-172-003-AA / HelD1.3, antibody G1-AA / MOR7480.1, and negative control mAb G1-AA / 4420 were diluted in 100 μl of FACS buffer (400 nM to 0.005 nM, 5-fold dilution). Washed cells were resuspended in the diluted antibody mixture and incubated at 4°C for 30 minutes, followed by one wash with FACS buffer. Next, 100 μl / well of secondary antibody (goat anti-human IgG Alexa Fluor 647-conjugated anti-human IgG) diluted 1:1000 in FACS buffer was added. Antibody (Invitrogen, A21445) was added and the cell / antibody mixture was incubated at 4°C for 20 min. Afterwards, the cells were washed again with FACS buffer and resuspended in 100 μl of PBS containing 7AAD (1:1000, Biotium, 40043) before analysis using a Canto II flow cytometer (BD Bioscience). Dead cells were excluded and analyzed using the APC channel (638 nm). Fluorescence was measured at 660 / 20. Geometric mean fluorescence intensity (GMFI) values were plotted against the log concentration of antibody, and the resulting curves were fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0434] The results are shown in Table 12. FS22-172-003-AA / E12v2mAb 2 and FS22-172-003-AA / HelD1.3 mock mAb 2 The human and cynoCD137 receptors expressed on the cell surface bind to EC 50 The positive control mAb bound to the human and cynoCD137 receptors with EC values ranging from 4.8 to 9.1 nM.50 The binding values were 1.45 nM and 4.4 nM, respectively. No binding was observed to DO11.10 or HEK293 cells, which did not overexpress CD137. 2 The specificity of the binding by β-glucan was confirmed.
[0435] [Table 13]
[0436] 9.7 Anti-human CD137 / PD-L1 mAb directed against CD137 and PD-L1 endogenously expressed on activated primary human T cells 2 Binding affinity of Anti-human CD137 / PD-L1 mAb against endogenously expressed CD137 and PD-L1 on activated primary human T cells 2 The affinity of T cells was determined using flow cytometry. To isolate T cells, peripheral blood mononuclear cells (PBMCs) were isolated from leukocyte-depleted cones, a by-product of platelet donation. Briefly, the contents of the leukocyte cones were washed with PBS and layered on a Ficoll (Sigma-Aldrich, 1440-02) gradient. PBMCs were separated by centrifugation, and cells that did not pass through the Ficoll gradient were collected. PBMCs were further washed with PBS, and the remaining red blood cells were lysed by adding 10 ml 1X red blood cell lysis buffer (eBioscience, 00-4300-54) according to the manufacturer's instructions. Pan T cells were isolated from the eluate using the Pan T Cell Isolation Kit II (Miltenyi Biotec Ltd, 130-095-130) according to the manufacturer's instructions. CD137 is a marker for activated CD8 + Rapidly expressed at high levels on T cells and activated CD4 +Because it is expressed at low levels on T cells (Xue-Zhong Yu et al., 2013), pan-T cells were stimulated for 24 hours using Dynabeads™ Human T-Activator CD3 / CD28 (Thermo, 11132D) according to the manufacturer's instructions. Human T-Activator beads were labeled FS22-172-003-AA / E12v2 mAb. 2 , FS22-172-003-AA / HelD1.3 mock mAb 2 , Before using the cell binding assay to test for binding of the G1-AA / E12v2 positive control anti-human PD-L1 antibody, the G1-AA / MOR7480.1 positive control anti-human CD137 antibody, and the G1-AA / 4420 negative control antibody, the antibodies were washed from T cells using a DynaMag™-15 magnet (Thermo, 12301D) according to the manufacturer's instructions.
[0437] Stimulated pan-human T cell suspensions were prepared in FACS buffer (DPBS (Gibco, 14190-094) containing 0.5% BSA (Sigma, A7906)) and plated at 1 × 10 in 100 μl of a round-bottom 96-well plate (VWR, 734-1797). 5 Cells were plated at 100 cells / well. Cells were diluted in FACS buffer for 1 minute. Wash twice and mAb 2 FS22-172-003-AA / E12v2, mock mAb 2 FS22-172-003-AA / HelD1.3, positive control antibody G1-AA / E12v2, positive control antibody G1-AA / 20H4.9, and negative control antibody G1-AA / 4420. The washed cells were incubated with anti-human CD4 + FITC-labeled antibody (BD Biosciences, 550628) and anti-human CD8 + Diluted antibody mix containing eFluor450-labeled antibody (Invitrogen, 48-0087-42) Resuspended in medium and CD4 + and CD8 +T cells were differentiated and incubated for 30 minutes at 4°C, then washed once in FACS buffer. Next, 100 μl / well of secondary antibody (goat anti-human IgG Alexa Fluor 647-labeled antibody, Invitrogen, A21445) diluted 1:1000 in FACS buffer was added, and the cell / antibody mixture was incubated for 20 minutes at 4°C. Afterwards, cells were washed again with FACS buffer and resuspended in 100 μl of PBS containing 7AAD (1:1000, Biotium, 40043) before analysis using a Canto II flow cytometer (BD Bioscience). Dead cells were removed and analyzed using the APC channel (638 nm 660 Fluorescence of the antibody was measured (1 / 20) to indicate test antibody binding. Geometric mean fluorescence intensity (GMFI) values were plotted against the log concentration of antibody, and the resulting curves were fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0438] FS22-172-003-AA / E12v2mAb 2 As shown in the MFI values in Figure 2, Primary human CD4 + T cells and CD8 + The PD-L1 positive control antibody G1-AA / E12v2 was found to bind to T cells. 2 and CD4 with similar MFI values. + and CD8 + T cells The results confirmed that PD-L1 was expressed on the cells.
[0439] G1-AA / MOR7480.1, a CD137 positive control, was found to bind to the same cells as above. However, the MFI was much lower than that observed with either FS22-172-003-AA / E12v2 or G1-AA / E12v2, which is likely due to the lower expression of CD137 on the cells compared with PD-L1 expression. Furthermore, the binding of G1-AA / MOR7480.1 to CD4 + T cells Rimo CD8+ T cells had higher MFI values. + stimulated CD4 rather than T cells + It is expected to observe lower CD137 expression on T cells (Xue-Zhong Yu et al, 2013), which is consistent with CD8 + In contrast to T cells, CD4 + CD4 on T cells 137 Explaining the low binding levels of the positive control antibody MOR7480.1, primary T cells, especially CD4 + This low CD137 expression seen on T cells was consistent with the mock mAb 2 This also explains the absence or minimal binding of Fcab in the form (FS22-172-003-AA / HelD1.3). There is a possibility that
[0440] 9.8 Anti-human CD137 / PD-L1 mAb by SPR 2 Binding of FcRn Fetal Fc receptor (FcRn) binding is important for antibody recycling (Martins et al. al., 2016). FS22-172-003-AA / lam-G02v3, FS22-172-003-AA / E12v2, and FS22-053-008-AA / E12v2 mAbs 2 The binding of α-glucan to human and mouse FcRn was measured using a BIAcore T200 (GE Healthcare ) was measured by SPR. G1-AA / HelD1.3 has no mutation in the CH3 domain. An isotype control IgG was included as a control.
[0441] In brief, mAb 2 Series S Sensor Chip CM5 (GE Healthcare, BR100530 ) and individually coated on flow cells 2, 3, and 4 to achieve a response of approximately 1000 RU. Flow cell 1 was activated / deactivated but left blank as a reference. Human FcRn (Acro Biosystems, FCM-H5286) or mouse FcRn (R&D systems, 9114-Fc) was dialyzed and diluted with MHBS-EP + The antibody was diluted in pH 6.0 or pH 7.4 buffer (10 mM MES, ForteBio, 18-5026; 1x HBS-EP, GE Healthcare, BR100669; 0.1 mg / ml BSA, Sigma, A7906) and injected at 2000–3000 nM in two-fold dilutions at 80 μl / min for 1 min onto flow cells 1, 2, 3, and 4, followed by a 3-minute dissociation period in buffer. No regeneration was required. The subtracted data (flow cell 2–flow cell 1, flow cell 3–flow cell 1, or flow cell 4–flow cell 1) were analyzed using Biacore T200 Evaluation Software 2.0, and the steady-state affinity of the model was used to determine binding. The binding data are shown in Table 13 and are for FS22-172-003-AA / lam-G02v3, FS22-172-003-AA / E12v2 and FS22-053-008-AA / E12v2 mAbs. 2 showed that mAb binds to human or mouse FcRn at pH 6.0 with similar affinity as the control antibody G1-AA / HelD1.3. No binding was observed to human or mouse FcRn at pH 7.4. This data suggests that FcRn binding is mediated by mAb 2 It was shown that it was maintained by
[0442] [Table 14]
[0443] 9.9 Anti-human CD137 / PD-L1 mAb on cells expressing Fcγ receptors by flow cytometry 2 Combination of Agonistic antibodies targeting TNFRSF members require cross-linking via Fcγ receptors to promote target clustering and activation to achieve in vivo activity (Li et al., 2013). However, to avoid potential off-target effects, such as systematic CD137 activation, and to reduce the potential for ADCC induction in immune cells expressing both targets, such as T cells, we developed an anti-human CD137 / PD-L1 mAb by introducing a LALA mutation into the CH2 domain (see Example 3.2 for details of the LALA format). 2 The Fcγ receptor binding capacity of anti-human CD137 / PD-L1 mAbs was determined to be reduced using flow cytometric cell binding to CHO cells overexpressing only FcγRIIA (ECACC Catalog No. 15042905), FcγRIIA (ECACC Catalog No. 15042903), FcγRIIA (ECACC Catalog No. 15042902), FcγRIIIA (ECACC Catalog No. 15042901), or FcγRIIB (ECACC Catalog No. 15042907). 2 We confirmed that the presence of the LALA mutation in the CH2 domain of IgG1 reduces the binding affinity to the aforementioned Fcγ receptor.
[0444] Briefly, a suspension of CHO.FcγRIIA.131H, CHO.FcγRIIA.131E, CHO.FcγRIIA.158F, CHO.FcγRIIA.158V, CHO.FcγRIIB, or CHO.WT was prepared in FACS buffer (DPBS (Gibco, 14190-094) containing 0.5% BSA (Sigma, A7906)) and diluted to 1 x 10 in 100 μl in a round-bottom 96-well plate (VWR, 734-1797). 5 Cells were plated at 1000 cells / well. Cells were analyzed by FACS. Wash once in buffer and mAb 2 FS22-172-003-AA / E12v2, a positive control for Fcγ receptor binding antibody G1 / 4420, and a negative control for Fcγ receptor binding antibody G1-AA / 4420 were added to 100 μl of F The antibodies were diluted in FACS buffer (500 nM to 0.03 nM, 4-fold dilutions). The washed cells were resuspended in the diluted antibody mixture and incubated at 4 °C for 30 min, followed by one wash with FACS buffer. Next, 100 μl / well of secondary antibody (goat anti-human IgG Alexa Fluor 488-labeled antibody, Stratech Scientific Ltd, 109-545-098-JIR) diluted 1:1000 in FACS buffer was added, and the cell / antibody mixture was incubated at 4 °C for 20 min, followed by one wash with FACS buffer. Cells were washed again with FACS buffer and resuspended in 100 μl of PBS containing 7AAD (1:1000, Biotium, 40043) before analysis using a CytoFLEX flow cytometer (Beckman Coulter). Dead cells were excluded and analyzed using the FITC channel (488 nm / 525 nm). Fluorescence was measured at 40°C. Geometric mean fluorescence intensity (GMFI) values were plotted against the log concentration of antibody, and the resulting curves were fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0445] FS22-172-003-AA / E12v2mAb 2 The results for all Fcγ receptor-expressing cells tested were The LALA mutations reduced binding to FcγRIIA, FcγRIIIA, or FcγRIIB, and the mAb binding via these receptors in vivo was not observed (or below the level of the negative control antibody G1-AA / 4420) (Figure 3 (A) FcgRIIA131H, (B) FcgRIIA131E, (C) FcgRIIB, (D) FcgRIIIA158F, (E) FcgRIIIA158V). 2 This indicates that cross-linking should also be reduced.
[0446] Example 10: mAb 2 Functional characterization 10.1 Primary human CD8 + Anti-human CD137 / PD-L1 mAb in T cell assays 2 Activity of The human primary T cell assay described in Example 3.5 uses mAb2 was used to test the activity of
[0447] Anti-human CD137 / PD-L1 mAb 2の For cell-based crosslinking, HEK293 cells overexpressing hPD-L1 (HEK.hPD-L1) were generated essentially as described in Example 3.5. HEK.hPD-L1 cells were engineered to express high levels of human PD-L1, and MDA-MB-231 cells, which express intermediate levels of human PD-L1, and low levels of human PD-L1, as quantified by antibody-binding beads (Quantum Simply Cellular, Bans Laboratories, Inc. Cat. No. 816A) according to the manufacturer's instructions. 1 (Table 14).
[0448] [Table 15]
[0449] CD8 + T cells were isolated and activated using anti-CD3 antibody as described in Example 3.5. HEK.hPD-L1 cells were cultured at 2 x 10 5 Cells were plated at 100 μl per well in 100 μl of T cell culture medium (RPMI medium (Life Technologies) containing 10% FBS (Life Technologies), 1× penicillin-streptomycin (Life Technologies, 15140122), 1 mM sodium pyruvate (Gibco, 11360-070), and 50 μM 2-mercaptoethanol (Gibco, M6250)) on a 96-well flat-bottom plate coated with anti-CD3 antibody (8 μg / ml). Once the HEK.hPD-L1 cells or HEK cells not transduced to express hPD-L1, which were used as a control, had attached after 4 hours of incubation, all T cell culture medium was removed and 5.0 x 10 cells were plated in 100μl of T cell culture medium containing T cells. 5Substitute at a concentration of 5.0 x 10 cells / ml 4 cells / well.
[0450] For cell-based crosslinking at lower physiological levels of PD-L1 expression, the human breast adenocarcinoma cell line, MDA-MB-231 (ATCC HTB-26), was used in the same manner as described for HEK.hPD-L1 cell-based crosslinking.
[0451] mAb 2 was diluted in T cell medium at 2x the final concentration starting at 50 nM and a 1:5 titration was performed. 2 The titration was added to the cells for a total assay volume of 200 μl and 1x antibody concentration.
[0452] Dilute the positive control anti-CD137 antibody (G1-AA / 20H4.9) in T cell media at 2x final concentration starting at 50 nM containing 50 nM crosslinker (anti-human CH2 antibody (mG1 / MK1A6)) and 1 A :5 titration was performed. 100 μl of diluted positive control antibody / crosslinker mix was added to the cells for a total assay volume of 200 μl and 1× antibody concentration.
[0453] The assay was incubated at 37°C, 5% CO2 for 72 hours. Supernatants were collected and assayed with the Human IL-2 ELISA Ready-SET-Go! Kit (eBioscience, Cat. No. 88-7025-88) according to the manufacturer's instructions. A plate reader equipped with Gen5 Software, BioTek was used. Plates were read at 450 nm using a chromatogram. Absorbance values at 630 nm were subtracted from absorbance values at 450 nm (corrected). Standard curves for calculating cytokine concentrations were based on four-parameter logistic curve fitting (Gen5 Software, BioTek). The concentration of human IL-2 (hIL-2) was plotted against the log concentration of antibody, and the resulting curve was fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0454] Table 15 shows the anti-human CD137 / PD-L1 mAbs tested in cell-based crosslinking. 2 EC of IL-2 release observed in T cell activation assays in the presence of 50 The positive control anti-human CD137 mAb, 20H4.9, had an EC of 0.21 to 0.31 nM when crosslinked with anti-hCH2 antibody in either assay. 50 All clones were active in the assay, each with a subnanomolar EC 50 mAb containing Fcab FS22-172-003 showed efficacy. 2 is H EK. mAbs elicited maximal T cell responses with EC50 values ranging from 0.19 to 0.31 nM in hPD-L1-based assays and 0.01 to 0.02 nM in MDA-MB-231-based assays. 2 A subset of mAbs (Fcab-containing FS22-053-008, FS22-053-011, FS22-053-014, FS22-173-003, and FS22-172-004) were also tested without cross-linking by PD-L1 expressed on HEK cells and, as expected, showed no activity in this assay. Figures 4 and 5 show the activity of the mAbs listed in Table 15. 2 Representative plots of IL-2 release for T cell activation assays are shown.
[0455] The FS22-053 and FS22-172 Fcab lines also showed the lowest PD-L1 expression in human milk in this assay. The adenocarcinoma cell line SK-BR-3 (ATCC HTB-30) was used for this study. As expected, low PD-L1 expression was associated with CD8+ T cell proliferation, consistent with the previous two assays. + T cell activation was reduced (data not shown).
[0456] [Table 16]
[0457] The results are shown in mAb 2We showed that mAb can bind to cells expressing different levels of PD-L1. Binding to cell-expressed PD-L1 was 2 This resulted in cross-linking of PD-L1, allowing it to bind to CD137 on T cells, cluster, and activate them as measured by IL-2 production. The level of activation observed was related to the level of cross-linking by binding to PD-L1, where mAb 2 bound to cells expressing higher levels of hPD-L1 (HEK.hPD-L1) with greater activation, while lower levels of PD-L1 expression induced less activation.
[0458] 10.2 Primary human CD8 + Anti-human CD137 / PD-L1 mAb cross-linked with different populations of HEK.hPD-L1 cells in a T cell activation assay 2 Activity of Because we observed that the expression level of PD-L1 by different cell lines influences CD137 activation, the mAbs tested 2 We decided to further investigate the effect of PD-L1 expression on the functional activity of HEK.hPD-L1 cells. In a population-based approach, we performed a similar assay to that described in Example 10.1, in which we varied the ratio of HEK.hPD-L1 to HEK.WT cells to modulate the level of human PD-L1 expression.
[0459] HEK.hPD-L1 cells were plated at different ratios with HEK cells that were not transduced to express hPD-L1 (HEK.WT), and the percentage of HEK.hPD-L1 cells in total HEK cells was shown in Figure 6 (100%, 50%, 25%, 12.5%, 6.5%, or 0%). HEK cells were plated at 2 x 10 5 Total HEK cells / well were plated in 100 μl of T cell culture medium (10% FBS (Life Technologies), 1X penicillin) on a 96-well flat-bottom plate coated with anti-CD3 antibody (8 μg / ml). containing streptomycin (Life Technologies, 15140122), 1 mM sodium pyruvate (Gibco, 11360-070), and 50 μM 2-mercaptoethanol (Gibco, M6250). After 4 hours of incubation, all HEK cells were allowed to adhere, and then all T cell culture medium was removed and 5.0 × 10 T cells were plated in RPMI medium (Life Technologies, 61870-044). 5 Replace with 100 μl of T cell culture medium containing 5.0 x 10 cells / ml 4 cells / well.
[0460] The assay was performed using anti-human CD137 / PD-L1 mAb 2 Uses FS22-172-003-AA / E12v2 The assay was performed using the same protocol as described in Example 10.1, except that the protocol described in Example 10.1 was followed. The anti-CD137 positive control antibody G1-AA / 20H4.9 was included with additional cross-linking via the anti-CH2 antibody. Antibody G1-AA / 4420 was used as a negative control.
[0461] The results in Figure 6 demonstrate that HEK.hIL-2 expression is significantly increased in the IL-1 / 2-positive cells, as indicated by the increased maximum hIL-2 concentrations observed. As the population of PD-L1 cells increased, the mAb 2 The positive control antibody G1-AA / 20H4.9 also showed increased activity of the anti-CH2 antibody. Maximum cross-linking was achieved and the highest maximum hIL-2 concentration was observed when 100% of the HEK cell population present was HEK.hPD-L1. Similar maximum hIL-2 concentrations were achieved when the cells were maximally artificially cross-linked by
[0462] The data show that the amount of PD-L1 present in the system (expressed by testing cell lines expressing different levels of PD-L1 on the cell surface or by adjusting the number of cells within the population presenting PD-L1) influences the response of mAb 2 Control cross-linking of mAbs 2However, even in the presence of low levels of PD-L1, the mAb 2 was still able to agonize CD137. 2 It is expected that activated T cells expressing PD-L1 will be present in the system, and that CD137 will be present. As the level of PD-L1 in the system increases, the agonistic effect will also increase. This mAb can induce CD137 agonism even in the presence of low levels of CD137. 2 In contrast, molecules bound to PD-L1 are likely too far apart to drive CD137 clustering, which is likely due to the mAb of the present invention. 2 As it is not expected to be an issue for molecules to be able to bind CD137 bivalently, as is the case for CD137 / PD-L1 molecules that bind CD137 monovalently, it is expected that they will have low efficacy in the presence of low levels of PD-L1.
[0463] 10.3 Anti-Human CD137 / PD-L1 mAb in Human Primary Mixed Lymphocyte Reaction Assays 2 Activity of Anti-human CD137 / PD-L1 mAb 2 The activity of was tested in a mixed lymphocyte reaction (MLR) assay (see Example 5.3.4). In the MLR assay, CD4 + We used T cells and monocyte-derived dendritic cells (iDCs) from a separate donor. Because immune cells contain physiological levels of immune checkpoint regulators, we used an MLR assay to detect T cell activation in response to human mAbs. 2 It can be confirmed that the effect is enhanced by
[0464] CD4 cells expanded as described in Example 5.3.4 + T cells and iDCs were generated.
[0465] The expanded T cells were thawed one day before the experiment, washed with AIM V medium (GIBCO, 12055-091), and incubated overnight in AIM V medium at 37°C and 5% CO2. Anti-CD137 and anti-PD-L1 antibodies and anti-human CD137 / PD-L1 mAbs listed in Table 16 2 The cells were cultured in 50 μl AIM V medium in a 96-well round-bottom plate (VWR, 734-1797). The antibody was diluted to 4x the final concentration. An anti-cytomegalovirus (CMV) gH glycoprotein antibody called MSL109 (described in WO 1994 / 016730 A1) containing the LALA mutation was included as a negative control. A 3-fold dilution series from 30 nM to 0.002 nM was tested. 1x10 mAb suspended in 50 μl of AIM V medium was used. 4 iDC cells and 1x10 suspended in 100µl of AIM V medium 5 Expanded CD4 + Both CD4 T cells were added to antibody dilutions and incubated for 5 days at 37°C + 5% CO2. The following negative controls were included: CD4 + T cells alone, iDC alone, CD4 + T cells + iDCs, and AIM V medium alone. Supernatants were collected, samples were diluted (1:25), and assayed for interferon gamma (IFN gamma) using a human IFN gamma ELISA Ready-SET-Go! kit (Life Technologies, 88-7316-77). The FN-γ concentration was measured using a plate reader equipped with Gen5 Software, BioTek. Plates were read at 450 nm. Absorbance values at 630 nm were subtracted from absorbance values at 450 nm (corrected). Standard curves for calculating cytokine concentrations were based on four-parameter logistic curve fitting (Gen5 Software, BioTek). Human IF The concentration of N-γ was plotted against the log concentration of antibody, and the resulting curve was fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0466] The anti-human PD-L1 antibody G1 / S70 inhibited EC 50The value was 0.06 nM, and the maximum level of IFN-γ (E max ) showed potent activity in the MLR assay with an EC of 1135 pg / ml (Table 16, representative Figures 7A and 7B). 50 indicates the concentration of mAb at which half of the agonistic response is achieved, while E max The values are absolute values indicating the maximum concentration of IFN-γ achieved in the assay. As expected, no activity was observed with the negative control G1-AA / MSL109 antibody. The positive anti-human CD137 antibody control G1-AA / 20H4.9 induced activity when cross-linked with the anti-hCH2 antibody. This indicates that CD137 expression may be low and PD-L1 blockade is so strong that PD-L1 blockade overwhelms CD137 signaling in this assay. Surprisingly, all anti-human CD137 / PD-L1 mAbs tested in this assay 2 had a very strong ECi of less than 0.04 in the range of 2626 to 3327 pg / ml. 50 Value and high E max This shows that mAb 2 shows increased potency in this assay over both PD-L1 and CD137 monoclonal antibodies.
[0467] [Table 17]
[0468] Anti-human CD137 / PD-L1 mAb following the same protocol as above 2 The activity of FS22-172-003-AA / E12v2 was tested in an MLR, but this time, each component (mock mAb 2 The study was again tested against the anti-human FS22-172-003 Fcab and anti-PD-L1 antibody G1-AA / E12v2, as well as combinations thereof.
[0469] The anti-human PD-L1 component antibody G1-AA / E12v2 was 50 The maximum level was 0.08 nM. Bell's IFN-γ(Emax ) showed potent activity in the MLR assay with a β-glucan-1-phosphate dehydrogenase (G1-AA / 4420) of 12421 pg / ml (Table 17; representative Figure 7C). As expected, the negative control G1-AA / 4420 antibody showed no activity. was not observed, and mock mAb 2 No activity was observed with the anti-human Fcab FS22-173-003. The positive anti-human CD137 antibody control G1-AA / 20H4.9 showed no activity when cross-linked with anti-hCH2 antibody. This suggests that CD137 expression may be low, and that PD-L1 blockade is so strong as seen above that PD-L1 blockade overwhelms CD137 signaling in this assay. As expected, anti-human CD137 / PD-L1 FS22-172-003-AA / E12v2 mAb 2 has a highly potent EC 50 value and a high E of 17,874 pg / ml max This shows that mAb 2 shows increased potency in this assay over either anti-PD-L1 and anti-CD137 monoclonal antibodies alone or the combination of both. 2 are mAb, respectively. 2 The results also show that the antibody had greater potency than the combination of two antibodies containing both the Fcab and Fab binding sites of the antibody.
[0470] [Table 18]
[0471] 10.4 Anti-Human CD137 / PD-L1 mAb in Antigen Recall T Cell Activation Assays 2 Activity of Anti-human CD137 / PD-L1 mAb in an antigen recall T cell activation assay by measuring immune responses to two different peptide pools containing physiologically relevant antigens 2 One pool was tested for the activity of CD8 +The second pool contains MHC class I-restricted peptides from cytomegalovirus, Epstein-Barr virus, and influenza virus (CEF) to test T cell activation, and the second pool contains CD4 + T cell activation was tested using MHC class II-restricted peptides from cytomegalovirus, Epstein-Barr virus, influenza virus, and tetanus toxin (CEFT). Because human PBMCs from a single donor were used, immune cells contained physiological levels of immune checkpoint regulators, and were stimulated by antigen presentation rather than cross-linking of the T cell receptor with anti-CD3 antibodies, the results of the assay demonstrate that antigen-driven T cell activation is comparable to that of mAbs in the human system. 2 Confirm that it is enhanced by
[0472] Cryopreserved peripheral blood mononuclear cells (PBMCs) were thawed, counted, and incubated in 10% fetal bovine serum (FBS) + 1 ng / ml IL-2 + 5 ng / ml IL-7, and 1 μg / ml CE. F peptide pool (Thinkpeptides, catalog number PX-CEF-G) or 1 μg / ml CEF 2 containing either a T peptide pool (Thinkpeptides, Cat. No. PX-CEF-G) 1.9 x 100 μl of Roswell Park Memorial Institute (RPMI) medium per well x10 5 Cells were seeded into 96-well flat-bottom plates. The cells were incubated at 37°C with 5% CO for 3 days. After 3 days, the medium was replenished with 22.5 μl of fresh RPMI containing 10% FBS and maintaining 1 ng / ml IL-2 and 1 ng / ml IL-7. The cells were incubated at 37°C with 5% CO for an additional 4 days.
[0473] Cells were collected, pooled together, and then plated at 1 x 10 per well in 150 μl of RPMI containing 10% FBS + 1 ng / ml IL-2 + 5 ng / ml IL-7, and either 1 μg / ml CEF peptide pool or 1 μg / ml CEFT peptide pool. 5Cells were distributed in 96-well round-bottom plates. 2 was diluted in the same medium that was added to the cells after seeding.
[0474] A 1:5 titration was performed in which a positive control anti-CD137 antibody (G1-AA / 20H4.9) and a positive control anti-PD-L1 antibody (G1-AA / E12v2) were each diluted in the same medium as the cells were seeded with, at 2x final concentrations starting at 400 nM, containing 400 nM crosslinker (anti-human CH2 antibody (mG1 / MK1A6)). 50 μl of either diluted positive control antibody / crosslinker mixture was added to the cells for a total assay volume of 200 μl and 1x antibody concentration.
[0475] The assay was incubated at 37°C, 5% CO for 72 hours. The supernatant was collected and purified using the MSD U-PLEX kit (Meso Scale Discovery, Cat. No. K15067L-2). Assays were performed according to the original instructions. Plates were read on a MESO QuickPlex SQ 120 electrochemiluminescence plate reader instrument using a 1:5 sample dilution. Cytokine concentrations were determined by the following method: The standard curve for calculation was calculated using MSD Discovery Workbench 4.0 software. and cytokine concentrations in the supernatants were fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0476] As shown in Tables 18 and 19, the anti-human PD-L1 antibody G1-AA / E12v2 showed a 0. EC of 0.06nM and 0.04nM 50 values (E of 65840 pg / ml and 86613 pg / ml, respectively) max ) and CD4 + and CD8 + EC showed activity in activating both T cells. 50 indicates the concentration of mAb at which half of the agonistic response is achieved, while E maxis an absolute value indicating the maximum concentration of IFN-γ achieved in the assay. The positive anti-human CD137 antibody control G1-AA / 20H4.9 had an EC of 0.33 nM when crosslinked with anti-hCH2 antibody. 50 value and E of 116,204 pg / ml max Values, CD8 + It showed activity in T cell activation, but CD4 + No activity was induced for T cell activation, which is due to the fact that CD137 expression is related to CD4 + CD8 compared with T cells + As expected, no activity was observed with the negative control G1-AA / 4420 antibody. Surprisingly, mAb 2 had EC values of 0.08 nM and 0.03 nM, respectively. 50 The value is CD4 + T cell activation and CD8 + The mAb was active in both assays of T cell activation. 2 was able to bind to PBMC-expressed PD-L1 and showed comparable PD-L1 activity on both cell types. Furthermore, binding to PBMC-expressed PD-L1 was significantly enhanced by mAb 2 The mAb was able to bind, cluster, and activate CD137 on both T cell subtypes, as measured by IFN-γ release. 2 The maximum concentration of IFN-γ released by T cells treated with + T cell activation and CD8 + For T cell activation, E of 86680 pg / ml and 188242 pg / ml, respectively. max The values were higher than any of the positive control antibodies. 2 shows increased activity in this assay over both PD-L1 and CD137 monoclonal antibodies.
[0477] [Table 19]
[0478] [Table 20]
[0479] 10.5 Anti-Human CD137 / PD-L1 mAb in PD-L1 Blockade Mouse DO11.10 T Cell Activation Assay 2 Activity of The activity of FS22-172-003-AA / E12v2 was investigated to investigate its PD-L1 checkpoint blockade activity. These were tested in a murine DO11.10 T cell activation assay to determine their activity against human PD-L1. Functional activity against human PD-L1 was examined in an IL-2 release assay using DO11.10 OVA T cells and LK35.2 B cell hybridoma cells, as described in Example 5.4.
[0480] The results are shown in Table 20. Anti-human CD137 / PD-L1 mAb 2 has an EC of 1.27 nM 50 FS22-172-003-AA / E12v2 demonstrated potent activity in the mouse DO11.10 T cell activation assay, demonstrating that FS22-172-003-AA / E12v2 binds to PD-L1 and blocks the interaction between PD-L1 and PD-1. Its activity was similar to that of the positive control anti-human PD-L1 antibodies G1-AA / E12v2 and G1-AA / S70, indicating that G1-AA / E12v2 is a potent anti-PD-L1 antibody. 2 molecule These results demonstrate that when incorporated into PD-L1, no loss of anti-human PD-L1 activity occurred.
[0481] [Table 21]
[0482] Example 11: Anti-human CD137 / PD-L1 mAbs in Cynomolgus Monkey Functional Assays 2 Functional cross-reactivity of 11.1 Anti-Human CD137 / PD-L1 mAb in Cynomolgus Monkey DO11.10 T Cell Activation Assay 2 Activity of Agonist molecule-mediated CD137 clustering on activated T cells induces T cell activation and downstream signaling, resulting in, but not limited to, IL-2 production. Anti-human CD137 / PD-L1 mAb activates cynomolgus monkey CD137-expressing DO11.10 cells. 2 The ability of the antibody to bind to cynomolgus monkey CD137 was tested in a T cell activation assay. A DO11.10 T cell activation assay was developed using DO11.10 T cells engineered to overexpress cynomolgus monkey CD137, and T cell activation was assessed by measuring IL-2 release.
[0483] DO11.10 cells (National Jewish Health) expressing full-length cynomolgus CD137 (SEQ ID NO: 189), designated "DO11.10.cCD137," were generated as described in Example 1.2 and confirmed to express cynomolgus CD137.
[0484] The following anti-human CD137 / PD-L1 mAbs: 2 The following mAbs were tested in this DO11.10 T cell activation assay: FS22-172-003-AA / lamG02v3, FS22-053-008-AA / E05v2, FS22-053-008-AA / E12v2, FS22-053-008-AA / G12v2, FS22-053-017-AA / E05v2, FS22-053-017-AA / E12v2, FS22-053-017-AA / G12v2, FS22-172-003-AA / E05v2, FS22-172-003-AA / E12v2, FS22-172-003-AA / G12v2. 2 Alternatively, G1-AA / MOR7480.1 positive control mAb was prepared by diluting it with or without anti-hCH2 antibody (mG1 / MK1A6) crosslinker and plated onto 96-well plates coated overnight with 0.1 μg / ml anti-CD3 antibody (clone 17A2, BioLegend, 100208). 2 x 10 cells were added to DO11.10.cCD137 cells in a round-bottom plate. 5 HEK.cyPD-L1 cells The cells were seeded and used as cell-based crosslinkers overexpressing cynomolgus monkey PD-L1. Cynomolgus monkey PD-L1 overexpressing cells were generated as described in Example 5.3.3 using the cynomolgus monkey PD-L1 described in Example 9.5. After 18 hours of incubation, the supernatant was collected and assayed with a mouse IL-2 ELISA kit (eBioscience, 88-7024-86) according to the manufacturer's instructions. The plate was read at 450 nm using a plate reader equipped with Gens Software, BioTek. The absorbance value at 570 nm was subtracted from the absorbance value at 450 nm (corrected). The standard curve for calculating cytokine concentrations was based on a four-parameter logistic curve fit (Gens Software, BioTek). The concentration of mIL-2 was 2 or log concentration of benchmark mAb and the resulting curves were fitted using the log(agonist) vs. response equation in GraphPad Prism.
[0485] All anti-human CD137 / PD-L1 mAbs tested in this assay 2 mAb 2 showed activity in the presence of HEK cells overexpressing cynomolgus monkey PD-L1, which crosslinks the mAb. 2 binds to both cynomolgus monkey PD-L1 and inhibits IL-2 production As a raw readout, DO11.10 demonstrates binding and clustering to cynomolgus monkey CD137, which induces T cell activation (see Table 21 and Figure 8). All anti-human CD137 / PD-L1 mAbs 2 showed EC values ranging from 0.06 to 0.11 nM only when crosslinked via cell-expressed cynomolgus monkey PD-L1. 50 values and E ranging from 8060 to 12300 pg / ml IL-2 maxshowed similar activity. When assayed in the absence of cynomolgus PD-L1 and using HEK cells that do not express cynomolgus PD-L1, it had no activity as a result of the lack of cross-linking. The positive control CD137 antibody G1-AA / MOR7480.1, which has been shown to be cross-reactive in cynomolgus monkeys (Fisher et al., 2012), Although all anti-human CD137 / PD-L1 mAbs show activity in this assay when cross-linked with anti-CH2, 2 showed a lower EC20 expression level, indicating cross-reactivity and better activity in the cynomolgus monkey CD137-expressing system. 50 value and higher E max It is better in both senses of value.
[0486] [Table 22]
[0487] 11.2 Anti-Human CD137 / PD-L1 mAb in Cynomolgus Monkey Primary Mixed Leukocyte Reaction Assay 2 Activity of Anti-human CD137 / PD-L1 mAb 2 The activity of was tested in a cynomolgus monkey mixed lymphocyte reaction (MLR) assay. Similar to the human MLR assay described in Example 10.3, this assay measures the cellular immune response that occurs between two allogeneic lymphocyte populations (same species, but genetically distinct). In this assay, CD4 + T cells and CD14 from another individual + Monocytes are used. Because immune cells contain physiological levels of immune checkpoint regulators, the MLR assay can be used to assess whether T cell activation is mediated by cynomolgus monkey-based mAbs. 2 It can be confirmed that the effect is enhanced by
[0488] CD4 + Isolation of T cells PBMCs were isolated from cynomolgus monkey blood samples by Ficoll gradient separation. +T cells are non-human primate CD4 + Cells were isolated using an isolation kit (Miltenyi Biotec Ltd, 130-091-102) according to the manufacturer's instructions. Cells were used fresh in the MLR assay.
[0489] CD14 + Isolation of monocytes Naive monocytes were isolated from cynomolgus monkey PBMCs using a non-human primate CD14 isolation kit (Miltenyi Biotec Ltd, 130-091-097) according to the manufacturer's instructions. Monocytes were used fresh in the MLR assay.
[0490] MLR assay Anti-human CD137 / PD-L1 mAb 2 FS22-172-003-AA / E12v2, anti-human PD-L1 antibody G1-AA / E12v2, and isotype control antibody G1-AA / 4420 were diluted to 4x the final concentra...
Claims
1. An antibody molecule that binds to programmed death-ligand 1 (PD-L1) and CD137, (a) a complementarity determining region (CDR)-based antigen-binding site of PD-L1; and (b) a CD137 antigen-binding site located in the CH3 domain of the antibody molecule. and wherein the CDR-based antigen binding site comprises, according to Kabat numbering: (i) SEQ ID NOs: 1, 2, 3, 4, 5, and 6 [E12v2], respectively; (ii) SEQ ID NOs: 1, 2, 3, 18, 19, and 20, respectively [E05v2]; or (iii) SEQ ID NOs: 1, 2, 3, 18, 19, and 29 [G12v2], respectively; or comprising the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 of The CDR-based antigen-binding site is, according to the ImMunoGeneTics (IMGT) numbering: (iv) SEQ ID NOs: 7, 8, 9, 10, 11, and 6 [E12v2], respectively; (v) SEQ ID NOs: 21, 8, 9, 22, 11, and 20 [E05v2], respectively; or (vi) SEQ ID NOs: 21, 8, 9, 22, 11, and 29 [G12v2], respectively; VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 as set forth in the CD137 antigen binding site comprises a first and a second sequence located in the AB and EF structural loops of the CH3 domain, the first sequence comprises a PPY sequence (SEQ ID NO: 78), the PPY sequence is located between positions 15 and 17 of the CH3 domain of the antibody molecule, and the numbering of the amino acid residues is according to the IMGT numbering scheme; antibody molecule.
2. The first and second sequences are (i) SEQ ID NOs: 79 and 83 [FS22-053-009], respectively; (ii) SEQ ID NOs: 79 and 86, respectively [FS22-053-011]; (iii) SEQ ID NOs: 79 and 89, respectively [FS22-053-017]; (iv) SEQ ID NOs: 79 and 92, respectively [FS22-053-014]; (v) SEQ ID NOs: 79 and 95, respectively [FS22-053-010]; (vi) SEQ ID NOs: 79 and 98, respectively [FS22-053-012]; (vii) SEQ ID NOs: 79 and 101, respectively [FS22-053-013]; (viii) SEQ ID NOs: 79 and 104, respectively [FS22-053-015]; (ix) SEQ ID NOs: 79 and 107, respectively [FS22-053-016]; (x) SEQ ID NOs: 79 and 110, respectively [FS22-053]; (xi) SEQ ID NOs: 117 and 114, respectively [FS22-172-002]; (xii) SEQ ID NOs: 120 and 114, respectively [FS22-172-004]; (xiii) SEQ ID NOs: 123 and 114, respectively [FS22-172-001]; (xiv) SEQ ID NOs: 126 and 114, respectively [FS22-172-005]; (xv) SEQ ID NOs: 129 and 114, respectively [FS22-172-006]; or (xvi) SEQ ID NOs: 129 and 114 [FS22-172], respectively; The antibody molecule of claim 1 having the sequence set forth in
3. The antibody molecule (i) SEQ ID NOs: 12 and 14 [E12v2], respectively; (ii) SEQ ID NOs: 23 and 25, respectively [E05v2]; or (iii) SEQ ID NOs: 23 and 30 [G12v2], respectively.
3. The antibody molecule of claim 1 or 2, comprising a VH domain and a VL domain as described above.
4. The antibody molecule (i) the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 set forth in SEQ ID NOs: 1, 2, 3, 4, 5 and 6, respectively, according to the Kabat numbering scheme [E12v2]; (ii) the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2 and VL CDR3 set forth in SEQ ID NOs: 7, 8, 9, 10, 11 and 6, respectively, according to the IMGT numbering scheme [E12v2]; and / or (iii) the VH domain and VL domain [E12v2] set forth in SEQ ID NOs: 12 and 14, respectively. The antibody molecule of claim 1 , comprising:
5. (i) the first sequence is located between positions 14 and 17 of the CH3 domain of the antibody molecule; and / or (ii) the second sequence is located between positions 91 and 99 of the CH3 domain of the antibody molecule; and The numbering of amino acid residues is according to the IMGT numbering scheme; An antibody molecule described in any one of claims 1 to 4.
6. The antibody molecule is selected from the group consisting of SEQ ID NO:84 [FS22-053-009], SEQ ID NO:87 [FS22-053-011], SEQ ID NO:90 [FS22-053-017], SEQ ID NO:93 [FS22-053-014], SEQ ID NO:96 [FS22-053-010], SEQ ID NO:99 [FS22-053-012], SEQ ID NO:102 [FS22-053-013], SEQ ID NO:105 [FS22-053-015], SEQ ID NO:108 [FS22-0 5. The antibody molecule of claim 1 , comprising a CH3 domain as set forth in SEQ ID NO:111 [FS22-053], SEQ ID NO:118 [FS22-172-002], SEQ ID NO:121 [FS22-172-004], SEQ ID NO:124 [FS22-172-001], SEQ ID NO:127 [FS22-172-005], SEQ ID NO:130 [FS22-172-006] and SEQ ID NO:132 [FS22-172].
7. The antibody molecule described in claim 6, wherein the CH3 domain sequence further comprises a lysine residue (K) immediately adjacent to the C-terminus of the CH3 domain sequence.
8. The antibody molecule comprises an antibody: (i) FS22-053-017-AA / E12v2 as set forth in SEQ ID NOs: 152 and 17, respectively; (ii) FS22-053-017-AA / E05v2 as set forth in SEQ ID NOs: 153 and 28, respectively; or (iii) FS22-053-017-AA / G12v2 as set forth in SEQ ID NOs: 154 and 33, respectively; 8. The antibody molecule of claim 1 , comprising a heavy chain and a light chain of:
9. The antibody molecule of claim 8, wherein the CH3 domain sequence of the heavy chain sequence further comprises a lysine residue (K) immediately adjacent to the C-terminus of the CH3 domain sequence.
10. The antibody molecule comprising a CH2 domain, (i) the antibody molecule has been modified to reduce or abolish binding of the CH2 domain of the antibody molecule to one or more Fcγ receptors; (ii) the antibody molecule does not bind to one or more Fcγ receptors, and / or (iii) binding of the antibody molecule to CD137 on immune cells and to PD-L1 bound to the surface of tumor cells causes clustering of CD137 on the immune cells. An antibody molecule according to any one of claims 1 to 9.
11. 11. One or more nucleic acid molecules encoding an antibody molecule according to any one of claims 1 to 10.
12. 12. One or more vectors comprising one or more nucleic acid molecules according to claim 11.
13. 13. A recombinant host cell comprising one or more nucleic acid molecules according to claim 11 or one or more vectors according to claim 12.
14. 17. A method for producing an antibody molecule according to any one of claims 1 to 10, comprising culturing a recombinant host cell of claim 13 under conditions for the production of said antibody molecule, and optionally further comprising isolating and / or purifying said antibody molecule.
15. 11. A pharmaceutical composition comprising an antibody molecule according to any one of claims 1 to 10 and a pharma- ceutically acceptable excipient.
16. A pharmaceutical composition for the treatment of cancer in an individual, comprising an antibody molecule according to any one of claims 1 to 10.
Citation Information
Patent Citations
Binding molecules that modulate a biological activity expressed by a cell
WO2018056821A1
